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Introduction
Anemia of chronic disease (ACD) is frequently encountered in inflammatory disor­
ders such as infectious diseases and auto-inflammatory diseases, and the second most 
prevalent cause of anemia after iron deficiency (ID).(1,2,3) The pathophysiology is 
immune-driven and includes the activation of proinflammatory cytokines that sup- 
press erythropoiesis and have important effects on body iron homeostasis. This thesis 
focuses on human iron homeostasis in patients with anemia and chronic inflammation, 
including malaria, placental malaria and rheumatoid arthritis (RA). Improved insight 
in iron homeostasis under these circumstances is needed to evaluate and treat these 
anemie patients.
1.1 Iron homeostasis, hepcidin and anemia
In humans, iron plays a crucial role in fundamental processes such as oxygen binding 
to hemoglobin in circulating red blood cells (RBCs). Adequate erythropoiesis is there- 
fore iron-dependent and insufficiënt availability of iron for erythropoiesis will result 
in the clinical syndrome of anemia. On the other hand, a surplus of iron may result 
in iron unbound to proteins, which is redox-active and contributes to cellular toxic- 
ity. Therefore, systemic iron homeostasis is tightly regulated by the iron regulatory 
hormone hepcidin and cellular iron levels are controlled by many strictly regulated 
iron-transporters and storage proteins. Hepcidin regulates the uptake of iron from 
the bowel and the release of iron from macrophages and hepatocytes by interacting 
with the sole known cellular iron exporter ferroportin, inducing its internalization 
and degradation. (5|6) Macrophages contribute to most of the iron entering the cir-
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culation by phagocytosis and recycling of iron of damaged or senescent RBCs. (7-* 
Intracellular storage of iron in macrophages and hepatocytes occurs in the form of 
ferritin. Iron from ferritin can be released from cells into the circulation and trans- 
ported to the bone marrow to be used for erythropoiesis. In case of sufficiënt iron 
stores, hepcidin levels are upregulated and as such inhibit gut iron absorption and 
sequester iron in macrophages (Figure 1 . 1 ) . Hepcidin levels are also increased by 
proinflammatory cytokines, particularly by interleukin-6 (IL-6). In contrast, low iron 
levels decrease hepcidin concentrations allowing intestinal iron absorption and iron 
release from stores until levels have normalized. ID and ACD may thus represent
Figure 1.1: Hepcidin function in iron homeostasis.
Hepcidin Controls the amount of iron absorbed from the diet and the release of iron from macrophages 
from the reticuloendothelial system (RES). There is a steady state of iron recycling from senescent 
red blood cells (RBCs) that are degraded in macrophages into iron. This iron is transported via 
transferrin towards the bone marrow where iron is essential for erythropoiesis. In states of iron 
deficiency (A), hypoxia and increased erythropoiesis hepcidin transcription is downregulated, while 
the opposite occurs when iron is abundant or when there is inSammation (B). Hepcidin- ferroportin 
interaction results in degradation of the iron exporter, which is present on the apical site of duodenal 
cells and macrophages. As a consequence, dietal iron uptake and macrophageal iron release are 
reduced. When hepcidin levels are low (A), uptake and/or release of iron into the circulation is 
no longer restricted and iron can be transported to the bone marrow via transferrin, provided that 
body iron stores are adequate. In inSammation (B), iron stores may be sufficiënt, but locked in 
macrophages (increased ferritin) and not available for erythropoiesis.
two ends of the spectrum of disturbed iron homeostasis: absolute iron depletion in 
ID versus iron maldistribution in ACD. The latter is explained by hepcidin-induced 
iron sequestration that results in less availability of iron for erythropoiesis, despite 
sufficiënt iron stores. Eventually, both forms of anemia feature hypoferremia and
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iron-restricted erythropoiesis. In addition, overlap syndromes may exist whereby ID 
and chronic inflammation co-exist. This may typically occur in malaria but also in 
chronic inflammatory conditions like RA (see discussion below). (9’1Q)
1.2 Malarial anemia
Anemia is highly prevalent in malaria-endemic areas: in Sub-Saharan Africa around 
67% of the preschool-aged children and 57% of the pregnant women are estimated to 
be anemie, mainly caused by ID. (n >12) In addition to ID, malaria infections contribute 
significant to the development of anemia in these and other tropical regions. (13>14) 
Malaria is caused by parasites of the Plasmodium species, which are transmitted to 
the human host by a mosquito bite. Upon transmission, the parasite develops in the 
liver and multiplies in hepatocytes, and, when released in the bloodstream, invade 
RBCs to continue their life circle (Figure 1.2). Various Plasmodium species are rec- 
ognized, including P. falciparum, P. ovale, P. malariae and P. vivax. Of these is P. 
falciparum associated with the most devastating symptoms of the malarial disease, 
that may range from severe anemia, feverish septic illness, to cerebral malaria and 
death. (15)
Different pathophysiological processes may contribute to the development of malar­
ial anemia including direct and indirect destruction (hemolysis) of parasitized and 
non-parasitized RBCs, inefficient and/or suppressed erythropoiesis, and dyserythro- 
poiesis. (18) During infection with Plasmodiae, infected erythrocytes are obviously lost 
by means of parasite maturation as well as through recognition by macrophages fol- 
lowing changes in erythrocyte membrane deformability and immune complex compo- 
sitions. (13) Moreover, for any parasitized RBCs, an estimated 10-fold of unparasitized 
RBC is affected, resulting in enhanced clearance of RBCs in the microvasculature of 
-particularly- the spleen. (13,19,2°) Anemia is especially prevalent in P. falciparum as 
this parasite can infect all stages of a RBC, in contrast to the other Plasmodiae which 
are less virulent and may not have the same capacity to infect all of these stages.
In addition, malaria induces a pro-inflammatory response resulting, among others, 
in IL-6 production which leads to suppression of erythropoiesis and elevation of cir- 
culating hepcidin levels. (14>18>21) This process may be very apparent in non-immune 
individuals, however, frequent exposure to infected mosquitos in highly endemic ar­
eas may also result in an asymptomatic chronic parasitemia in which the acquired 
immunity is sufficiënt to control but not to eliminate the malaria infection. Subjects 
with asymptomatic parasitemia, the parasitemia without the classical attacks, may 
also have a suppressed hematopoiesis and elevated hepcidin levels. r'22'> Finally, nutri- 
tional deficiencies and particularly ID are highly prevalent in malaria-endemic areas.
5
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Figure 1.2: Schematic presentation oflife cycle P. falciparum and pathophysiology 
of malarial anemia.
Sporozoites are transmitted via a mosquito bite into the blood stream, where they migrate to the liver 
to grow and multiply into merozoites. Once in the circulation, merozoites initiate the erythrocytic 
stage by infecting red-blood cells (RBCs). Inside the erythrocyte the parasite passes through the ring, 
trophozoite, and schizont stages until the RBC bursts: the blood stage in which the host suffers from 
the characteristic inSammatory storm that features clinical malaria. During the rupture of RBCs, 
also parasite products are released into circulation. The life circle continues when gametocytes are 
ingested by mosquitos and transmitted to other hosts. Both infected and uninfected RBCs can be 
sequestered in the microcirculation and/or cleared from the bloodstream by macrophages. In these 
cells, iron is liberated from heme by the enzyme heme oxygenase (HO-1) and exported to the cytosol 
via the divalent metal transporter-1 (DMT1) and natural resistance-associated macrophage protein-1 
(Nrampl) (not depicted). (,6’17) The excess iron is incorporated into ferritin, which is the main iron 
storage protein, or exported back to the plasma via ferroportin. Hepcidin that is upregulated in 
malaria may interact with ferroportin leading to decrcased iron availability for erythropoiesis. The 
erythropoiesis can also directly be affected. These factors a11 may contribute to malarial anemia.
Especially children and young women are at risk for ID, a consequence of inadequate 
iron intake and absorption, increased iron requirements during growth or pregnancy, 
and loss of iron due to intestinal parasites, bleeding during menstruations or delivery.
6
1.3. Placental malaria and iron homeostasis in pregnancy
1.3 Placental malaria and iron homeostasis in preg­
nancy
In pregnancy, malaria parasites sequester in the placenta, leading to placental mal­
aria. (23) More specific, parasitized RBCs bind to the placenta receptor chondroitin 
sulfate A and then sequester in the intervillous space of the placenta. Here, Plas- 
modiae are relatively protected from the maternal immune system allowing parasite 
densities to be higher in the placenta than in the peripheral circulation. This may 
also explain why P. falciparum malaria is more prevalent in pregnancy. A low 
grade inflammatory reaction in the placenta is often apparent, with monocyte and 
macrophage infiltrations and cytokine production, accumulation of infected RBCs 
and thickening of the trophoblastic basement membrane, all which are thought to 
negatively influence adequate delivery of nutrients to the fetus. ^  This may (partly) 
explain why placental malaria is associated with fetal growth restriction, reduced birth 
weight, preterm delivery and anemia. (26>27) Typically primigravidae are affected, as 
antibodies against placental-type parasites do not (yet) offer protection against these 
adverse outcomes. (28)
Even during a normal healthy pregnancy, particularly from the second trimester on- 
wards, significant changes in circulating blood volume occur, resulting in increased 
erythroid mass and iron needs and making all pregnant women prone to ID and ane­
m ia /29) The role of hepcidin in iron homeostasis during pregnancy is unknown at 
time of studies. During pregnancy, several physiologic factors may influence serum 
hepcidin levels, which may also vary during the course of gestation. On the one 
hand, ID, hypoxia, or increased erythropoiesis down-regulate the expression of hep­
cidin, while on the other hand, (low grade) inflammation, as is observed at end of 
pregnancy, up-regulates hepcidin levels.(30^  Mice experiments have shown that fetal 
hepcidin plays a role in the regulation of placental iron transport, which is prioritized 
to fulfill the demands of the growing fetus at cost of maternal iron stores. (3r> When 
the fetal iron levels rise, fetal hepcidin levels rise as well resulting in less iron transfer 
over the placenta from the mother to the fetus through an unknown mechanism. (32) 
To conclude, pregnancy increases the iron demand of the mother and pregnant women 
with low iron reserves are therefore at increased risk for ID. The risk to develop ane­
mia becomes very high when placental malaria is present too. The role of hepcidin 
in these interactions during pregnancy are unknown and subject of this thesis.
1.4 Diagnosis of iron deficiency in (chronic) inflam­
mation and malarial anemia
Anemia is also frequently observed in patients with chronic inflammatory diseases 
like RA. (10) The chronic inflammatory nature of the disease causes cytokine-mediated
7
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down-regulation of the erythropoiesis (33) while at the same time the iron availabil- 
ity for heme synthesis is reduced by elevated hepcidin levels. (1’3,34) In addition, the 
causes of anemia in patients with RA may also include drug-related bone marrow sup- 
pression, hemolysis and -importantly- ID due to gastrointestinal blood losses, e.g. by 
non-steroidal anti-inflammatory drugs. (10)
It is important that the diagnosis of ID can be made in inflammatory conditions, both 
in malarial anemia as well as in the anemia of RA, since ID can be treated with iron 
supplementation, the diagnosis may prelude further investigations to its cause and it 
may prevent unnecessary prescription of iron supplementation.
So far, the serum iron status parameters iron, transferrin saturation and ferritin have 
been used mostly. However, these parameters are all influenced by inflammation 
(Table 1.1). For example, ferritin and transferrin are acute phase proteins whose 
levels will change in case of concomitant infectious or inflammatory diseases (ACD). 
Therefore, Standard additional testing of ferritin with C- reactive protein (CRP) is 
recommended in malarial areas. (35>36>37,38)
Another marker is the soluble transferrin receptor (sTfR), which represents the amount 
of transferrin receptors of cells, particularly of the erythroid precursor cells in the bone 
marrow and therefore reflects the degree of iron demand of erythroblasts. How­
ever, sTfR levels may be falsely raised when the erythropoietic rate is high due to 
other reasons, or in opposite direction- suppressed by inflammation-mediated inhibi- 
tion of erythropoietic activity. (39-40-41) This makes the interpretation of an individual 
sTfR value difficult when both changes in erythropoietic activity and iron stores occur 
simultaneously. The use of the sTfR- index (sTfR divided by ferritin) has been 
advocated instead as it combines markers of iron demand with iron storage. (37>38>40) 
Recent analytical developments made it possible to measure serum hepcidin concen- 
trations for clinical practice (34), but its value in diagnosing ID under inflammatory 
conditions needed to be evaluated and is studied in this thesis. Apart from the mea- 
surement of circulating iron parameters, also automated hemocytometry has been 
used to differentiate ID from other causes of anemia. Mean cell volume (MCV) and 
mean cell hemoglobin (MCH) are still commonly used in diagnostic algorithms for ane­
mia. However, their utility has been challenged with as main drawback that they are 
average values generated from the assessment of the total volume of erythrocytes, thus 
decreasing the sensitivity for detecting (recent) changes the younger subpopulations of 
these cells. Furthermore, these parameters are unreliable in hemoglobinopathies. ^  
Recently, new hematological parameters have been developed such as hemoglobin con­
tent of reticulocytes (Ret-He or CHr) and RBCs (RBC-He or CH; depending on the 
inanufacturer of the automated hematology analyzer, respectively) which reflect the 
hemoglobinization of the earliest released reticulocytes that only circulate for one- two 
days and that of mature erythrocytes, respectively. <-'13-1 Reduced Ret-He and RBC-He 
values indicate that (recent or longstanding) reduction in iron availability for ery-
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thropoiesis affects hemoglobinization. (44^  These properties in combination with the 
fact that Ret-He or RBC-He are not directly affected by inflammation, make them 
interesting additional tools in detecting ID in chronic inflammatory disorders. (2'44>45)
iron deficiency 
IDA
iron maldistribution 
ACD
both conditions
ID/ACD
Hepcidin
Ret-He (CHr)
RBC-He (CH)
Iron
Ferritin
Transferrin
TS
sTfR
sTfR-index
reduced
reduced
reduced
reduced
reduced
increased
reduced
increased
increased
increased 
normal? 
normal? 
reduced 
increased 
normal/ reduced 
reduced 
normal 
reduced
subject of our studies 
subject of our studies 
subject of our studies 
reduced 
increased 
reduced 
reduced 
normal/ increased 
increased?
T able 1.1: S eru m  iron sta tu s p a ra m eters in iron d eficien cy  anem ia (ID A ) , anem ia  
o f  chronic d iseases ( A C D )  or  in a com bin ation  o f  b o th  iron disorders J 1’2’3) 
Abbreviations: Ret-He, reticulocyte-hemoglobin content; RBC-He, erythrocyte-hemoglohin content; 
TS, Trnnsferrin Saturation; sTfR, soluble trans ferrin receptor; sTfR-index, sT fR / log ferritin.
1.5 Iron supplementation: risk and benefits
ID can be treated relatively simple by iron supplementation, which may have an 
important effect on health outcome. This also applies to patients with a chronic 
inflammatory disorder, such as RA, as it has been demonstrated that they can ab- 
sorb iron and increase hemoglobin levels after oral supplementation. (46>47,48,49) In 
malaria-endemic areas, iron supplementation has been shown to improve childhood 
cognitive development, growth and women’s health/50,51) In pregnancy, iron supple- 
mentation has been proven to reduce anemia, iron deficiency and low birth weight. (52) 
A major WHO strategy to control anemia in developing countries was to implement 
widespread iron supplementation programs through iron food fortification. However, 
this strategy was questioned after the results of a large blinded and randomized iron 
supplementation trial were published that reported increased malaria-related morbid- 
ity and mortality in a subgroup of children that were iron replete and received iron 
supplementation. (53)
Similar concerns were raised for pregnant women in malaria-endemic areas. Recently, 
a systematic review reported that iron supplementation did not increase the risk of 
P. falciparum malaria in pregnancy. However, no information about maternal iron
9
1. Introduction
status was available and studies were heterogeneous in methodology and regarding the 
presence of peripheral or placental malaria. (54) Current guidelines recommend that 
universal iron supplementation in pregnancy should be given together with malaria 
prevention strategies, until more information has become available about diagnosing 
ID in this group. (55)
The mechanisms underlying possible adverse outcomes of iron interventions in malaria 
areas remain poorly understood. Iron is not only an essential micronutrient, for hu- 
mans but for many more microorganisms as well. Iron supplementation could disturb 
a delicate balance between microorganisms trying to access iron through various iron 
acquisition systems and the host limiting iron availability by inducing hypoferremia 
upon infiammation. (56.57>58,59) Especially, intramacrophageal growing microorganisms 
like Mycobacterium tuberculosis, Salmonella spp. and Plasmodium may profit from 
iron supplementation in infiammatory conditions. (58’59) In addition, iron status also 
influences the immune effector functions of macrophages. In evolutionary terms, 
ID is thought to confer protection against these micro-organisms, which may explain 
why the host response to infection is hepcidin-mediated extracellular and hepatocel- 
lular iron restriction and why ID is so prevalent in areas with a high infection burden. 
This thesis also addresses co-infection of P. falciparum and non-typhoidal salmonel- 
lae (NTS): NTS are a prominent cause of bloodstream infection in malaria-endemic 
areas. (60) Malaria is a suggested risk factor for NTS infections and in this thesis the 
link to increased (cellular) iron availability will be further explored. Indeed, several 
studies showed that iron loading is associated with increased survival of Salmonella 
spp. within macrophages, while cellular iron deprivation results in the opposite. (61>62) 
In conclusion, complex interactions exist between iron and inflammation/infection of 
which many aspects are still unknown.
1.6 Outline of thesis
This thesis is divided in three sections, each addressing a specific focus.
The first section aims to improve insights on the complex interaction between iron 
homeostasis and malaria infection. In Chapter 2 the hypothesis is explored that 
malaria results in changes in iron distribution within macrophages, which may be 
beneficial for the intracellular growing Salmonella spp. and as such may help to 
explain the assumed risk of iron supplementation in malaria endemic areas. Chap­
ter 4 further explores this hypothesis by assessing the direct effects of P. falciparum 
on macrophage iron biology in an in vitro model. The effects on macrophage iron 
regulatory genes and cellular iron distribution are analyzed after erythrophagocytosis 
of both uninfected and parasitized RBCs.
Section 2 describes iron homeostasis during pregnancy in healthy women and during
10
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placental malaria. Pregnant women are at risk for ID for which iron supplementa- 
tion is an effective therapy. However, iron supplementation may have side effects in 
malaria-endemic regions. It is difficult to assess whether women are iron deplete as 
conventional iron status parameters all have their shortcomings. Therefore, there is 
a clear need for parameters with better test characteristics to detect body iron status 
in inflammatory conditions. We investigated the added value of serum hepcidin mea- 
surements in pregnancy for this purpose. In Chapter 5, the course of hepcidin and 
iron status parameters in normal pregnancy are assessed, while the same laboratory 
parameters are also studied in mothers with and without placental malaria and the 
cord-blood of their newborns (Chapter 6).
Section 3 analyzes the value of conventional and the new iron parameters, hepcidin 
and red blood cell indices Ret-He and RBC-He, in the diagnosis of ID in chronic 
rheumatic diseases. These patients suffer frequently from anemia because (low grade) 
inflammation affects erythropoiesis and body iron homeostasis, resulting in ACD. 
However, concurrent ID may be present as well and it is important to identify ID 
among patients with ACD as its treatment may have significant impact on health. 
However, this distinction is difficult with conventional iron status parameters. In 
Chapter 7, the value of hepcidin and automated hemocytometry of red cells in the 
differentiation of ID and ACD is assessed in anemie patients with RA. In a subsequent 
study, we evaluate these new red blood cell parameters as functional measures of ID 
in predicting a response to iron supplementation therapy in anemie patients with a 
chronic inflammatory disorder (C hapter 9).
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The iron link between malaria and 
invasive non-typhoid Salmonella 
infections
Susanne van Santen, Quirijn de Mast, Dorine W. Swinkels, André J.A.M. van der 
Ven
Trends in parasitology 2013;29(5):220-7
2. Iron, Malaria and Salmonella
Abstract
Epidemiological studies have demonstrated an association between malaria and in- 
vasive non-typhoid Salmonella (NTS) infections, especially in children. We explore 
the role of iron as a possible cofactor in this association. Malarial disease, among 
others, is associated with enhanced erythrophagocytosis and inflammation, which in- 
creases the iron content of macrophages and thereby also the survival of Salmonella 
spp. within macrophages. Whether iron supplementation programs augment the risk 
of invasive NTS infections in malaria-endemic regions is an important global health 
issue that still needs to be determined.
2.1 An introduction to the association between ma­
laria, Salmonella and iron
Malaria and invasive non-typhoidal Salmonella (NTS) infections are both prominent 
causes of severe illness and death in sub-Saharan Africa, particularly in children. 
Although infections with NTS usually cause a self-limiting diarrheal illness in high- 
income countries, these microorganisms have emerged as a leading cause of blood- 
stream infections with subsequent increased mortality in sub-Saharan A frica /63,60) 
In these areas, malaria is predominantly caused by Plasmodium falciparum, and many 
people are estimated to be at high transmission risk. (64)
Iron deficiency is very common in areas which suffer from a high burden of malaria 
and invasive NTS disease. (6n-* Iron supplementation was a common intervention un- 
til a large clinical trial in preschool children on the Tanzanian island Pemba, which 
is an area of holoendemic malaria transmission, showed that routine iron and folie 
acid supplementation was associated with an increased risk for hospital admission 
and death. (53) In a subanalysis of this trial in children whose baseline iron status was 
assessed, adverse events of iron and folie acid supplementation were more common in 
children without iron deficiency. In response, the World Health Organization (WHO) 
recommended to restrict iron supplementation to those children with proven iron de­
ficiency. (66) The debate on benefits and possible harm of iron supplementation and 
fortification in malaria-endemic areas continues. 6^7^  For example, recent Cochrane re- 
views concluded that iron supplementation and fortification in malaria-endemic areas 
are probably safe, in the case that access to healthcare facilities are present. (68>69-70) 
The mechanisms underlying the possible adverse outcome of iron interventions remain 
poorly understood. One of the ways that iron may exert its harmful effects in malaria- 
endemic areas is through predisposing individuals to malaria and NTS coinfection. 
In this review, we first focus on the epidemiological evidence of the co-occurrence of
16
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Salmonella bacteremia and P. falciparum malaria, followed by a discussion of how 
malaria influences macrophageal iron homeostasis. Subsequently, we address the role 
of iron in the individual pathogenesis of Salmonella and malaria infections and, fi- 
nally, explore the iron-related pathways that may be involved in the co-occurrence of 
malaria and invasive NTS disease.
2.2 Epidemiological evidence for malaria and Sal­
monella coinfections
The association between malaria and Salmonella dates back to the 19th century, 
when typhomalarial fever was a common diagnosis of army surgeons. (71) In addi- 
tion, a physician reported in 1929: The epidemiological relation of paratyphoid C 
to malaria in British Guiana is interesting. Not only does the disease become much 
more prevalent in coincidence with malarial out breaks, but its virulence increases ten- 
fold. (72) Many decades later, in 1987, Mabey and coworkers renewed attention to this 
topic. They described the co-occurrence of NTS bacteremia and malaria parasitemia 
in Gambian children. (73)
Since then, several prospective studies have reported similar findings. A study in 166 
Kenyan children with NTS bacteremia reported that around three quarters of them 
had concurrent malaria parasitemia or recent malaria. (74) There was a clear seasonal 
trend in NTS bacteremia with the highest incidence during the rainy season when 
malaria rates peaked. In a study in children in Malawi with severe malaria, nearly 
5% had positive blood cultures, of which NTS was the most common isolate. ^  
Children with severe malarial anemia had the highest risk for NTS bacteremia. A 
similar outcome was found in two Kenyan studies and one Tanzanian study, in which 
NTS was the most common bloodstream isolate in children with parasitemia/76,77) 
whereas Streptococcus pneumoniae and Haemophilus influenza were common isolates 
in aparasitemic children. (77’78) In Kenya, NTS bacteremia was also significantly more 
common in rural areas with intense malaria transmission, in contrast to urban sites 
with less malaria burden where Salmonella typhi and S. pneumoniae were more preva­
lent. <79>
More evidence came from a systematic review and meta-analysis of community ac- 
quired bloodstream infections in Africa. (80) This meta-analysis included 58 296 pa~ 
tients with febrile illness of whom almost three-quarters were children. A total number 
of 5578 (9.6%) bacterial or fungal bloodstream infections were diagnosed, of which 
NTS was the most common isolate, accounting for 29.1% of the isolates recovered 
overall and 42.3% of pathogenic isolates in adults. Malaria parasitemia was docu- 
mented in 11 814 o f the cases, and 769 (6.5%) of these cases had concurrent bacterial 
or fungal bloodstream infection. Additional support for the existence of coinfection
17
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was derived from an observation in Gambia and Kenya where the reduction in malaria 
infections was associated with a concurrent decline in NTS, whereas the incidence of 
pneumococcal bacteremia remained stable. (81>82)
Together, these studies show that invasive NTS disease and malaria are among the 
most common causes of fever in sub-Saharan Africa and, even though blood cultures 
are often not available or can be falsely negative, the data presented above suggest 
that coinfection of malaria and invasive NTS are common. This is in contrast to 
findings from Northern Africa and Asia, where invasive NTS disease appears to be 
relatively rare, and enteric fever caused by S. typhi and Salmonella paratyphi are 
more common causes of fever. (83) The lower infection burden of both malaria and 
HIV in these areas and the fact that parasite densities are considerably lower in vivax 
malaria most likely contribute to these regional differences in NTS epidemiology. 
How can this apparent association of malaria and invasive NTS disease in sub- Saha- 
ran Africa be explained? Although there is no doubt that environmental factors (e.g. 
rainy season, humidity(63)) are important, several observations also support the im- 
portance of host factors. For example, prevalence rates of Salmonella-positive stools 
remain relatively stable year round, whereas NTS-bacteremia has a seasonal varia- 
tion with a peak in the number of cases when malaria rates are also highest. (73’74) 
The well-described link between invasive NTS disease, HIV infection, malnutrition, 
and (severe) malarial anemia also suggests host-specific modulations. (74>75’76) These 
modulations involve several immune and non-immune mechanisms, and we suggest to 
include malaria-induced changes in the host iron homeostasis as one of the possible 
factors that predispose to invasive NTS, as described below.
2.3 Malaria affects macrophage iron homeostasis
In humans, the Plasmodium parasite first grows and multiplies in hepatocytes, fol- 
lowed by a blood stage characterized by a cycle of red blood cell (RBC) invasion, 
intraerythrocytic parasite multiplication, and RBC burst, which is responsible for the 
characteristic inflammatory storm that is a feature of clinical malaria. Both infected 
and uninfected RBCs are cleared from the bloodstream by macrophages of the retic- 
uloendothelial system taken up in phagosomes (Figure 2.1A). Iron is liberated from 
heme by the enzyme heme oxygenase 1 (HO-1) and exported to the cytosol via the 
divalent metal transporter-1 (DMT-1) and natural resistance-associated macrophage 
protein-1 (Nramp-1), which are localized predominantly to early and late phago­
somes, respectively (Figure 2.1C) (16,17) In the cytosol, the excess iron is incorporated 
in ferritin molecules, which is the main iron storage protein, or exported back to 
the plasma via the sole cellular iron exporter ferroportin. To deal with the exces-
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Figure 2.1: Interaction of malaria and Salmonella with macrophage iron.
Phagocytosis of both uninfected and infected red blood cells (RBCs) (A) is increased during the 
blood stage malaria infection, (19), which results in degradation of the RBCs by proteolytic enzymes 
into heme. (B) HO-1 converts heme into iron (and carbon monoxide and biliverdin). (C) Excess 
iron is transported to the cytosol via phagosomal transporters divalent metal transporter-1 (DMT-1) 
and resistance-associated macrophage protein-1 (Nramp-l(16)) and further processed: (i) stored in 
ferritin (D), and (ii) used in metabolic processes or released from the cell via ferroportin (E . (84>85)).
(F) Meanwhile, parasite products activate the innate immune system via Toll-like receptors (TLRs) 
2, 4 and 9. W . This systemic response during malaria induces hepatic hepcidin production; (E) hep­
cidin functions by blocking ferroportin. t34’87) In addition, monocytes and macrophages also express 
hepcidin upon stimulation with various pro-infiammatory cytokines and parasitized RBCs, (88’89’S0)
(G) which may result in autocrine ferroportin blocking. (H) In addition, inflammatory stimuli in- 
hibit ferroportin and modulate cellular iron uptake by DMT-1 and transferrin receptor. (90>91) As a 
consequence of these processes iron is sequestered in macrophages. (I) Salmonella enters the cell via 
endocytosis and proliferates in phagosomes. Nramp-1 expression is required to control Salmonella 
growth by depleting the phagosome of iron (C). (92) In a coinfection, Salmonella spp. may benefit 
from the increased cellular iron induced by a malaria infection and establish an infection. Whether 
both pathogens reside in the same macrophage during invasive NTS infection and malaria as depicted 
in the figure is unknown. Ulustration by A. Kartikasari.
sive supply of heme and free iron in conditions with increased erythrophagocytosis, 
these proteins axe all upregulated to maximize iron recycling by macrophages (Figure
19
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2.1, Table 2.1). Malaria is also associated with intravascular and extravascular 
hemolysis. (20) Pree circulating hemoglobin and heme are bound by haptoglobin and 
hemopexin, respectively, taken up by macrophages via specific receptors (CD163 and 
CD91, respectively) and then processed as described above via the HO-1 system/93) 
In addition to erythrophagocytosis and hemolysis, malaria is also associated with a 
pronounced inflammatory response. Inflammation is well known to have a major im­
pact on iron homeostasis, predominantly mediated by the iron regulatory hormone 
hepcidin. Human iron homeostasis is tightly regulated via hepcidin, produced in 
the liver by proinflammatory cytokines such as interleukin (IL)-6 and suppressed in 
conditions of iron deficiency or increased erythropoietic activity. 3^4-* Hepcidin acts 
by binding and subsequent degradation of the sole cellular iron exporter ferroportin, 
mainly situated on duodenal enterocytes and macrophages. As a consequence, 
hepcidin simultaneously prevents iron absorption from the diet and the recycling of 
iron after erythrophagocytosis in macrophages. This hepcidin-mediated, macrophage 
iron withholding is currently regarded as an ancient host defense mechanism against 
extracellular pathogens by depriving these pathogens of iron. (59) Previous work has 
shown that febrile malaria is associated with a strong increase in systemic hepcidin 
levels and pronounced disturbances in iron distribution, characterized by hypofer- 
remia and increased ferritin levels. (94-95>96) Studies in Indonesian schoolchildren^22) 
and Beninese women^9^ with asymptomatic P. falciparum parasitemia, and a study 
in volunteers participating in an experimental malaria infection (96) showed that dis­
turbances in iron homeostasis already occur with mild inflammation.
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2. Iron, Malaria and Salmonella
Macrophages also express hepcidin upon stimulation with an array of infectious and 
inflammatory stimuli including parasitized RBCs, (88>89>90) which may lead to au- 
tocrine ferroportin degradation and iron withholding. In addition to the effects of 
hepcidin, inflammation also leads to increased uptake of both transferrin-bound and 
nontransferrin-bound iron via modulation of transferrin receptors and DMT-1. (91>1) A 
schematic description of systemic iron metabolism during malaria infections is given 
in Figure 2.2. The role of iron in malaria infections is discussed in Box 1.
In summary, during malaria infections macrophageal iron contents increase as a re­
sult of these putative effects of enhanced erythrophagocytosis, cytokine activation, 
and hepcidin upregulation.
2.4 Iron is an essential micronutrient for Salmonella
To establish a systemic infection, Salmonella spp. have to invade the epithelial wall of 
the intestine, after which the bacteria are ingested by immune effector cells and trans- 
ported to lymph nodes, the spleen, and other organs. (108>109) Salmonella spp. reside 
within modified phagosomes in macrophages where replication is promoted and killing 
evaded. (108>109) Iron is an essential micronutrient for replication, and Salmonella spp. 
(similar to other intracellular pathogens) harbor various iron acquisition systems, 
such as the siderophores enterobactin and salmochelin. (57) Salmonella spp. can also 
upregulate HO-1 expression in macrophages, resulting in increased iron supply from 
heme. Several studies have directly related macrophage iron content to Salmonella 
pathogenesis. These studies showed that iron loading is associated with increased sur­
vival of Salmonella spp. within macrophages, whereas cellular iron deprivation results 
in the opposite. (62,61) In response to a Salmonella infection, macrophages try to re- 
duce the availability of intracellular iron both by increasing the incorporation of free 
iron into ferritin and cellular iron release via ferroportin (Table 1 ).(92>62’110) Another 
iron transporter that appears crucial in the control of Salmonella is Nramp-1. As 
mentioned above, Nramp-1 is localized to late phagosomes in which Salmonella spp. 
reside, where it depletes the phagosomes of iron (Figure 2.1C). This limits growth 
of intracellular pathogens, (17) and its expression was required to control Salmonella 
growth. (92) Apart from Nramp-1, ferroportin and DMT-1 are also located in phago- 
somal and endosomal membranes and to mycobacterium-containing phagosomes/111) 
Although little is known about the functional role of ferroportin and DMT-1 in these 
endosomal and bacteria-containing phagosomes, it is conceivable that they are im­
portant in modulating endosomal iron flows. Hepcidin peptide was also detected 
intracellularly in mycobacterium-containing phagosomes, (112) where it may control 
local ferroportin expression, (9°) and in high concentrations exert direct antibacterial
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Iron flows in normal conditions Iron flows m malaria
salmonella
Figure 2.2: Systemic effects of malaria on body iron stores.
(A) A  schematic presentation of iron flows in normal circumstances. Hepcidin Controls the amount 
of iron absorbed from the diet and the release of iron from macrophages from the reticuloendothe- 
lial system. (34) There is a steady state of iron recycling from senescent RBCs that are degraded in 
macrophages into iron. This iron is transported via transferrin in the circulation towards the bone 
marrow where iron is essential for erythropoiesis. Body iron losses are minimal and not regulated.
(B) Iron flows in malaria. During malaria infection the body iron homeostasis changes, but total 
amount of body iron remains similar as is visualized by the change in the size of boxes. Inflamma­
tory factors increase hepcidin release (106>107,B9,96) a consequence, absorption o f iron Grom the diet 
is impaired, iron is redistributed to macrophages, less iron is bound to transferrin, and iron stores 
become depleted. Finally, the erythropoiesis is impaired, due to hepcidin-mediated iron restriction, 
in addition to malaria-specific inhibitory factors (e.g., cytokines, hemozoin). (106) Also, a blood stage 
malaria, infection is hallmarked by hemolysis and increased phagocytosis o f parasitized and nonin- 
fected RBCs, which also augments the macrophage iron content. As suggested, the increased iron 
availability in malaria could facilitate the growth and replication of Salmonellae spp. Abbreviation: 
EP, erythrophagocytosis.
activity. (113)
In addition, the interaction with iron also occurs in the gut lumen, the main starting 
point of invasive NTS disease. For example, oral iron supplementation influenced the 
colonization of Salmonella spp. in the intestines of African children. (114) The num- 
ber of fecal enterobacteriae, predominantly Salmonella spp., significantly increased at 
the cost of non-iron-dependent, nonpathogenic lactobacilli, and this correlated with 
a fecal marker (calprotectin) of gut inflammation, although no overt clinical disease 
was observed. (114^  Recent in vitro data also demonstrated that iron increased the 
virulence of prevalent enteric pathogens, including SalmonellaS115) Indeed, gut mi-
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crobiota differed in iron-depleted versus iron-replete rats, and iron supplementation 
increased neutrophilic infiltration of the colonic mucosa/116-* This is in agreement 
with observations suggesting that the development and function of the gut immune 
system is iron-dependent. (11T)
Taken together, the interaction between the host and Salmonella spp. includes the 
modulation of intracellular iron availability. On the one hand, Salmonella spp. utilize 
various iron acquisition systems to access iron; on the other hand, the host response 
aims to deprive phagosomes of iron, via the endosomal iron exporter Nramp-1, as well 
as the cytosol by way of upregulation of ferroportin. It is conceivable, but speculative, 
that P. falciparum, or Salmonella in phagosomal compartments, modulate these iron 
regulatory proteins to increase their iron availability, whereas the host aims to deplete 
the phagosome of iron.
2.5 How malaria leads to more Salmonella infec­
tions: the link with iron
Despite the strong epidemiological evidence for a link between malaria and invasive 
NTS disease, the biological mechanisms underlying this link are still incompletely 
understood. Several mechanisms have been implicated, including malaria-associated 
impairments of immune function, antigen presentation, cytokine dysregulation, bacte- 
rial seeding of the bloodstream because of microvascular parasite sequestration in gut 
mucosa, and the effects of iron, heme, and the malaria pigment hemozoin. (82) The rel- 
ative importance of iron, heme, and hemozoin and the exact pathways are unknown. 
In any case, the following partly overlapping pathways are potentially involved.
Macrophage iron retention in malaria favors NTS multiplica- 
tion
As described above, malaria leads to intramacrophageal iron sequestration, which is of 
nutritional benefit to the intracellularly growing Salmonella. Apart from the systemic 
effects o f hepcidin and cytokines on macrophageal iron homeostasis, the redistribution 
to specific locations of macrophages also seems important. The observation that 
malaria parasites and Salmonella spp. frequently reside in close proximity is therefore 
of special interest: malaria-infected RBCs are retained in the slow microcirculation of 
the red pulp zone in the spleen/118) whereas Salmonella spp. reside predominantly in 
phagocytic macrophages of the red pulp and marginal zone of the spleen. (119) Another 
study in which mice were coinfected with malaria and NTS also found a marked 
increase in macrophages containing hemozoin and neutrophil infiltrates of Salmonella
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in the red pulp of the spleen. (12°) The latter is also exemplified by the preferential 
presence of Salmonella spp. in (iron-rich) hemophagocytic macrophages. (108)
Modulation of the host immune response by iron
In addition to a direct influence on Salmonella growth, iron status also influences the 
immune effector functions of macrophages, and disturbances in the iron load of the 
body have been linked to increased susceptibility to infections. (59>58) An interesting 
example is the finding that iron loading of macrophages inhibits their interferon 7 
(IFN7 ) expression. (57) IFN7  is an essential part of the immune response against in- 
tracellular pathogens and is crucially involved in protection against both malaria ^ 121 ^  
and Salmonella. (108) The suggestion that hemophagocytic cells provide a place for 
Salmonella spp. to establish a chronic infection as a consequence of iron overload 
that interferes with immune function is in line with this hypothesis. (108) Conversely, 
iron deficiency may negatively affect innate and cellular immunity, (122-* both processes 
important for Salmonella host defense. (59)
Iron-dependent effects of erythrophagocytosis, hemozoin, and 
hemolysis on macrophage function
The vast proportion of iron in the human body is incorporated in hemoglobin. Dur­
ing the intraerythrocytic stage, Plasmodium digests large amounts of hemoglobin 
into heme, which is highly deleterious for both the parasite and the host and therefore 
polymerized by the parasite into inert hemozoin. (123) Macrophages clear both infected 
and uninfected RBCs and hemozoin, which impairs macrophage function. (i20.i23.i24) 
Hemolysis is another component that may explain the increased susceptibility to 
Salmonella spp. during malaria infection. (120>125) Host defense strategies to prevent 
heme toxicity include the binding of heme to hemopexin and albumin, the internaliza- 
tion of these heme protein complexes by macrophages and, ultimately, the degradation 
of heme into iron via upregulation of HO-1 . (93) A recent study showed that malaria 
NTS coinfection of mice causes acute, fatal bacteremia with increased bacterial load; 
features reproduced by phenylhydrazine hemolysis or hemin administration. (12s) In 
this study, heme and upregulation of HO-1 were associated with dysfunctional mat- 
uration and mobilization of granulocytes upon NTS infection, which resulted in au 
impairment of their oxidative burst and bacterial killing ability. In addition, pharma- 
cotherapeutic inhibition of HO-1 prolonged survival of NTS and malaria coinfected 
mice. However, HO-1 was also reported to confer protection against non-cerebral 
forms of severe malaria (126-* and may mediate the well-known protection of sickle cell 
anemia against malaria. (12V) This suggests a dual role for heme and HO-1 and sug- 
gests that chronic hemolysis facilitates NTS infections as a result of modulation of
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host immune responses in combination with the increased iron availability induced 
by HO-1 activity. (125) The three mechanisms described above for the connection be- 
tween malarial infection and invasive NTS may also explain the reported link between 
severe malarial anemia and invasive NTS. The pathogenesis of malarial anemia is 
multifactorial and includes hemolysis, erythrophagocytosis of infected and uninfected 
erythrocytes, and iron delocalization due to the effects of hepcidin, all processes that 
favor invasive NTS, as delineated above and illustrated in Figures 2.1 and 2.2.
Stimuli Iron H em e Inflam m ation p R B C s Salmonella.
H epcidin no effect (90) n.a. t  Ts
e.g., IL-6 , LPS (89>90)
| Tg (106,88) t  T s (110>
Ferroportin t  Pts<87> 
t  Ts (90)
■f Ts^84,85) 4. Ptl, hepcidin (90>91) 
4- Ts
LPS, IFN7 , TNFa
n.a. 'j' T s / (62,110) 
no effect
H -ferritin f  Pts<87> t  Ts<84> t  Ts? n.a. t  Ts/<62’110) 
no effect
H O -1 n.a. | Tg (84,85) t  IL- 10, not LPS<128) tT s < 125> "f Ts (62,110)
D M T -1 4.Ptl(87> 
t  Ts? (8°)
no effect (129) t  Ts LPS,
IFN7 , TNFa (91)
n.a. | Tg (62,110)
Nram p-1 n.a. t  Ts<129) t  Ts LPS<130) n.a. n.a.
Table 2.1: Overview of how iron regulatory proteins of macrophages (vertical col­
umn) are affected by various components related to malaria infection (iron, heme, 
inflammatory stimuli, pRBCs) as well as by Salmonella.
The consequence of these alterations is discussed in Figure 2.1.
Ahbreviations: LPS, lipopolysaccharide; TNFa, tumor necrosis factor ct; IFN'y, interferon 7 ; n.a., no 
reports available, Pts, post-lranscriptional; Ts, transcriptional; Ptl, post-translational; TL, transla- 
tional.
2.6 Concluding remarks and future directions
The interplay between iron, malaria, and invasive NTS infections is intriguing and 
complex to unravel. The epidemiological evidence supporting an association between 
these infections is convincing. Also, the specific features of malaria on one hand, 
whereby parasites reside in erythrocytes and hemolysis, erythrophagocytosis and in- 
flammation are important, and the widely present and intracellular growing NTS on 
the other hand, makes iron a logical candidate to explain this association. More- 
over, NTS, more than other bacteria, especially benefits in this scenario from its 
sophisticated iron acquisition systems. However, host iron status also influences the 
risk for other intracellular infections such as Mycobacterium tubercul.osis. (131>132) Can 
these observations also explain the debated findings of an increased risk for malaria- 
associated morbidity and mortality after iron supplementation? (53) An increased in- 
cidence of invasive NTS may contribute to increased morbidity and mortality after
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iron supplementation in malaria-endemic regions. Diagnostic facilities for invasive 
NTS disease are not widely available in many malaria-endemic countries, and, es- 
pecially in areas where asymptomatic parasitemia is common, severe febrile disease 
may incorrectly be attributed to malaria. Therefore, we suggest that future trials 
assessing the safety of iron supplementation should specifically include diagnostics 
for invasive NTS. Moreover, molecular studies exploring the interaction between P. 
falciparum and macrophage iron homeostasis are needed to understand the role of 
iron in the interplay with host immune responses. Modulation of macrophage iron 
regulatory proteins and iron distribution may also provide an explanation for NTS 
bacteremia during malaria infections that warrant further studies. These insights 
may have important implications in nutritional public health programs in developing 
countries.
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Ven
Reply to
Host-mediated regulation of superinfection in malaria. Portugal S, Carret C, 
Recker M, et al. Nat Med 2011;17(6):732-7
3
Nature Medicine 2011;17(ll):1341-42

To the Editor:
With great interest we read the paper by Portugal, et a l /106) who reported that 
increased production of the iron-regulatory hormone hepcidin is responsible for inhi- 
bition of the liver-stage of malaria infection during ongoing blood-stage parasitemia. 
Febrile malaria in humans is indeed associated with high circulating hepcidin lev- 
els, but, in our opinion, two aspects of this study need further consideration. 
First, the authors excluded a role for immune responses in preventing malaria su­
perinfection by using mice deficient in components of various pathways of the innate 
and adaptive immune systems. However, the authors did not report the circulating 
hepcidin concentrations or hepatic hepcidin expression levels in these mice. Their 
model predicts that hepatic hepcidin expression would be unchanged in these mice, 
yet inflammatory cytokines are key inducers of hepatic hepcidin expression. (5>133) 
Moreover, confirmation of their findings in hepcidin-knockout mice would have fur­
ther strengthened their conclusion. (134)
Second, the limited data available in humans are not apparently consistent with the 
idea that an increase in hepcidin production inhibits liver-stage malaria infection. 
Chronic hepatitis C virus (HCV) infection is highly prevalent in many maiaria- 
endemic regions, and recent evidence has shown HCV infection to be associated 
with reduced hepatic hepcidin expression with secondary hepatocyte iron accumu- 
lation. (135>136) According to the model proposed by Portugal, et al. (101) this would be 
expectod to result in a favorable growth environment for liver-stage parasites. Instead, 
the emergence of blood-stage malaria parasites was delayed in people with HCV in 
Gabon. (13T) Of course, other factors related to HCV infection, such as immunosup- 
pression, may negate the effects of hepcidin on the liver-stage infection, and these 
clinical observations, therefore, do not fully refute a role for hepcidin.
In conclusion, Portugal, et al. 1^06^  have reported intriguing data that suggest a role 
for hepcidin in malaria pathogenesis beyond anemia and iron dysregulation, but ad- 
ditional clinical studies are needed to substantiate the claims.
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Malaria-induced alterations in 
macrophage iron handling: an 
explorative study
Susanne van Santen, Quirijn de Mast, Erwin T. Wiegerinck, André J.A.M. van der 
Ven, Dorine W. Swinkels
4- Malaria and Macrophage Iron Handling
Abstract
A im : Iron supplementation remains controversial in malaria endemic areas since the 
balance between beneficial versus possible harmful effects has not yet been set. To 
increase our insights in the potential mechanisms by which iron status could affect 
parasite replication and hence the clinical sequelae of malaria, we explored the effects 
of P. falciparum infected red blood cells (pRBCs) on macrophage-derived hepcidin 
and other components of cellular iron homeostasis.
M ethods: The gene expression of the iron regulatory genes hepcidin (Hamp), fer- 
roportin, HO-1, H-ferritin, DMT-1 as well as intracellular iron concentrations were 
assessed in human M l differentiated macrophages and in mouse RAW macrophages af- 
ter challenge with either pRBCs or uninfected red blood cells (uRBCs). Macrophages 
were also co-stimulated with either IFN7  or hepcidin and primed with an iron chela- 
tor. Intracellular iron concentrations were measured with the calcein AM method and 
by Energy-dispersive X-ray microanalysis.
Results: Phagocytosis of uRBCs and pRBCs influenced M l and/or mouse macro­
phage iron homeostasis, including heme-mediated upregulation of ferroportin, ferritin 
and HO-1 transcripts and an increase in the labile iron pool and cellular ferritin ex­
pression. We observed no increase in macrophage hepcidin expression after exposure 
to pRBCs or uRBCs. Compared with uRBCs, pRBCs had no significant effects on im­
portant iron handling genes, neither by direct interaction of pRBCs with macrophages, 
nor after priming and co-stimulation with hepcidin or IFN7 . pRBCs did also not 
change the expression of iron genes following iron deprivation of macrophages. 
Conclusion: Our data support the hypothesis that malaria affects iron homeostasis 
of macrophages; however, erythrophagocytosis in general appears to be more impor­
tant than specific P. falciparum-induced inflammatory changes in macrophage iron 
genes. Erythrophagocytosis is associated with an increase of intracellular iron, ferro­
portin and HO-1 gene expression.
4.1 Introduction
The life cycle of the Plasmodium parasite occurs primarily within erythrocytes and 
includes the invasion of red blood cells (RBCs) after an initial growth stage in the 
liver, followed by a rupture of these RBCs by which per mature parasite approxi- 
mately 20 new parasites are released, ready to infect new RBCs. 1^5-* The clearance of 
parasitized RBCs (pRBCs) by macrophages during blood stage malaria infection is 
an important part of the host defense against Plasmodiae. Phagocytosis of uninfected 
RBCs (uRBCs) is also increased during malaria. (14>18) In response to the phagocyto­
sis of RBCs, macrophages up-regulate the iron metabolizing protein heme oxygenase
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(HO-1), the enzyme responsible for the degradation of heme into iron, as well as the 
iron storage protein ferritin that sequesters potentially toxic cytosolic iron /129,6,138) 
In addition, the transcription or function of other iron regulating proteins that play a 
role in macrophage iron recycling may also change, including the transporters fer- 
roportin, divalent metal transporter-1 (DMT-1) and natural resistance-associated 
macrophage protein-1 (Nrarnp-1). ( I39,138>140,16) DMT-1 and Nramp-1 localize mainly 
to early and late phagolysomes of macrophages, respectively, and are involved in 
iron export from these organelles into the cytosol, while ferroportin is the sole cel- 
lular membrane bound iron exporter. (17,5) Both iron and heme have important roles 
in transcriptional and posttranscriptional control of all these iron regulatory pro­
teins. As a consequence, erythrophagocytosis results in increased iron accumulation 
in macrophages/129,84) and increased cellular iron release/129,139,138) Increased iron 
turnover has indeed been shown in malaria patients, however, not only because of 
increased erythrophagocytosis but also because of intra- and extravascular hemoly- 
sis. (19>20>124) The activation of the innate immune response during parasitemia may 
also influence systemic iron homeostasis, among others by the upregulation of the 
iron regulatory peptide hormone hepcidin/94,22,96,95) Hepcidin causes the degrada­
tion of ferroportin leading to reduced uptake of iron from duodenal cells and iron 
sequestration in reticuloendothelial cells. (5) The peptide is mainly produced by hepa- 
tocytes and induced among others by the inflammatory cytokines interleukin (IL)-6, 
IL-1 and pRBCs. (89>106.141.142) However, inflammatory and infectious stimuli includ­
ing P. falciparum may also directly alter macrophage iron handling via upregulation 
of macrophage hepcidin transcripts/143,144,145,90,89,88,146,147) Macrophages are char- 
acterized by heterogeneity, covering a spectrum of activation status including the 
classic pro-inflammatory (Ml) phenotype, induced among others by lipopolysaccha- 
rides and interferon-7 (IFN7 ), as well as the alternative activated (M2) macrophage, 
mirroring T  helper cell (Th)l/Th2 polarization)/148) In acute malaria, IFN7 -driven 
Thl cells are dominating the host response while Thl /Th2 balance may be shifting 
upon multiple malaria infections. (149) Consequently M l macrophages may be mostly 
present during acute malaria infections, however no data on the presence of M l/M 2 
macrophages during malaria are presently available. Iron handling of M l or M2 
macrophages is however very different as pro-inflammatory cytokines trigger a down- 
regulation of ferroportin and HO-1 and an upregulation of ferritin and Nramp-1 lead­
ing to iron sequestration in M l macrophages while M2 macrophages are characterized 
by an iron release-prone phenotype. (150>151) Iron accumulation in M l macrophages is 
a well known bacteriostatic mechanism and one of the mechanisms underlying the 
anemia associated with chronic inflammation. Several aspects during malaria may 
interfere differently with the described players of macrophage iron handling. There- 
fore, the present study explored the in vitro effects of pRBCs on macrophage iron 
concentration and distribution as well as the expression of iron regulatory proteins
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hepcidin, ferroportin, HO-1, Nramp-1, ferritin, and DMT-1. In addition, the effects 
of iron chelation, hepcidin and IFN7  on macrophage iron handling after exposure to 
pRBCs were explored.
4.2 Methods
Materials and stimuli
Polyclonal antibodies to RBCs were obtained from Abcam, probenecid was from 
Sigma Aldrich. Calcein AM (Invitrogen) was diluted to 1 mM in DMSO stock so- 
lution, stored in -20“C and used in final concentration of 0.2 fiM. Lipopolysacharide 
(LPS) was used in 10-100 ng/ml (Sigma). Recombinant mouse IFN7  (R&D systems) 
was dissolved in PBS with 0.1% LPS-free bovine serum albumin and added to cells 
at 10 ng/ml. Synthetic hepcidin-25 (Peptide International) was aliquoted in 0.1 nM 
and stored in -80°C before use. Bioactivity of synthetic hepcidin-25 was confirmed by 
a cell-based ferroportin-internalization assay as described by Nemeth et al, ^  which 
was kindly performed by Dr Gille, (Pieris AG, Freising, Germany). Freshly prepared 
ferric ammonium citrate (FAC) and desferroxamine (DFO) were from Sigma and sal- 
icylaldehyde isonicotinoyl hydrazone (SIH) was a generous gift of Drs Cabantchik 
(Hebrew University of Jerusalem, Israël) and Ponka (McGill University, Montreal, 
Canada).
Cells and stimulation assays
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of healthy 
donors by Ficoll-Paque (Pharmacia Biotech) gradiënt. PBMCs were resuspended in 
culture medium (RPMI 1640) supplemented with gentamycin, glutamine, pyruvate 
and 10% fetal bovine serum (Gibco, Invitrogen) at a concentration 10x106 cells/ml. 
Adherent monocytes were kept for 6 days in 5% CO2 at 37°C in the presence of 50 
ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF, R&D Systems) 
for differentiation in M l macrophages.
RAW 264.7 mouse macrophages (gift from Prof Cabantchik, further indicated as 
RAW macrophages) were similarly cultured and maintained in Dulbecos modified 
Eagles Medium (DMEM, Gibco, Invitrogen) supplemented with 10% fetal bovine 
serum, Hepes, glutamine, pyruvate, penicillin and streptomycin. RAW cells lack a 
functional Nramp-1 protein. -152^ LPS or IFN7  have been reported to increase Nramp- 
1 mRNA, (153) without effecting Nramp-1 protein expression of these cells. (154^  Un- 
less otherwise specified, the RAW macrophages were seeded in a concentration of 
0.75xl06/ml and allowed to adhere overnight to obtain a confluence of approximately 
80% before incubation with the various stimuli for 3 or 20 hrs. In priming/co- 
stimulation experiments RAW cells were incubated with 10 ng/ml IFN7 , 100 nM
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hepcidin or 50 fiM DFO for 18 hrs, after which plates were carefully washed and su- 
pernatants were replaced with fresh medium containing the indicated stimuli for the 
appointed duration in the presence of 10 ng/ml IFN7  or 300 nM hepcidin, respectively.
P. falciparum culture
Asynchronous cultures of NF54 strain parasites were harvested at a parasitemia of 
10-20% and the mature asexual stages were purified by centrifugation on a 63% 
Percoll density gradiënt as previously described. (155) In all experiments pRBCs were 
immediately utilized, in a 1:5-10 ratio of pRBCs to macrophages. uRBCs were derived 
from the same RBC pool as their parasitized counterparts. These cells were either 
kept for two days in separate, but similar culture system as the pRBCs (co-cultured 
uRBCs), or stored in the fridge at 4°C for two days (cooled uRBCs).
Opsonization and phagocytosis of RBCs
After purification, RBCs were incubated for 60 minutes at 37° C with anti-RBC anti­
body (1:200). The RBCs were washed twice to remove unbound antibody and were 
resuspended to the required concentration before addition to the cells. At the in­
dicated incubation times, the erythrophagocytosis process was ended by carefully, 
but extensively washing of the cells with warm PBS, before and immediately after 
non-ingested RBCs were lysed for 3 minutes in NH4CI at 37°C. The same treatment 
was applied to all stimulation experiments. We observed that untreated co-cultured 
uRBCs and pRBCs were minimally phagocytosed by the differentiated macrophages 
and RAW cells. In contrast, immunoglobulin treated, opsonized RBCs were clearly 
erythrophagocytosed.
R N A  extraction and Q-PCR
After treatment, cells were lysed with Qiagen lysis buffer supplemented with f3- 
mercaptoethanol. Total RNA was extracted using the commercially available RNAeasy 
kit according to the manufacturer instructions (all from Qiagen). The mRNA yield 
and purity were measured on a spectrophotometer (NanoDrop 1000, Thermo Scien- 
tific). cDNA synthesis was performed with a reverse transcription master mix from 
Biorad following the manufacturers instructions. Samples were stored at -20°C un- 
til use. The expression of target genes was analyzed by Q-PCR on the ABI prism 
7900 sequence detection system (Applied Biosystems). Each Q-PCR was performed 
in duplicates in a reaction mixture using SybrGreen or TaqMan Universal Master 
mix as described previously/156) Primer sequences are shown in Table 4.1 and all 
are purchased from Applied Biosystems. Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was used as housekeeping gene. The threshold cycle values of each sample
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were normalized to GAPDH and expressed by the delta delta method as described 
previously. (157-1
Western blot
Expression of ferroportin and ferritin was evaluated at the protein level in RAW cells. 
Ferroportin antibody was purchased from Alpha Diagnostics; ferritin and /3-actin an- 
tibodies were from Sigma. Subcellular protein fractions were extracted from cells 
that had been stimulated with opsonized uRBCs and pRBCs for 20 hrs as described 
above in 6 well plates. According to the Proteoextract subcellular extraction kit 
(Calbiochem, Merck) we purified cystosolic and membrane fractions. Total protein 
content was determined by Bradford assay. Samples were mixed with Sample Buffer 
(0.5 M Tris (hydroxymethyl)aminomethane hydrochloride (Tris-HCl), pH 6.8, glyc­
erol, 10% sodium dodecyl sulfate (SDS) bromophenol blue and milli-Q water) and 
heated at 95°C for 10 minutes. Proteins were electrophoretically separated on a 15% 
SDS-polyacrylamide gel. The protein was transferred to a Hybond low-fluorescent 
polyvinylideendifluoride (LFP PVDF) membrane (GE Healthcare), which was then 
incubated with blocking solution (Odyssey Blocking Buffer with PBS 1:1) for 1 hr 
followed by an overnight incubation at 4°C with the primary antibody (1: 500 rabbit 
antihuman ferritin, 1:500 rabbit antimouse ferroportin antibody, and 1:20 000 mouse 
antihuman /3-actin). After several washes in PBS 0.1% Tween 20, the blots were 
incubated with 1: 20 000 Alexa Fluor-680 labeled goat antirabbit (Molecular probes) 
and 1: 10 000 IRDye800 labeled goat antimouse (Rockland) at room temperature and 
revealed by infrared fluorescence detection (Licor Odyssey scanner).
Assessment of labile iron
The calcein AM assay was applied to measure the cytosolic labile iron pool. l-158-) Cells 
were grown in glass bottom culture dishes and after the end of erythrophagocytosis 
incubated with Calcein AM and probenecid for 20 minutes. Cells were visualized 
real time using a reverse fluorescence microscope (80x). Minimal 10 visual fields were 
imaged per single culture dish, before and after 5 minutes incubation with the iron 
chelator SIH. The difference in fluorescence before and after chelation of the selected 
macrophages, expressed as the delta fluorescence, was analyzed with Image J Software 
in the corresponding fluorescence images. Also, the number of phagocytosed RBCs 
per macrophage were recorded.
Energy-Dispersive X-ray spectroscopy
Transmission Electron Microscopy and Energy-Dispersive X-ray (EDX) microanalysis 
were performed for Identification of RAW cells and their composition. EDX micro-
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analysis in the transmission electron microscope allows determinations on much finer 
scale, using semi-thin sections. RAW cells were incubated with the indicated condi- 
tions for 20 hrs, carefully collected in a tube and spun down after which supernatant 
was replaced and the cell pallet fixed with 2% glutaraldehyde in 0.1 M sodium ca- 
codylate buffer for 2 hrs at room temperature. Samples were washed three times with 
0.1 M sodium cacodylate buffer. Samples were then dehydrated and processed for em- 
bedding in epon resin. Polymerization was performed in a 60’ C oven. Thin sections 
were then cut using a diamond knife and mounted on copper grids (100 mesh). For 
EDX measurements the ultrathin sections were approximately 200 nm and examined 
using an Jeol 1200 /  STEM (Jeol Ltd., Japan) in combination with a Thermo Noran 
microanalysis six system (Thermo Fisher Scientific). Accelerated voltage of 60 KeV 
was used for X-ray microanalysis. X-ray spectra and maps for iron distribution were 
acquired.
Statistics
Data are presented and analyzed using Graphpad Prism version 5 (GraphPad Software 
Inc) and SPSS statistics software version 18. Statistical tests used are indicated in 
the Figure legends. P-values <.05 were considered statistically significant.
4.3 Results
Effect of uRBCs and pRBCs on iron handling genes in human 
macrophages
Hepcidin gene expression is not increased
Whereas LPS as a positive control induced a strong increase in Hamp mRNA ex­
pression, exposure to pRBCs resulted in a small decrease in Hamp gene expression 
compared to uRBCs after 3 and 20 hours incubation (Figure 4.1A and 4.1G). There 
was no difference in Hamp mRNA expression after exposure to non-opsonized or op- 
sonized uRBCs or pRBCs.
Since IL-6 is a well known inducer of Hamp expression, (89-147) We were interested in 
the effect of pRBCs on IL-6 gene expression, using LPS as a positive control. Indeed, 
LPS stimulation of M l macrophages significantly increased IL-6 mRNA expression, 
while opsonized pRBCs increased IL-6 mRNA significantly compared to opsonized 
uRBCs at 20 hrs incubation. Stimulation with non-opsonized RBCs only marginally 
increased IL-6 expression (Figure 4.1B and 4.1H).
Taken together, P. falciparum infected RBCs increased IL-6, but not Hamp expression 
in M l macrophages irrespective of whether RBCs were opsonized or not. Moreover,
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effects of pRBCs on Hamp expression were not significantly different to those observed 
for uninfected RBCs.
Expression of (other) genes involved in iron handling
Ferroportin is as the sole cellular iron exporter of importance in the regulation of 
macrophage iron content. The inflammatory stimulus LPS is known to suppress fer­
roportin expression, which results in macrophage iron retention. (143,159,91,6,160,161,90) 
Also in our experiments, LPS decreased ferroportin expression in the M l macrophages 
after an overnight incubation (Figure 4.1C and 4.11).
In contrast, previous studies indicate an increase in ferroportin transcripts in mouse 
macrophages after erythrophagocytosis mediated by heme iron /84’85’129) Surprisingly, 
we found a downregulation of ferroportin mRNA between 2 and 6 hrs incubation with 
opsonized uRBCs, no effect using opsonized pRBCs, and small increase with nonop- 
sonized RBCs and after iron loading (FAC).
Release of iron from heme requires heme oxygenase 1 (HO-1) activity, which is in­
creased by erythrophagocytosis and hem e/84’85,129) Indeed, we found a significant 
upregulation of HO-1 gene expression of M l macrophages at all time points with 
both opsonized uRBCs and pRBCs. Upon 2 to 6 hrs incubation this increase was sig­
nificantly higher for pRBCs compared to uRBCs. As expected, non-opsonized RBCs 
had no effect on HO-1 (Figure 4.1D and 4.1J). Also, LPS did not affect HO-1 expres­
sion, corroborating previous studies with PBMCs. (16°)
Likewise, non-opsonized RBCs did not induce H-ferritin gene expression in macr­
ophages, while erythrophagocytosis of both control and parasitized RBCs increased 
H-ferritin gene expression significantly after an overnight stimulation (Figure 4.1F 
and 4.1L). H-Ferritin is an important protein that stores iron to protect against ox- 
idative damage and is transcriptionally regulated by oxidative stress and heme and 
post-transcriptionally regulated by iron and heme. (-162-)
We also assessed the expression of iron transporters DMT-1 and Nramp-1. (163) Both 
have been described to influence iron distribution within the cell and are upregu- 
lated after erythrophagocytosis/140,16) although regulatory mechanisms are unclear. 
Inflammatory stimuli have been reported to increase Nramp-1 expression, probably 
in an attempt to control intracellular infections/17) In line with these reports, we 
observed an transient increase in Nramp-1 expression after 3 or 4 hrs incubation 
with LPS (Figure 4.1E and 4.1G). The effect of stimulation with opsonized or non- 
opsonized pRBCs on Nramp-1 were non-significant, whereas iron loading with FAC 
induced its expression at 3 hrs. Moreover, none of the stimulations, neither uRBCs 
nor pRBCs affected the transcription of the iron importer DMT-1 (data not shown), 
which is in agreement with posttranscriptional regulation of DMT-1.
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Figure 4.1: Gene expression of iron regulatory genes in M l polarized macrophages 
afber stimulation with nonopsonized (nonops) and opsonized uninfected red blood 
cells (uRBC) or parasitized RBCs (pRBC), LPS orferric ammonium citrate (FAC).
The upper panel represents the 3 and 20 hrs stimulations (A-F), respectively; the lower panel the 
experiments with opsonized RBCs for 2, 4, 6 and 20 hrs (G-L), respectively. Results are shown as 
relative differences as compared to the me an value of unstimulated macrophages, which is set at 1 and 
presented in the dashed horizontal line. Data are expressed as me an with the error bars presenting 
the Standard error of the rnean of 5 individual donors (3 donors for LPS and FAC stimulations in 
A -F  and the 6 hrs experiments in G-H). Mann-Whitney non-parametric testing was used to compare 
opsonized uRBCs, pRBCs and LPS with Controls and Friedman non-parametric testing for dependent 
data was appüed to assess the difference per stimulus over time within the 3 related time points (G-L; 
*P<0.05, **P<0.01, ***P<0.005). With Wilcoxon rank test uRBCs were compared with pRBCs 
per time point (# P < .05)
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In summary, stimulation of M l differentiated human macrophages with both uRBCs 
and pRBCs induced HO-1 and ferritin expression while no changes in ferroportin, 
Nramp-1 or DMT-1 transcripts were noticed.
Effect of uRBCs and pRBCs on iron regulatory genes in 
mouse macrophages (RAW Cells)
In establishing a practical laboratory model to continue our studies on macrophage 
iron metabolism, focusing on intracellular iron staining and priming, we assessed the 
response of pRBCs in mouse RAW macrophages. These cells are known to increase 
Hamp mRNA upon incubation with L P S  or other inflammatory stimuli, (i43.164>110) 
( 159,90,160) w j1jc j1 we confirmed for L P S  after 3  hrs incubation (Figure 4 .5 ) .
We compared the effects of opsonized uRBCs and pRBCs on iron regulating genes of 
RAW cells with the M l differentiated macrophages. In general, these response were 
similar: no significant changes in Hamp or DMT1 mRNA; increases in HO-1 and 
ferritin transcripts; and no significant differences induced by pRBCs in comparison 
to uRBCs. The increase in IL-6 mRNA was similarly more with pRBCs compared to 
uRBCs, but the effect was in contrast to the human macrophages only observed after
3 hrs incubation (data presented in Figure 4.5).
In contrast to human macrophages, mouse macrophages increased their ferroportin 
mRNA upon incubation with uRBCs and pRBCs, which was more for uRBCs after 
an overnight incubation.
No synergistic effects after IFN7  priming and co-stimulation
Since IFN7  is crucially involved in protection against malaria, we were interested 
to study the effects of pRBCs on the iron regulatory genes of interest after priming 
and co-incubation with IFN7 . Interestingly, in co-infection with intracellular living 
bacteria, IFN7  has been found to synergistically increase iron uptake, ferroportin ex­
pression and iron export, HO-1 and H-ferritin expression, while IFN7  alone had no 
affect on iron uptake and release. (165’m ) As a consequence, the co-infection resulted 
in reduced amounts of labile iron and restricted bacterial growth. During malarial 
infections IFN7  is known to enhance phagocytosis, to increase inducible nitric oxide 
synthase (iNOS) production of monocytes and to prime toll like receptor (TLR) re- 
sponses in reaction to blood stage parasites.(-121^  However, the influence of IFNy in 
macrophage iron metabolism during malaria is unknown.
IFN7  alone had no effects on macrophage Hamp expression and suppressed ferroportin 
mRNA (Figure 4.5A), corroborating previous findings. C144*90*165.91.111) jn addition, no
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changes in HO-1, H-ferritin and DMT-1 gene expression of RAW cells after IFN7  in- 
cubation were observed.
In the mouse macrophages, priming with IFN7  and 3 hrs co-stimulation with uR- 
BCs or pRBCs had no effects on Hamp mRNA (Figure 4.6). IFN7  priming and 
co-stimulation with RBCs increased IL-6 mRNA, which was more for pRBCs com- 
pared to uRBCs at both time points. There was no synergistic effect with pRBCs 
after IFNy priming and co-stimulation for any of the other iron regulatory genes of 
interest. In agreement with our previous observations in non-primed conditions, the 
increase in ferroportin and HO-1 mRNA was relatively suppressed after co-stimulation 
of pRBCs with IFN7  compared to control RBCs (Figure 4.6C and 4.6D).
No synergy of pRBCs with hepcidin priming and co-stimulation
Hepcidin is increased in malaria infections. (95>94>166) By adding hepcidin to our in vitro 
model we studied the hepcidin-effect on macrophage iron homeostasis during blood 
stage malaria infection. However, we found no changes of Hamp gene expression after 
hepcidin pre-incubation followed by co-stimulation with uRBCs or pRBCs (Figure 
4.6). Moreover, no additional effects of hepcidin on ferroportin and HO-1 expression 
after erythrophagocytosis were observed. Also, hepcidin priming and stimulation 
suppressed the increase in IL-6 mRNA after incubation with uRBCs and pRBCs, in 
line with a previous report after hepcidin priming and LPS-incubation. (16r)
No differences in iron genes with pRBCs after iron depletion
Immune responses of iron-depleted macrophages were altered upon incubation with 
the pro-inflammatory stimulus LPS, i.e. impaired in some studies (168>169) and en- 
hanced in others, (167-170) which may be of relevance since iron deficiency is frequently 
encountered in malaria endemic areas. However, we observed no change in Hamp 
expression with either uRBCs or pRBCs stimulation in iron deprived RAW cells and 
no other specific effects on the iron genes of interest (Figure 4.6).
Protein expression of ferroportin and ferritin
Since ferroportin and ferritin are also importantly regulated at the posttranscriptional 
level, we aimed to support our findings at the protein level in RAW cells. In contrast 
to our findings of ferroportin mRNA, we found a decrease in ferroportin protein after 
an overnight incubation with uRBCs or pRBCs, and no change in ferroportin protein 
after LPS incubation (Figure 4.2). However, ferritin protein was clearly enhanced 
after incubation with pRBCs, while no change in expression was observed for uRBCs 
and LPS compared to control condition.
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Figure 4.2: Ferroportin and ferritin protein content alter overnight incubation in 
R A W  cells with opsonized uninfected red blood cells (uRBC) or parasitized RBCs 
(pRBC) and LPS.
Ferroportin was assessed in the membrane fraction (n=3) and ferritin in the cytosolic protein fraction 
(n=l). (A) Mean reiative difference compared to control condition normalized for /3-actin concentra- 
tion as quantiSed by infrared fluorescence detection. (B) Representative blot of ferroportin (upper 
panel) and ferritin (lower panel), lane 1 to 6: control, uRBCs, pRBCs, LPS, ferritin Standard and 
Odyssey marker (M W  indicated in kDa). /3-actin is shown (42 KDa). Arrows show Ferroportin (Mw 
of 62 kDa) and ferritin (H-ferritin 21 kDa and L-ferritin 19-25 KDa).
Intracellular iron assessment after infection with uRBCs and 
pRBCs
With EDX microscopy cellular spot measurements of elemental compound composi- 
tions are performed, raising the opportunity to measure elemental iron at subcellular 
levels. We stimulated RAW macrophages with uninfected and parasitized RBCs and 
measured iron counts in organelles. We observed similar low number of iron counts 
in the various parts of the cell that were below the detection level after incubation 
with both uRBCs and pRBCs. However, high counts of iron were detected in spots 
in macrophages infected with pRBCs, compatible with the distribution of hemozoin 
(Figure 4.3, spot 1 and 2). Hemozoin is an insoluble crystal containing iron that is 
produced by the parasite to protect itself from heme that has become available after 
its digestion of hemoglobin in the cell. Apparently, this technique is not sensitivé to 
differentiate small differences in iron concentrations throughout the cell. The labile 
iron pool was assessed by the Calcein AM method. This methodology allowed to esti- 
mate differences in cytosolic iron concentrations and to visualize macrophages with or 
without internalized RBCs. In line with expectations, macrophages with internalized 
RBCs had increased cytosolic iron in comparison to macrophages without (Figure 
4.4A). Overall, pRBCs increased the labile iron pool more than uRBCs.
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Figure 4.3: Illustration ofelectron and Energy-Dispersive X-ray (EDX) microscopy 
in macrophages incubated with pRBCs for 3 hrs.
(A) Plain electron microscopy picture of an individual R A W  cell with parasite products (hemozoin) 
engulfed. (B) EDX spot measures (IDs 1 to 15) throughout the cell with corresponding iron (Fe) 
counts presented on the right. The background level for Fe is around 30 counts. (C) and (D) 
Related pictures of 6 hrs continuous EDX-exposure: the green spots in (D) localize iron counts (Fe 
K) corresponding with the structures in (C, grey image). The concentration of black spots in (C) and 
green spots in (D) represent iron-rich hemozoin. These illustrations are courtesy of Dr. H. Dijkman 
(Department of Pathology, Radboud UMC, Nijmegen).
Intracellular iron after short-term IFN7 , FAC or hepcidin co-stimulation
In the presence of IFN7  was the increase in labile iron after infection with pRBCs 
reduced (Figure 4.4B), compatible with previous observation with Salmonella co- 
infections. (62) Iron loading by means of FAC co-incubations resulted in similar levels 
of cytosolic iron content irrespective of the macrophages had RBCs engulfed or not 
(Figure 4.4C). In addition, labile iron was increased in RAW cells in the presence of 
both hepcidin and RBCs (Figure 4.4D, note the difference in scale of y-axis), which is
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Figure 4.4: The intracellular iron content upon 3 hrs incubation with uninfected 
or parasitized RBCs.
Intracellular iron is assessed by the calcein A M  method. Depicted are iron measurements of 
macrophages (m) that had been stimulated with control RBCs, but had not engulfed any RBCs 
(left white bar), that had engulfed uRBCs (light grey bar), and similarly macrophages that had been 
in contact with pRBCs but had not engulfed any (right white bar) and macrophages with pRBCs 
phagocytosed (dark grey bar). In addition, cells received no additional stimulations (A), were co- 
stimulated with IFN-y (B), FAC (C) and hepcidin (D). Control RBCs are not co-cultured. Results 
are depicted relative to the me an value measured in control macrophages. * significant differences 
of uRBCs with pRBCs for Buorescence in macrophages without RBCs or with RBCs, respectively, 
by Kruskal- Wallis and Dunns post-testing.
in agreement with hepcidin-induced cellular iron retention. Interestingly, this increase 
was less in pRBCs than in not co-cultured uRBCs.
In conclusion, short-term IFN7  and hepcidin co-stimulation relatively reduced the in­
crease in cellular labile iron after incubation with pRBCs compared to uRBCs. These 
observations suggest that under these conditions, the host aims to reduce macrophage 
iron availability as a defense strategy or that parasites modulates iron flows towards 
other cellular compartments, among which are mitochondria or lysosomes.
4.4 Discussion
We observed that erythrophagocytosis of uRBCs and/ or pRBCs had major influences 
on macrophage iron homeostasis that involved heme-mediated upregulation of ferro­
portin and HO-1 transcripts, an increase of the labile iron pool and cellular ferritin 
expression. Secondly, we observed no increase in macrophage hepcidin gene (Hamp) 
expression after exposure of macrophages to pRBCs. Moreover, we demonstrated that 
relative to uRBCs, pRBCs did not induce significant effects on important macrophage 
iron handling genes, neither by direct interaction of pRBCs with macrophages, nor 
by priming and co-stimulation with hepcidin or IFN7 . These iron genes were also not 
altered upon exposure to pRBCs after iron deprivation of macrophages. 
Macrophages play an essential role in the recycling of iron by continuous erythrophago-
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cytosis of senescent RBCs. Blood stage malaria infections are typically featured by 
an enhanced process of erythrophagocytosis and hemolysis that involves both unin­
fected and parasitized RBCs. (19’2°) Both processes result in an increased availability 
of heme, as was also present in our model. Hemoglobin and heme have important 
functions in the transcriptional regulation of HO-1, ferroportin and ferritin. (160>85>84>6) 
Indeed, uRBCs and pRBCs increased the gene expressions of HO-1, ferroportin and to 
lesser extent H-ferritin in human and mouse macrophages. This in combination with 
reduced ferroportin protein expression (this difference is discussed below) may explain 
the increased cellular iron contents observed after erythrophagocytosis and indicate 
that the turnover of macrophage iron is likely to be increased during malaria. In 
human macrophages we found that opsonization was required for these effects, which 
suggests a specific role for erythrophagocytosis in the regulation of these genes.
The inflammation-mediated effects of malaria infection on hepcidin and other iron 
regulatory genes were small suggested by the similarities in the responses induced 
by uRBCs and pRBCs. This is likely explained by a dominance of heme after ery­
throphagocytosis of pRBCs in combination with the observation that P. falciparum 
is, in comparison to LPS, only a weak inducer of IL-6 mRNA.
Interestingly, ferroportin was relatively less upregulated after infection with pRBCs 
compared to uRBCs in RAW cells. This phenomenon was also observed after co- 
infection and priming with IFN7  and hepcidin. Possibly malaria-related factors op- 
pose the dominance of heme in transcriptional ferroportin expression which agrees 
with the suppressive effects of pro-inflammatory factors on ferroportin mRNA. (m >143) 
(90,159,91,160,161) -p0 note) an overnight incubation with RBCs suppressed ferroportin 
protein and this apparent discrepancy suggests differences in control of ferroportin 
that is subject to posttranscriptional regulation by the binding of the iron regulating 
protein (IRP) on the iron responsive element (IRE) of the ferroportin mRNA and 
posttranslationally via hepcidin. (87)
The dominant effects of heme may also explain why in malaria no synergy in upreg- 
ulation of ferroportin, HO-1 and ferritin mRNA was observed in co-stimulation with 
IFN7 , as was observed in contrast to other intracellular growing pathogens Salmonella 
spp. and mycobacteria in conjunction with IFN7 .(165>]n ) Moreover, it may explain 
why priming and co-stimulation of hepcidin, importantly present in malaria infec­
tions/95’94’166) had no additional effects on iron handling genes in pRBCs treated 
macrophages.
Our work also suggests that hepatocytes are the main source of the elevated levels 
of hepcidin in malaria, considering that neither in humans nor in mice macrophages 
Hamp mRNA is increased upon challenge by indirect malaria-related factors or by 
direct phagocytosis of pRBCs. This contrasts with previous findings in PBMCs or 
differentiated macrophages in which pRBCs increased Hamp mRNA/88’147) and this 
may argue for cell or plasmodial strain specific responses. Alternatively, the increased
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macrophage iron load as a result of hemolysis and erythrophagocytosis may weaken 
the inflammatory stimulus on hepcidin expression by suppressing macrophage Hamp 
upregulation^167) In conclusion, our data suggest that macrophage hepcidin produc- 
tion does not contribute to elevated serum hepcidin levels as observed in patients with 
malaria infections.
In conjunction, the here described changes in ferroportin, HO-1 and H-ferritin tran­
scripts suggest increased availability of intracellular iron in bloodstage malaria and 
the subtle suppression of the ferroportin mRNA increase after phagocytosis of pRBCs 
may argue for P. falciparum specific effects on (sub)cellular iron distribution. Unfor- 
tunately, we were not able to assess subcellular iron. We tried to assess endosomal 
iron by the use of an (in-house synthesized) endosomal iron probe as published by 
Fakih and coworkers/172) but were not able to reproduce their findings (data not 
shown). As a proof of principle, with the EDX method high elemental iron counts 
were measured in hemozoin structures of the parasite. However, the methodology 
was not sensitive enough to detect differences in the low-iron concentration region 
between the various subcellular locations. Therefore, we used the calcein AM assay 
that reflects the cytosolic labile iron pool, but does not inform us about any other iron 
located in other compartments of the cell. Nevertheless, with this assay, we were able 
to confirm that erythrophagocytosis of both uRBCs and pRBCs result in increased 
intracellular iron and that the labile iron pool was more increased with pRBCs. This 
suggests an alteration of cellular milieu that could be beneficia! for the parasite. On 
the other hand, IFN7  and hepcidin opposed this pRBC-induced increase in labile iron 
fitting with the concept of nutritional immunity and host-mediated iron-withholding 
responses. (59)
The design of our studies faced several challenges that may have led to some limita- 
tions. First of all our findings feature a background noise with relative large Standard 
errors in the majority of the results, compatible with the biological variation of live 
parasites and PBMCs. Second, since cells were continuously stimulated with erythro­
cytes during the indicated time periods as to simulate the in vivo situation, data on 
gene and protein expression of iron handling genes are the sum of various time points 
after erythrophagocytosis. Third, co-cultured uRBCs served as a control for parasite- 
mediated effects under the assumption that laboratory-induced hemolysis and aging 
with subsequent changes of erythrocytic membranes were similar for both pRBCs 
and uRBCs. Of note, also the presence of uRBCs reflect important effects seen in 
malaria infections, such as enhanced erythrophagocytosis. Moreover, we were limited 
to one laboratory strain of P. falciparum, the NF 54, which we selected because of 
the broad experience with this strain in in vivo experiments. (173) Also, the extrapo- 
lation of results obtained in mouse macrophages to the human situation should to be 
performed with care. However, the wide experience with the cell line used and the 
similarity of results in with those obtained with human macrophages give confidence
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in our model. This study is largely based on gene expression profiles which warrants 
careful extrapolation to changes in protein levels, given the time specific kinetics of 
mRNA that might differ from posttranscriptional and posttranslational regulations. 
Future experiments should therefore include these assessments and should also focus 
on the (immunological) consequences of elevated or repleted body iron stores in the 
perspective of erythrophagocytosis of uRBCs and/ or pRBCs. The influences of heme 
and hemolysis that were so strongly apparent in our studies may also be of relevance 
of other diseases than malaria that feature hemolysis. It would be interesting to study 
macrophage iron metabolism in patients with hemolyitc anemia during infections or 
sepsis.
From our in vitro studies in human Ml and/or mouse macrophages it can be concluded 
that erythrophagocytosis of uRBCs and pRBCs results in both increased cellular iron 
turnover in terms of increased HO-1 and ferroportin gene expressions, and increased 
cellular iron as assessed by increased intracellular iron and ferritin. We observed only 
minor malaria-specific alteration in our macrophage studies, that are consistent with 
a further but marginally increase in macrophage iron levels. Our data also suggest 
that the effects on macrophage iron metabolism occur independently of the malaria 
parasite or its inflammatory response, and are an effect of the parasite on the RBCs.
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T able 4 .1: PCR primer sequences
Abbreviations: mu, mouse; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; Hamp, hepcidin- 
gene; DMT-1, the divalent metal transporter- /; TTj-6, interleukin 6; HO-1, heme-oxygenase 1; Nramp- 
1, natural resistance-associated macrophage protein-1.
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Figure 4.5: Gene expression o f iron regulatory genes in R A W  macrophages after 
stimulation with opsonized uninfected red blood cells (uRBC) or parasitized RBCs 
(pRBC), LPS, IFN'y and hepcidin for 3 and 20 hrs, respectively.
Results are shown as relative differences compared to the mean value of unstimulated macrophages, 
which were set at 1 and presented in the dashed horizontal line. Data are expressed as mean with 
the error bars presenting the Standard error of the mean of at least 4 independent experiments. 
Mann- Whitney non-parametric testing was used to comp a re  the results of uRBCs, pRBCs and LPS 
with control condition (*P<0.05, **P<0.01, ***P<.005) and with Wilcoxon rank test uRBCs were 
compaxed with pRBCs per time point (#P<0.05).
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F igu re 4 .6: Gene expression of iron regulatory genes of R A W  macrophages after 
3 and 20 hrs stimulation with opsonized uninfected red blood cells (uRBC) or 
parasitized RBCs (pRBC) and LPS.
Cells were primed overnight and co-stimulated with IFN'y or hepcidin or primed overnight with iron 
chelator DFO. Controls were primed with the speciSc condition and cultured with medium for the 
indicated time points. Presentation of results differs from other Ggures: results are shown as relativa 
differences of compared to the mean value of unstimulated Controls at 3 hrs (set as 1.0). Data are 
expressed as mean with the error bars presenting de Standard error of the me an of at least 4 indepen­
dent experiments. Mann-Whitney non-parametric testing was used to assess the differenee between 
control and uRBCs, pRBCs and LPS, IFN'y or hepcidin per priming and/or co-stimulation exper­
iment with DFO, IFN'y and hepcidin, respectively (*P<0.05, **P<0.01, ***P<0.005). Wilcoxon 
rank testing was applied to compare uRBCs with pRBCs per condition and time point (#P<.05).
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5. Hepcidin in Pregnancy
Abstract
Background: Iron deficiency is a commonly encountered problem in pregnancy and 
a frequently observed cause of pregnancy- associated anemia. We longitudinally as- 
sessed the iron regulatory hormone hepcidin during gestation and postpartum and 
related hepcidin to conventional indicators of iron status and inflammation. 
M ethods: Thirty-one healthy pregnant women were included and 81 blood sam­
ples from the three trimesters, directly and 6 weeks postpartum were analyzed for 
hemoglobin, the iron parameters: iron, total iron binding capacity, transferrin satu- 
ration, ferritin, soluble transferrin receptor and hepcidin, and CRP and leucocytes as 
markers of inflammation.
Results: Hepcidin concentration decreased gradually from the first to the second and 
third trimester to undetectable levels (0.5 nmol/L) which was paralleled by decreas- 
ing hemoglobin levels and changes in iron parameters indicative for iron deficiency. 
During gestation hepcidin levels correlated with iron parameters, but not with in­
flammatory markers. Postpartum, hepcidin increased immediately to levels similar 
as assessed at early pregnancy.
Conclusions: We conclude that hepcidin levels were suppressed during the second 
and third trimester of pregnancy, which was likely determined by the occurrence of 
iron deficiency. These data give insight in iron homeostasis during normal pregnancy.
5.1 Introduction
Pregnancy involves many adaptations in the internal milieu of the mother. Early 
pregnancy is characterized by a sudden drop in vascular resistance, leading to de­
creased blood pressure, renal sodium retention, plasma volume expansion and conse- 
quently to a decrease in hemoglobin concentration. (174) In response, erythropoiesis is 
steadily increased to maintain hemoglobin levels, but at cost of exhausting maternal 
iron reserves/29^  In addition, iron stores are further depleted by the growing fetus 
and placenta, particularly at the third trimester. Altogether, pregnancy has been 
estimated to cost about 1000 mg of iron, which is substantial for the mother/29) 
Even iron supplemented women have a drop in hemoglobin with a nadir at 25 weeks 
gestation. (175) Therefore, iron deficiency is likely to occur during pregnancy and is 
an important cause of pregnancy-associated anemia, particularly in women with low 
iron reserves such as in low-income countries. (12>11)
Hepcidin, a liver-derived peptide hormone, functions as the regulator of systemic iron 
homeostasis and its discovery 10 years ago tremendously increased our insight in hu­
man iron biology. (34) Hepcidin negatively regulates iron availability for the developing 
erythron via binding to and subsequent degradation of the only known cellular iron
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exporter ferroportin, a protein that is highly expressed in the plasma membranes 
of macrophages and hepatocytes and the basolateral membrane of duodenal ente- 
rocytes. Consequently, low serum hepcidin levels maximally facilitate dietary iron 
delivery from iron storage sites as macrophages and hepatocytes, while increased hep­
cidin inhibits these pathways. Persistently increased hepcidin levels result in anemia 
of chronic disease due to iron restricted erythropoiesis. (34>1)
In pregnancy several potential counterbalancing physiologic factors may influence 
serum hepcidin levels, which also vary during the course of gestation. On the one 
hand, in iron deficiency, hypoxia, or in states of increased erythropoiesis, hepcidin is 
reduced to allow maximal iron delivery to plasma, while on the other hand, in inflam­
matory states hepcidin is raised and iron is retained in enterocytes, macrophages and 
hepatocytes and not available for erythropoiesis. (34) At present, our knowledge about 
circulating hepcidin during healthy pregnancy in humans is I i mited (17fi>177>178>179) and 
no intrarindividual longitudinal data of hepcidin of women during the course of ges­
tation and postpartum are available. Therefore, we aimed to assess serum hepcidin 
levels and conventional indicators of iron status and inflammation at five time points 
during the course of healthy pregnancy and postpartum, to improve our insights in 
the physiology of iron homeostasis during pregnancy.
5.2 Materials and methods
Study population
Thirty-one apparently healthy pregnant women were selected at the first prenatal 
visit from the outpatient obstetrics ward of the Radboud University Nijmegen Medi- 
cal Center between 2009 and 2011. Participants were of Northern European (n=29) 
or Southeast Asian (n=2) descent and above 18 years old with an expected normal 
pregnancy based on a normal hematologie blood count, renal function and liver en- 
zymes at first visit. No other exclusion criteria were applied. Approval of the local 
ethical committee was obtained and informed consent in compliance with the Decla- 
ration of Helsinki was required before inclusion.
Data collection
Blood samples were collected at five defined time periods: 9-15 weeks, 19-25 weeks 
and 29-35 weeks of gestation; within 24 h postpartum and at 6 weeks after delivery. 
We obtained 22, 21, 16, 14 and eight blood samples of 31 women at these subsequent 
time points. Twelve women provided blood samples in each of the three trimesters. 
An overview of data collection and details of reasons of missing data are described in
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Supplementary Table 5.3. Medical records were searched for information on medical 
history, maternal age, complications and delivery mode.
Laboratory analysis
Non-fasting samples were collected and routinely processed within 3 h for the anal­
ysis of hematological indices and routine biochemical parameters. Serum was then 
divided into aliquots that were stored at -80"C and thawed before the analysis of 
hepcidin and soluble transferrin receptor (sTfR). Hematological parameters were de- 
termined on an automated hematology analyzer (Sysmex, Etten-Leur, The Nether- 
lands) and serum concentrations of iron, transferrin, creatinine, urate, C-Reactive 
protein (CRP), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), and 
glucose on the Architect (Abbott Diagnostics, Hoofddorp, The Netherlands). The 
serum total iron binding capacity (TIBC, mol/L) was calculated from transferrin 
(g/L) multiplied by 25. The percent transferrin saturation (TS) was calculated as 
100 times the serum iron concentration divided by the TIBC. Ferritin and sTfR (ref- 
erence value (0.76-1.76) 10~3 g/L) concentrations were quantified as described. ' 18°) 
The sTfR-index (sTfR divided by log-transformed ferritin) was calculated.(-40^ A rel­
ative increase in either sTfR or the sTfR- index is a indicator for iron deficiency or 
enhanced erythropoiesis. (29>181.39.174) The lower limit of detection for CRP is 5 10-3 
g/L and below detection values were analyzed as 2.5 10‘3 g/L.
Measurements of serum hepcidin-25, the bio-active form of hepcidin, (further in the 
text denoted as ’hepcidin’) were performed by a combination of weak cation exchange 
chromatography (WCX) and time-of-flight mass spectrometry (TOF MS) as described 
previously. (182^  Hepcidin concentrations were expressed as nmol/L (1 nmol/L= 2.789 
g/mL) and the lower limit of detection of this method was 0.5 nmol/L; average coefïi- 
cients of variation were 2.7% (intra-run) and 6.5% (inter-run). (182) For this study, hep­
cidin concentrations below the lower limit of detection were included as 0.25 nmol/L 
in the statistical calculations. The reference range for the WCX-TOF MS method 
is <0.5- 12.3 nmol/L (median 2.0 mmol/L),(183) and is calculated from the refer­
ence values measured by our inhouse ELISA metho. (184^ based on the regression line: 
(ELISA - 1.00)/1.52 =  WCX-TOF MS that was derived from the results obtained by 
both methods for the saine samples. (182)
Statistical analysis
Data are presented as medians with the interquartile range (IQR) unless otherwise 
stated. Laboratory parameters were log-transformed to obtain normal distributed 
data and all statistic analyses were performed on log transformed values. To assess
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the change of individual parameters in time of the 31 subjects we used linear mixed 
models for longitudinal data including pairwise comparisons for all time periods: the 
gestational period and the postpartum measurements. Significance was determined 
at the 0.05 level. Also, a subanalysis was performed in the 12 subjects with complete 
follow-up during the gestational period. The Spearmans rank test was used for cor- 
relation analyses at the specified periods.
All statistical analyses were carried out using the Statistica! Package for the Social 
Sciences (SPSS) software package, version 18.0 (SPSS Inc., Chicago, IL,USA).
5.3 Results
Characteristics of the study population
The characteristics and obstetric data of the study population are shown in Table 
5.1. The median age at parturition was 33.1 years and it was the first pregnancy for 
13 (42%) of the women. Twenty (65%) of the deliveries were uncomplicated. One 
subject developed pre-eclampsia and her outcome variables were included in the anal­
yses, since they were within the range of those with uneventful gestation.
In the course of gestation, hemoglobin decreased gradually from 127 g/L to 112 g/L 
(Table 5.2). By the third trimester three subjects had a hemoglobin level below 105 
g/L. In addition, ALT concentration decreased and glucose and urate concentrations 
increased, while markers of inflammation (CRP and leucocytes), platelet count and 
creatinine levels remained similar during the three trimesters of pregnancy. However, 
creatinine levels increased and CRP, leukocytes and glucose levels were elevated di- 
rectly postpartum, but affcer 6 weeks all these parameters had normalized.
Hepcidin and iron parameters during pregnancy
Early pregnancy hepcidin levels were median 1.85 nmol/L (IQR 1.10-4.10 nmol/L) 
and decreased to undetectable levels (<0.5 nmol/L) in all but one subject towards 
the third trimester (Figure 5.1, Supplementary Table 5.5). After parturition hepcidin 
concentrations were again detectable, median 3.0 nmol/L (IQR 0.7-9.2 nmol/L), com- 
parable to first trimester and 6 weeks postpartum values. In addition, the concentra­
tions of ferritin and iron and TS were lowest towards end-pregnancy, in accordance 
with the increased sTfR, sTfR-index and TIBC levels at the third trimester. Also 
ferritin increased directly postpartum.
These observations during pregnancy were similar in a subanalysis of 12 women who 
provided blood samples in each of the three trimesters: hepcidin and the discussed
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Number, (% )
Age, years 33.1 (±5.4)a
Parity
0 13 (42)
1 11 (36)
>2 7 (23)
Medical indication antenatal care
patiënt preference 23 (74)
medical historyb 5(16)
Complications current pregnancyc 3(10)
Delivery mode
uncomplicated 20 (65)
instrumental delivery 1 (3)
elective caesarean 6(19)
secondary caesarean 4(13)
T able 5.1: Obstetric characteristics of the study population of 31 pregnant women
aMean (SD). b SpeciRcation of medical indication of pregnancy care: hypothyroid and diabetes mel- 
litus; hypothyroid and hypertension, all well controlled; heterozygous mutation in the gene encod- 
ing for Factor 5 Leiden; psychiatric history and age above 40 years. c SpeciScations of complica- 
tions: spinal disc herniation, hypertension which was controlled with one antihypertensive drug and 
preeclampsia at end- pregnancy, respectively.
iron status parameters all changed comparing the first trimester with the second or 
third, while leucocytes and CRP values were unaffected (data not shown).
In fact, 6 weeks postpartum, CRP and all iron status parameters were similar to the 
first trimester values, with the exception of sTfR and sTfR-index levels that were still 
relatively elevated.
Biochemical correlations of hepcidin during pregnancy
Hepcidin levels were in the gestational period, but not postpartum, associated with 
hemoglobin concentration and the iron status parameters (except iron concentration), 
while CRP or creatinine levels were not related (see Supplementary Table 5.3). The 
strongest effects were observed for ferritin and sTfR- index concentrations, the corre- 
sponding correlation coefïicients were 0.687 and 0.672, respectively, P - values <0.0001. 
Of interest, directly postpartum hepcidin concentrations had a tendency to correlate 
with CRP levels (correlation coëfficiënt 0.483, P-value 0.08).
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F igu re  5.1: Hepcidin, iron status param eters and C-reactive protein levels o f study 
population in tbe speciSed time periods during and after pregnancy.
Depicted are medians with the interquartile range. Asterisks represent the significance in relation 
to first trimester values; analyzed with linear mixed models as explained in Methods, *P <0.05, 
**P <0.001, ***P <0.000. TIBC, tota1 iron binding capacity; sTfR, soluble transferrin receptor; 
sTfR-index, sTfR divided by log ferritin.
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trimester 1
(n=2 2 )
trimester 2
(n=2 1 )
trimester 3
(n=16)
24 hours pp
(n=14)
6  weeks pp
(n=8 )
Gestation, weeks 
Hemoglobin, g/L 
Leucocytes, 109/L 
Platelets, 109/L  
CRP, 10- 3 g/L 
Creatinine, /umol/L 
Urate, mmol/L 
Glucose, mmol/L 
ALT, U/L 
LDH, U/L
10.9 (1.4) 
127 (6 )
9.8 (8.3-11.0) 
266 (64)
4.3 (2.5-14.5) 
51 (6 )
0.15 (0.13-0.19) 
4.5 (3.9-4.7) 
17 (14-25) 
337 (297-397)
21.9 (2.0) 
117 (6 )***
8.5 (7.8-12.6) 
251 (65)
2.5 (2.5-7.0) 
50 (5)
0.16 (0.14-0.20) 
4.4 (4.0-4.9) 
16 (9-22) 
315 (278-371)
32.1 (1.5)
1 1 2  (1 1 )*** 
10.4 (8.8-12.9) 
248 (58)
4.3 (2.5-12.3)
49 (6 )
0.19 (0.15-0.23)*** 
4.7 (4.4-5.6 )
13 (3-13)*** 
347 (324-380)
39.5 (1.5)
109 (14)***
15.4 (13.1-19.2) 
228 (82)
10.0 (5.9-21.0)*** 
56 (11)*
0.26 (0.24-0.31)***
5.4 (4.4-7.3)***
9 (3-13)***
446 (409-526)***
6.1 (0.7)
127 (11)
6.4 (5.6-8.9) 
291 (36)
2.5 (2.5-5.1)*** 
67 (6 )
0.25 (0.22-0.30)***
4.5 (4.1-4.6)
36 (33-48)*** 
320 (294-365)
T able 5.2: Laboratory parameters of study population during and after pregnancy
Data are presented as medians with interquartile range or means with Standard deviation. pp, postpartum; CRP, C-Reactive protein; ALT, 
alanine aminotransferase; LDH, lactate dehydrogenase. Asterisks represent the signiücance in relation to first trimester vaJues; analyzed with 
linear mixed models as explained in Methods, *P <0.05, **P <0.001, ***p <0.000.
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5.4 Discussion
In this study we longitudinally assessed hepcidin levels during the course of preg­
nancy. Hepcidin concentrations decreased from the first trimester to the second and 
third trimester and increased immediately after parturition. In addition, hepcidin 
correlated with hemoglobin and body iron status reflected by ferritin, TIBC, TS and 
sTfR(-index) levels.
Several factors may determine hepcidin concentrations in pregnancy (Figure 5.2). 
The development of gestational iron deficiency in our cohort was supported by de­
creased ferritin and iron, and increased TIBC and sTfR (-index) levels, as reported 
previously. ^ 185’186’181,187,188) This may largely explain the reduced and even unde- 
tectable hepcidin levels in nearly all women in their third trimester. In addition, the 
increased sTfR observed at end-pregnancy may also reflect increased erythropoietic 
activity (186>174) which additionally reduces hepcidin levels.
In contrast, hepcidin is induced by inflammatory stimuli, (34>141) and hepcidin levels 
were associated with CRP levels in a large study conducted in the general popu- 
lation. (184) Since pregnancy is known to induce a state of low grade inflammation, 
particularly during the first trimester and at parturition/189^  we expected a rela- 
tive increase in hepcidin concentration at these time points. However, biomarkers 
of inflammation, CRP and leucocytes, were not associated with hepcidin levels dur­
ing gestation, but showed a tendency to correlate directly postpartum. Possibly, 
these biomarkers do not completely reflect pregnancy-associated inflammation and 
interleukin-6, a well studied inducer of hepcidin expression, (34) might be better as­
sociated with gestational hepcidin levels. Nevertheless, it seemed that the presumed 
low-grade inflammatory state of pregnancy does not outweigh the iron deprived con- 
dition of healthy pregnancy. In addition, recent in-vitro and mouse studies suggest 
an inhibiting effect of estrogens on hepcidin synthesis, (190>191) which is an interesting 
observation that requires further investigations in pregnancy. All together, it appears 
that the physiological suppression of hepcidin levels during pregnancy is the body’s 
ultimate effort to maximize iron availability to maintain hemoglobin levels and other 
iron dependent metabolic processes. t1,34)
This study is unique in the longitudinal assessment of hepcidin levels during the gesta­
tional period and two postpartum time points. We were limited by the missing data 
that compromised the individual follow-up. However, the uniform direction of the 
results obtained, as confirmed in a subanalysis of women whose blood samples were 
available during all time points, provide confidence in results obtained. In addition, 
our findings on gestational serum hepcidin levels were in agreement with previously 
assessed hepcidin concentration in first, second and third trimester(179) as were the 
increased hepcidin levels directly postpartum. (178) Another limitation is that we were 
not informed about the use of over-the-counter iron supplements. However, iron
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F igu re 5.2: Schematic presentation of proposed actors involved in hepcidin regu- 
lation during pregnancy.
In the course of pregnancy, materna1 iron stores deplete as a consequence of an increased iron need 
by the growing fetus. Moreover, iron is needed for erythropoiesis to maintain maternal hemoglobin 
levels that drop as an effect of plasma expansion due to a reduction in peripheral vascular resistance 
and a decrease in blood pressure. Low body iron stores are reflected by the reduced cellular iron 
storage protein ferritin and reduced transferrin saturation (TS), a measure for circulating iron. The 
increase in erythropoiesis is noted by increased circulating levels of the soluble transferrin recep­
tor protein (sTfR). Both the increased erythropoiesis and reduced body iron stores suppress serum 
hepcidin levels. On the other hand, (low grade) inflammation during the gestational period and 
postpartum increases hepcidin levels. The consequences of the hemodynamic changes on hepcidin 
levels are unknown. A net effect o f these actors is a gradual decrease of hepcidin in the course of 
pregnancy, an immediate increase directly postpartum and a normalization hereafter.
supplements were not routinely prescribed and reserved for those with hemoglobin 
concentration below 105 g/L and reduced mean cell volume (<80 fL) in accordance 
with national guidelines.
We believe that our observations contribute to a better understanding of the (patho)- 
physiology of iron deficiency anemia in pregnancy. In fact, there is a need for studies 
that improve our insights in changes in iron homeostasis during gestation, since they 
might ultimately lead to the discovery of the biomarker of iron status that is best 
associated with maternal and fetal outcome and should provide the rationale for in- 
tervention with iron supplements. (192’193)
The low to undetectable hepcidin levels towards the end of pregnancy imply that
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oral iron supplementation is maximally absorbed to replenish iron stores aiming to 
maintain hemoglobin levels. (194>195) This is especially relevant for pregnant women in 
the developing world. These women are at risk for (severe) iron deficiency^12,196) and 
conventional iron status parameters fall short in the differentiation of iron deficiency 
anemia and anemia in conditions of high infectious burden. (9) In these women high 
hepcidin levels would prevent the uptake of iron and as such question the merits of 
prescribing iron. In this perspective, point of care hepcidin measurement might pro- 
vide guidance for iron supplementation for pregnant women in the tropics.
In conclusion, hepcidin levels decrease in the course of healthy pregnancy and are 
associated with serum iron parameters suggestive of iron deficiency.
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5.5 Supplement al Tables
Number o f  subjects trimester 1 trimester 2 trimester 3 24 hours pp 6 weeks pp
3
2
1
2
1
5
1
1
1
2
1
i
5
3
1
1
31 22 21 16 14 8
T able 5.3: Overview of data collection for the participating women
The gray boxes denote the availability of hepcidin and other parameters of interest per subject in 
the speciSed time periods. The distribution over time per subject (total of 31 subjects) are depicted 
in horizontal direction and total number of subjects per time period (total of 5 time periods) can be 
found below each column. Reasons for missing data are: 1) moving to an other region (4 samples); 2) 
blood donation not in speciSed time period (4 samples); 3) errors with blood collection (6 samples) 
and 4); no show or unknown (60 samples).
whole group
(n=81)
trimester 1-2-3
(n=59)
24 hours pp
(n=14)
Hemoglobin 0.275# 0.015® 0.474# <0.0001® 0.067# ns®
C R P 0.322 ns -0.049 ns 0.483 ns*
Iron 0.100 ns 0.206 ns 0.123 ns
T IB C -0.483 <0.0001 -0.633 <0.0001 -0.344 ns
TS 0.243 0.029 0.379 0.003 0.174 ns
ferritin 0.516 <0.0001 0.687 <0.0001 0.265 ns
sT fR -0.293 0.008 -0.500 <0.0001 -0.360 ns
sTfR-index -0.452 <0.0001 -0.672 <0.0001 -0.411 ns
T able 5.4: Correlation o f the study parameters with hepcidin during the speciGed 
periods during and after pregnancy
Denoted are squared R-values (&) and P-values o f Spearmans correlations of signiücance ). *P- 
value .08. pp postpartum; ns, not significant; CRP, C-Reactive protein; TIBC, total iron binding 
capacity; TS, transferrin saturation; sTfR, soluble transferrin receptor; sTfR-index, sTfR divided by 
log ferritin.
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trimester 1
(n=2 2 )
trimester 2  
(n=2 1 )
trimester 3
(n=16)
24 hours pp
(n=14)
6  weeks pp
(11= 8 )
Hepcidin, nmol/L 
Hepcidin <0.5, nmol/L* 
Iron, /imol/L 
TIBC, /imol/L#
TS, %
Ferritin, fj,g/L 
sTfR, 10- 3 g/L 
sTfR-index. mg//ig
1.85 (1.10-4.10) 
1 (4.5)
18.5 (11.8-24.3) 
68.1 (9.8)
25.0 (16.4-33.7)
44.5 (26.8-63.3) 
0.97 (0.85-1.15) 
0.62 (0.50-0.73)
0.25 (0.25-1.20) 
8  (38)
15.0 (12.0-23.5) 
81.3 (14.2)
21.5 (15.2-32.3)
16.0 (9.5-48.0) 
1 .0 2  (0.86-1.28) 
0.75 (0.59-1.17)
0.25 (0.25-0.25) 
15 (94)
9.50 (7.0-15.0) 
103 (8.7) 
9.75 (6.8-14.6) 
7.5 (5.3-15.8)
1.59 (1.29-2.01)
1.60 (1.18-2.68)
3.00 (0.66-9.22) 
3 (25)
10.0 (6.0-14.5) 
91.3 (12.7)
10.8 (8.0-14.4) 
15.5 (8.5-23.3) 
1.52 (1.18-2.21) 
1.14 (0.86-2.56)
1.35 (0.73-2.40) 
1 (13)
19.0 (12.3-24.0) 
68.3 (9.1)
28.4 (16.2-39.1)
41.5 (21.0-56.5) 
1.47 (0.91-2.37) 
1.15 (0.53-1.49)
T able 5.5: Hepcidin and iron status parameters of study population in the predeöned time periods during pregnancy 
Depicted are medians with interquartiie range, uniess otherwise speciSed: #mean with Standard deviation; *number with percentage, pp 
postpartum; TIBC, totaJ iron binding capacity; TS, transferrin saturation; sTfR, soluble transferrin receptor; sTfR-index, sTfR divided by log 
ferritin.
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6. Iron Homeostasis during Placental Malaria
Abstract
In malaria-endemic areas, iron deficiency and placental Plasmodium falciparum in- 
fection commonly coexist. In primigravidae and their newborns, hepcidin and other 
iron parameters were evaluated in groups and classified according to placental P. fal­
ciparum and maternal anemia status. Mothers had relatively high hepcidin levels 
considering their low iron status. In cord-blood, levels of hepcidin, hemoglobin, and 
other iron parameters were also similar for groups. We conclude that maternal hep­
cidin is not significantly altered as a function of placental infection and/or anemia. 
Importantly, fetal hemoglobin and iron status were also unaffected, regardless of the 
presence of placental infection or maternal anemia.
6.1 Introduction
Placental malaria is a significant public health problem, because it is consistently as­
sociated with maternal morbidity and poor birth outcome. (2M97>198) iron deficiency 
is also highly prevalent in malaria- endemic areas, and, apart from Plasmodium fal­
ciparum infection, another well-known risk factor for maternal anemia and perinatal 
complications. (27’n ) Therefore, iron supplementation is considered a logical public 
health intervention. However, not all studies of iron supplementation in malaria en­
demic regions have shown favorable results. (53’199) The iron regulatory hormone hep­
cidin has been reported to inhibit the intestinal iron uptake and the release of iron from 
macrophages by degrading the sole cellular iron export protein ferroportin. (5>20°) In­
flammatory stimuli, including those associated with P. falciparum infection, increase 
hepcidin production, resulting in low plasma iron levels and reduced bone marrow 
iron supply. (94>22>133) .
During blood-stage malaria infection, P. falciparum-infected erythrocytes can bind 
chondroitin sulphate A on syncytiotrophoblasts, leading to their accumulation in pla­
cental intervillous spaces. Syncytiotrophoblasts express iron regulatory proteins in­
cluding ferroportin, which is responsible for iron release into the fetal circulation. (201) 
In addition, animal studies revealed that hepcidin and iron levels in the fetal liver 
may also regulate maternal-fetal iron transport. (202>203>204) .
We aimed to study maternal and fetal hepcidin and other iron parameters to improve 
our understanding of human placental iron transport. Therefore, we retrospectively 
assessed plasma concentrations of these indices in primigravidae as a function of pla­
cental P. falciparum infection and maternal anemia, and in corresponding cord-blood 
samples.
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6.2 Materials and Methods
Study population and design
Archived samples from a malaria in pregnancy study, carried out in an area of Gabon 
characterized by stable meso- to hyperendemic malaria transmission, were used for 
this study. (205) Paired maternal and umbilical cord-blood samples were obtained at 
time of parturition from pregnant women attending the Albert Schweitzer Hospital in 
Lambaréné, Gabon from July 2000 to February 2004. Medical records of the mothers 
were examined to determine whether malaria episodes were detected and appropri- 
ately treated during pregnancy. Age at delivery, number of previous pregnancies, and 
the childs birth weight and length were recorded. Antenatal universal iron supple­
mentation during pregnancy was local practice (following the WHO recommendation 
of 60 mg iron daily for all pregnant women); however, therapy compliance was not 
recorded. (12)
Samples from primigravidae without peripheral parasitemia (determined by micro- 
scopy) who gave birth to singleton live births and who had no signs or symptoms 
of systemic infection were included. Primigravid women were selected for this study, 
because they are more susceptible to P. falciparum infection than multigravidae and 
have a higher risk of adverse outcome. Further sample selection was performed 
on the basis of placental infection status, defined as the presence of P. falciparum 
parasites in giemsa-stained placental blood impression smears, and on the presence 
or absence of maternal anemia, defined as a hemoglobin concentration below 10 g/dL. 
This selection procedure resulted in four groups: (1) no placental malaria and no ane­
mia, (2) no placental malaria and anemia, (3) placental malaria and no anemia, and 
(4) placental malaxia and anemia. Sample size was determined by the availability of 
paired maternal and umbilical cord samples that matched the selection criteria. 
Informed consent, including approval for future measurements was obtained from 
mothers before inclusion. Ethical clearance for the study was given by the Ethics 
Committee of the International Foundation of the Albert Schweitzer Hospital in Lam­
baréné.
Laboratory analysis
Giemsa-stained thick and thin smears of both maternal and cord-blood and impression 
smears of placental blood were assessed microscopically for the presence of P. falci­
parum parasites. Hemoglobin concentrations were determined by a Standard hema- 
tology analyzer. Blood samples were stored at -80 °C for further analysis. Plasma 
concentrations of iron, total iron-binding capacity (TIBC), ferritin, soluble transferrin 
receptor (sTfR) and C-reactive protein (CRP) were determined as described previ-
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ously. (94) Plasma hepcidin-25 measurements were performed in 2009 by a combina­
tion of weak cation exchange chromatography and time-of-flight mass spectrometry 
(TOF MS). An internal Standard (synthetic hepcidin-24; Peptide International Inc., 
Louisville, KY) was used for quantification (www.hepcidinanalysis.com) . (206) Peptide 
spectra were generated on a Microflex LT matrix-enhanced laser desorption/ionization 
TOF MS platform (Bruker Daltonics). Plasma hepcidin-25 concentrations were ex­
pressed as nmol/L. The lower limit of detection of this method was 0.5 nmol/L; 
average coefficients of variation were 2.7% (intrarun) and 6.5% (interrun). The me- 
dian reference level of plasma hepcidin-25 is 4.2 nmol/L, with a range of 0.5 - 13.9 
nmol/L. (207)
The reliability of the archived samples for the present study was assessed by mass 
profiling of eight paired cord and maternal samples. We found the peptide spectra 
to be similar to that of freshly frozen sera. More specifically, degradation products 
as observed in sera that had been inadequately stored for a prolonged period of time 
were absent throughout the peptide profile (i.e., at m/z 5,000-6,000 and m/z 7,000- 
8,500), providing confidence in the good quality of the samples.
Statistical analysis
Data are expressed as median values with interquartile range (IQR). Differences 
among groups were tested by Kruskall-Wallis tests. Differences between two groups 
were assessed by Mann- Whitney test. Missing values were assumed to be at random. 
CRP concentrations < 5 mg/L were included in the analyses as CRP concentrations 
of 5 mg/L. Significance was defined as two-tailed (P<0.05). The statistical software 
packages SPSS 16.0 (SPSS Inc., Chigago, IL) and GraphPad Prism 4.00 (GraphPad 
Software Inc., San Diego, Ca) were used for all data analyses.
6.3 Results
Study group characteristics
A total number of 69 primigravidae were stratified in four groups according to pla­
cental P. falciparum infection status and hemoglobin level. The characteristics of the 
study population are shown in Table 1. Hemoglobin concentrations were 12.8 g/dL 
(IQR 11.6 - 13.4) and 8.2 g/dL (IQR 7.5 - 8.8) in non-anemic and anemie mothers, 
respectively. There were no differences in the four study groups in either white blood 
count or platelet numbers. CRP concentrations were elevated in most women, with 
the highest values in those with placental infections. The percentage of low birth 
weight ( i.e., a birth weight below 2.5 kg) was relatively high in all subgroups (range
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18.8-35.7%). Despite a trend for lower birth weight in the groups with anemia, there 
was no significant difference in birth weight among the groups.
O
Ec
c
'oQ.<D
Figure 6.1: Plasma concentrations of hepcidin stratified for anemia and placental 
infection status.
Data are depicted for maternal and coid-blood, the line represents the median value. □ =  no pia- 
cental malaria and no anemia; o=  no placcnLal malaria with anemia; • placental malaria and no 
anemia;▼ =  placental malaria with anemia.
Maternal hepcidin and iron parameters
Maternal plasma hepcidin concentrations were similar across the groups (P=0.70; Fig­
ure 6.1). Moreover, no significant differences in plasma iron concentration, transferrin 
saturation, TIBC, and ferritin concentration were found across the groups (Table 6.1). 
However, serum ferritin concentrations were higher in the group of women with pla­
cental malaria as a whole compared with women without placental malaria. Marked 
differences were also observed for sTfR concentrations and the highest and lowest 
values were in women without placental infection and with and without anemia, re­
spectively.
Cord-blood parameters
Cord parameters were independent of hemoglobin and malaria status of the mother 
(Table 2). Concentrations of hemoglobin, hepcidin and other iron status indices were
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Placental malaria - Placental malaria +
Characteristic Anemia* -
(n= 21)
Anem ia +
(n=  18)
Anemia -
(n= 16)
Anemia +
(n=  14)
Age, years 18.0 (17.0-19.0) 17.0(16.0-19.3) 17.0 (16.0-18.0) 17.0 (16.8-19.3) .43
Hemoglobin,g/dL 13.2 (11.9-13.8) 8.2 (7.6-8.5) 12.2§ (11.2-13.2) 8.3 (6.6-9.3) .00
Cell counts,109/L
W B C 11.0 (9.2-18.0) 10.5 (9.2-13.0) 11.0 (9.2-13.8) 10.0 (7.6-12.0) .72
Platelets 185 (142-245) 207 (130-163) 152 (109-191) 190 (126-259) .21
C RP, mg/L 12.0 (5.0-31.0) 17.5 (6.0-43.3) 25.0§ (11.0-47.3) 32.0^(17.8-67.5) .43
C R P clO , n (%) 10 (47.6) 8§ (44.4) 4  ^ (25.0) 2§ (14.3) .005
Iron parameters
Hepcidin, nmol/L 4.2 (1.6-8.0) 2.8 (0.5-13.1) 4.2 (2.0-8.1) 3.2 (0.9-5.0) .70
Iron, mol/L 9.0 (8.0-12.5) 8.0 (4.8-15.3) 8.0 (6.0-12.0) 7.5 (4.8-13.8) .55
TIBC, mol/L 80.0(73.5-89.5) 83.0(73.3-102) 86.0 (73.0-104) 80.0 (59.5-85.3) .25
TS, % 11.2 (7.9-18.3) 9.4 (5.9-20.5) 8.1 (5.9-16.5) 9.6 (6.6-19.4) .55
Ferritin, g/L 30.0(16.0-45.0) 29.0(11.0-147) 44.0 (19.3-121) 86.0 (20.5-220) .37
sTfR, mg/L 1.4 (1.2-2.1) 2.3§ (1.4-3.6) 2.0 (1.5-2.4) 1.6 (1.5-2.3) .09
T able 6.1: Clinical data and iron status indices in pregnant women.
Data are presented as median with intcrquartile range. Anemia was defined as hemoglobin concen­
tration below 10 g/dL (6.2 mmol/L).
* Vaiues represent differences among the four groups by Kruskall- Wallis test.
§ P<0.05 and 1 P<0.01, compared with the group o f mothers without placental malaria infection 
and without anemia (by Mann-Whitney test).
WBC, white blood cell count; CRP, C- reactive protein; TIBC, total iron-binding capacity; TS, 
transferrin saturation; sTfR, soluble tiansferrin receptor.
similar across the four groups. CRP concentrations were not elevated in all groups, 
and there was neither anemia nor signs of iron deficiency (i.e., hypoferremia, high 
TIBC, or low plasma ferritin concentrations).
6.4 Discussion
In the current study, the effects of placental P. falciparum infection and anemia on 
hepcidin and iron parameters in mothers and their offspring were assessed and some 
important findings are hereby reported. First, we show that primigravid women with 
or without placental infection and with or without anemia have relatively low fer­
ritin concentrations, low plasma iron concentrations and low transferrin saturation 
as well as high TIBC concentrations, suggesting some degree of iron deficiency. We 
refrained from assessing iron deficiency by previously used formulas (e.g., the sTfR 
to log ferritin ratio), because they have not been standardized or validated for our 
study population. (39)ln pregnancy, iron deficiency resulting from a physiologic in­
crease in erythroid iron demand is indeed a common finding. Moreover, nutritional
74
6.4 . Discussion
Placental malaria - Placental malaria +
Characteristic Anemia* - Anem ia + Anemia - Anemia + pS
(n= 21) (n=  18) (n= 16) (n=  14)
Birth weight, kg 2.8(2.5-3.0) 2.6(2.4^2.8) 2.9(2.6-3.2) 2.7(2.1-3.0) .32
LBW , n(%) 4(19.0) 5(27.8) 3(18.8) 51(35.7) .65
Birth length, cm 50.0(48.5-50.0) 49.0(48.0-50.0) 50.0(49.0-50.0) 48.0^(46.5-49.3) .09
Hemoglobin, g/dL 15.1(13.8-16.0) 14.2(13.0-15.2) 13.9^(12.5-14.7) 14.6(12.9-15.6) .21
Cell counts, 109/L
W B C 12.8(10.0-15.1) 11.6(8.3-14.2) 12.4(9.6-14.4) 10.1(8.4-13.3) .94
Platelets 299(246-364) 296(202-367) 265(218-319) 273(231-301) .58
C R P<5 mg/L, n(%) 20(95.2) 16(94.1) 15(93.7) 14(100.0) .79
Iron parameters
Hepcidin, nmol/L 4.5(2.8-6.8) 5.5(2.4-9.5) 3.7(3.0-6.9) 4.4(1.8-6.5) .33
Iron, mol/L 22.0(19.5-28.0) 20.0(14.0-27.0) 19.0§ (18.0-21.0) 17.0§( 13.0-22.0) .14
TIBC , mol/L 41.0(37.0-46.5) 43.0(36.0-52.5) 46.0(35.8-47.8) 33.5(59.5-85.3) .39
TS, % 57.1(45.5-70.9) 45.5(32.7-59.4) 42.9§ (35.1-60.0) 61.0(39.0-69.6) .64
Ferritin, g/L 122(97.0-290) 146(84.0-217) 161(131-224) 137(89.3-193) .72
sTfR, mg/L 2.3(1.9-2.8) 2.3(1.9-3.7) 2.4(1.8-2.8) 1.8(1.6-3.1) .44
T able 6.2: Clinical data and cord-blood iron status indices in newborns.
Data are presented as median with interquartile range. Anemia was defined as hemoglobin concen- 
tration below 10 g/dL.
® Values represent differences among the four groups by Kruskall-Wallis test.
§ P <0.05 compared with the group of mothers without placental malaria infection and without 
anemia(by Mann- Whitney test).
1 P <0.05, compared with the group of mothers with anemia but without placental malaria (by 
Mann- Whitney test).
& Low birth weight was defined as a weight below 2.5 kg.
WBC, white blood cell count; CRP, C- reactive protein; TIBC, total iron-binding capacity; TS, 
transferrin saturation; sTfR, soluble transferrin receptor; LBW, low birth weight.
iron deficiency is also highly prevalent in malaria-endemic regions, even despite im- 
plementation of active iron supplementation programs.I-208)
Second, we found that maternal plasma hepcidin concentrations were not altered by 
placental infection and that hepcidin concentrations were relatively high, consider- 
ing the presence of iron deficiency. The expression of hepcidin is principally regu- 
lated by a combination of factors: hypoxia, increased erythropoietic activity and iron 
deficiency suppress hepcidin expression, whereas inflammatory cytokines (especially 
interleukin-6) stimulate the production of hepcidin. (209) The relatively high hepcidin 
concentrations in the group of anemie mothers without placental malaria are therefore 
remarkable. The slightly elevated CRP values in some women in this group may be 
explained by the normal increase in CRP measurements in the third trimester and at 
parturition, and mild inflammation could also have contributed to these relatively high 
hepcidin levels. (21°) It should be noted that only subjects with a parasite-negative pe-
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ripheral blood smear were included in this study to diminish the potentially confound- 
ing effects of higher-grade systemic (inflammatory) infection. Parasitemia in pregnant 
women is associated with higher inflammatory markers together with higher urinary 
hepcidin concentrations. (95’2n) Indeed, very high hepcidin concentrations were mea- 
sured in African children with clinical malaria whereas slightly raised hepcidin levels 
were found in those with lower density parasitemia. (94>22)
Third, we found a trend for lower sTfR concentrations in anemie women with placen­
tal infection compared to mothers without infection. Because sTfR is a marker for 
erythropoietic activity, this may suggest that placental parasitemia is associated with 
reduced erythroid progenitor proliferation. (39)
The functional consequences of these fmdings are uncertain, although one might spec- 
ulate that the effectiveness of iron supplementation in the study participants may be 
reduced by the relatively high hepcidin concentrations. However, iron retained in the 
erythrocyte precursor by hepcidin degradation of ferroportin, may well compensate 
for this decreased iron supply and/or at least partly, protect against anemia/212) 
Finally, we found no effect of placental infection or maternal anemia on cord-blood 
concentrations of hemoglobin, CRP, hepcidin, and other iron parameters. This is 
in agreement with a study conducted in Malawi that also found no significant ef­
fect of peripheral or placental P. falciparum infection on cord blood concentrations 
of hemoglobin, CRP, and sTfR and only a slightly effect on ferritin. (213) Moreover, 
among Nigerian women, placental infection was strongly associated with maternal 
anemia, but not with the mean hematocrit in their newborns. *-214) Interestingly, al­
though the clinical implications are still to be elucidated, placental hepcidin mRNA 
expression was increased in P. falciparum infected placentas and was negatively cor- 
related with birth weight, but it was not associated with maternal anemia. (215) In the 
present study, the relationship between low birth weight and placental infection was 
absent, which may be attributed to the low birth weights of newborns of non-diseased 
mothers.
Our study is limited by its retrospective character, the absence of long term data, 
the lack of information on premature delivery, its relatively small sample size and the 
usage of archived samples. Concerning the latter, both the normal MS profïles of all 
serum samples without signs of degradation products as well as the broad range in 
concentrations of the laboratory markers observed provided confidence in the relia- 
bility of the data obtained.
The study is, however, unique in the selection of primigravidae and cord-blood sam­
ples with either placental P. falciparum infection, anemia, or both in combination 
with the exclusion of peripheral parasitemia.
In conclusion, neither placental infection nor maternal anemia was related to mater­
nal and cord hepcidin concentrations and iron status. Our data also suggest that 
iron metabolism is biased to maintaining the fetal iron supply, even in the presence
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of maternal anemia and iron deficiency. Here, the fetus seems to be the winner in the 
maternal- fetal conflict, deriving its nutrients independently from maternal iron and 
placental malaria infection. Whether the effectiveness of iron supplementation of 
pregnant women in the third trimester is impaired by the moderately elevated hep­
cidin concentrations needs to be determined in future studies.
Acknowledgements
We are grateful for the ever cheerful and helpful assistance of the staff of the maternity 
unit of the Albert Schweitzer Hospital and to the mothers for their willing participa- 
tion. The authors also thank Siem Klaver for his contribution to the logistics of the 
plasma measurements.
77

III
The diagnosis of iron 
deficiency in chronic 
inflammation

Hepcidin and hemoglobin content 
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7. Iron Deficiency in Rheumatoid Anemia
Abstract
Objective. To explore the utility of the novel iron indices hepcidin, reticulocyte- 
hemoglobin content (Ret-He), and erythrocyte-(red blood cell) hemoglobin content 
(RBC-He) for detection of iron deficiency in rheumatoid arthritis (RA) patients with 
anemia and active inflammation and to compare these indices with conventional pa­
rameters of iron deficiency.
Methods. Blood samples from 106 outpatients with RA were analyzed in a cross- 
sectional exploratory study. Forty patients were classified as having either iron defi­
ciency anemia (IDA), anemia of chronic disease (ACD), their combination (IDA/ACD), 
or ” other anemia” based on biochemical parameters for inflammation and iron defi­
ciency. The ability of serum and urine hepcidin, Ret-He, and RBC-He measurement 
to discriminate among these states was evaluated.
Results. Hepcidin content in serum from patients in the IDA group as well as that 
from patients in the combined IDA/ACD group differed significantly from that in 
serum from patients in the ACD group. This difference was also observed with hep­
cidin in urine, Ret-He and RBC-He, although with less significance. The area under 
the receiver operating characteristic curve for serum hepcidin was 0.88 for the com- 
parison of IDA/ACD patients with ACD patients and 0.92 for the comparison of the 
combined IDA group and IDA/ACD group to all other patients with anemia. Hep­
cidin at <2.4 nmol/L had a sensitivity of 89% and a specificity of 88% to distinguish 
IDA/ACD from ACD. Both Ret-He and RBC-He measurements also allowed differ- 
entiation between these latter groups with a sensitivity of 67% and 89%, respectively, 
and a specificity of 100% and 75%, respectively.
Conclusion. Serum hepcidin and, to a lesser extent urine hepcidin, Ret-He and 
RBC-He are potential useful indicators for detecting iron deficiency in RA patients 
with anemia and active inflammation.
7.1 Introduction
Rheumatoid anemia is typically multifactorial and related to the chronic inflamma­
tory nature of the disease, and includes iron deficiency, mainly due to therapy-induced 
gastrointestinal blood loss. The detection of iron deficiency in a population with ane­
mia of chronic disease (ACD) is of clinical relevance, since 1) iron deficiency anemia 
(IDA) is treatable, 2) the diagnosis may prelude the need for further investigations 
into the cause of the anemia, and 3) it may prevent unnecessary prescription of iron 
supplementation.
Unfortunately, diagnosis of iron deficiency with currently available laboratory pa­
rameters is hampered by the lack of a gold Standard and is even more complex and
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nonspecific when concomitant inflammatory conditions are present/45,9) Proinflam- 
matory stimuli contribute to ACD directly by inhibition of erythropoiesis and in- 
directly by decreasing the iron available for heme synthesis/1) The latter may be 
attributed to inflammation-induced increased levels of the iron regulatory peptide 
hepcidin. Elevated hepcidin levels reduce intestinal iron absorption as well as iron 
release from macrophages through interaction, internalization, and degradation of 
the cellular iron exporter ferroportin, resulting in iron sequestration in the reticu- 
loendothelial system/209,217) Consequently, the total body iron content is normal, 
but less iron is available for erythropoiesis. In contrast, in IDA, in which there is 
an absolute iron deficiency, hepcidin is suppressed, which leads to induction of iron 
absorption from the gut.
Since hepcidin has been shown to be differently affected by inflammation and iron 
deficiency, it has been advocated as a potential biomarker to assess iron deficiency in 
patients with inflammatory conditions. (218>219>220,182)
The hemoglobin (He) contents of erythrocytes (red blood cells (RBCs)) and of retic- 
ulocytes (RBC-He and Ret-He) have also been explored as biomarkers for diagnosing 
iron deficiency/221,222,44,223) Ret-He and RBC-He reflect the hemoglobinization of the 
earliest-released reticulocytes, which circulate for only 1-2 days, and that of mature 
erythrocytes, respectively. (43) Reduced Ret-He and RBC-He values indicate that the 
iron supply for the bone marrow is too low to allow normal hemoglobinization/44) 
Since these parameters are not directly affected by inflammation but are functional 
measures of iron availability, they might be of relevance to detect iron deficiency in 
conditions of chronic inflammation, such as rheumatoid arthritis (R A )/222)
To assess the added diagnostic value of measuring serum and urine hepcidin, Ret- 
He, and RBC-He (measured as reticulocyte Hgb equivalents (Ret-He) and RBC Hgb 
equivalents (RBC-He), respectively), for the detection of iron deficiency in patients 
with anemia and inflammation, we explored their diagnostic characteristics and com­
pared them with conventional indices of iron status in a cross-sectional study of 106 
outpatients with RA.
7.2 Patients and Methods
Study population
The study population consisted of 106 patients with RA who consecutively attended 
the outpatient clinic at Radboud University Nijmegen Medical Centre, a tertiary care 
facility, for routine evaluation between March 2007 and March 2008. In this ex- 
ploratory cross-sectional study, no other inclusion or exclusion criteria were applied. 
The local ethics committee approved the study, and written informed consent was
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obtained from all participants, in compliance with the Declaration of Helsinki. 
Anemia was defined, according to the World Health Organization criteria, as a hemo­
globin concentration of 8.1 mmol/1 (13 g/dL) for men and 7.4 mmol/1 (12 g/dl) for 
women. Patients with anemia were divided into 4 groups, based on biochemical pa­
rameters for inflammation and iron deficiency (see below).
Laboratory analysis
Biochemical marker levels and hematologie indices were determined in all partici­
pants on the day of their routine outpatient visit. Blood counts were measured with 
an automated hematology analyzer (Sysmex 2100; Sysmex). Hemoglobin content pa­
rameters were reported as Ret-He and RBC-He and are reported in fmoles (1 fmole 
— 16.11 pg).The following parameters were measured using an Abbott Aeroset an­
alyzer: iron, plasma transferrin concentration, total iron-binding capacity (TIBC), 
and creatinine (reagents from Roche Diagnostics), C-reactive protein (CRP), ala- 
nine aminotransferase, lactate dehydrogenase and haptoglobin (reagents from Abbott 
Laboratories), and bilirubin (reagent produced in-house). The percent plasma trans­
ferrin saturation was calculated as 100 times the serum iron concentration divided by 
the TIBC. Ferritin, vitamin B12, and folie acid were quantified with a solid-phase, 2- 
site chemiluminescent iminunometric assay (Immulite 2500, Diagnostic Products).The 
erythrocyte sedimentation rate (ESR) was determined using a StaRRsed Compact 
ESR analyzer (Mechatronics). Serum concentrations of soluble transferrin receptor 
(sTfR) were measured immunonephelometrically on a BN II System (Dade-Behring). 
The sTfR-index (sTfR divided by log-transformed ferritin values) was calculated. (40) 
Thalassemia was discriminated from IDA using previously described formulas. (43-224) 
The glomerular filtration rate was assessed using the Modification of Diet in Renal 
Disease formula. (225^
Serum hepcidin-25 was measured by a combination of weak cation exchange chro- 
matography and time-of-flight mass spectrometry as described previously (182) Serum 
hepcidin concentrations were expressed as nmol/L (1 nmol/l= 2.789 g/ml). The lower 
limit of detection with this method was 0.5 nmol/L; average coefficients of variation 
were 2.7% (intra-run) and 6.5% (inter-run). The median reference level of serum 
hepcidin is 4.2 nmol/L, with a range of 0.5- 13.9 nmol/L. (20r) In this study, serum 
hepcidin concentrations below the lower limit of detection were recorded as 0.4 nmol/L 
for statistical calculations.
Urine hepcidin was assessed by a method similar to that used for serum hepcidin. 
Values were normalized to urine creatinine values and reported in nmol/mmol crea­
tinine. The lower limit of detection for urine hepcidin was 0.05 nmol/L.
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Classification of anemia
In the RA patients with anemia, we classified the anemia as IDA, ACD, or a combina­
tion of the two (IDA/ACD) by modifying previously described algorithms. C1.218-227) 
to a scheme appropriate to our patiënt population. Specifically, patients with anemia 
as defined above were classified as having IDA if active inflammation (defined as a 
CRP level of >10 mg/ml or an ESR of >30 mm/hour) was absent and at least 1 of 
the following 2 conditions was met: 1) transferrin saturation <20% and ferritin level 
<30 fj,g/ml; 2) sTfR index >1 mg/ug. Patients were classified as having ACD if active 
inflammation was present and at least 1 of the following 2 conditions was met: 1) 
transferrin saturation <20% and ferritin level >100 g/ml; 2) sTfR index <1 m g/ug  
and ferritin level >30 /ig/ml. Patients were classified as having IDA/ACD if active 
inflammation was present and at least 1 of the following 2 conditions was met: 1) 
transferrin saturation <20% and ferritin level <100 /ig/ml; 2) sTfR index >1 mg/fig. 
Patients with anemia that could not be classified according to these definitions were 
categorized as having ”other anemia” . RA patients without anemia were studied as 
Controls.
Assessment of disease activity
RA disease activity was assessed using the Disease Activity Score in 28 joints (228) 
(DAS28). A DAS28 score of <3.2 is considered to represent low disease activity. (229-*
Statistical analysis
The median value and interquartile range (IQR) for each continuous parameter were 
determined. Depending on the data distribution (as assessed by Kolmogorov- Smirnov 
and Levenes normality testing), Standard parametric and nonparametric tests were 
applied. Spearmans rank correlation testing was used for correlation analysis. Re- 
ceiver Operating Characteristic (ROC) analysis was performed to evaluate the accu- 
racy with which hepcidin and the hemoglobin content parameters differentiated the 
groups of patients with anemia. The area under the ROC curve (AUC) was generated, 
including the sensitivity and specificity for each possible cutoff of the specific parame­
ter. An AUC value of 1 represents the perfect discriminating test. The Youden index 
([sensitivity +  specificity]-l) was used to select the optimal cutoff value. p-values less 
than 0.05 were considered significant. All statistical analyses were carried out using 
SPSS version 16.0.
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7.3 Results
Population characteristics
The characteristics of the 106 RA patients are reported in Table 7.1. Forty patients 
(37.7%) were anemie; of these 40, 10 (25.0%), 9 (22.5%), 8 (20.0%), and 13 (32.5%) 
fulfilled the predefined criteria for IDA, IDA/ACD, ACD and other anemia, respec­
tively. Renal function, results of liver biochemistry tests, and vitamin B12 and folie 
acid levels were comparable among groups, and none of the patients had signs of 
hemolysis or thalassemia. Disease activity as assessed by the DAS28 was significantly 
increased in anemie versus non-anemic patients; however, the score was similar among 
the different anemia groups.
In accordance with the selection criteria, median CRP and ESR values were signif­
icantly increased in both the IDA/ACD and the ACD groups. Notably, 20 (30.3%) 
of the non-anemic RA patients and 7 (53.8%) of the patients in the other anemia 
category also had increased levels of inflammation markers. Further group differences 
apart from those due to selection criteria, were as follows: IDA patients were younger 
(median age 50.5 years, versus 73.0, 68.5, and 62.0 years in the IDA/ACD, ACD, 
and other anemia groups, respectively and had significantly lower mean corpuscular 
volume (MCV) compared to the patients with ACD. MCV values in the other anemia 
groups were similar to those in the non-anemic Controls.
Hepcidin and hemoglobin content
Median serum hepcidin concentrations in both the IDA and the IDA/ACD groups 
were significantly different from that in the ACD group (median [IQR] nmol/L 7.4 
[2.6-11.0], 0.4 [0.4-0.8] and 0.7 [0.4-2.2] in the ACD, IDA, and IDA/ACD groups, 
respectively [P=0.001 ACD versus IDA, P=0.009 ACD versus IDA/ACD]) (Figure 
7.1 and Table 7.2). This difference was also demonstrated in the comparison of IDA 
patients or IDA/ACD patients with non-anemic Controls (P<0.001 and P=0.001, re­
spectively). In contrast, serum hepcidin concentrations in ACD patients were similar 
to those in Controls (P=0.20). A similar trend was observed with regard to hepcidin, 
RBC-He, and Ret-He as regard to urine hepcidin, although statistica! significance 
between anemia groups was only reached in the comparison between IDA and ACD 
patients (P=0.008). In addition, ACD patients differed from IDA patients by signifi­
cantly higher RBC-He values (P=0.03) and from IDA/ACD patients by significantly 
higher Ret-He values (P=0.02). None of the hemoglobin content parameters differed 
between the ACD group and the non-anemic Controls.
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No anemia IDA ID A /A C D ACD other anemia Pt
(n=6 6 ) Ot-HII (n=9) (n=8 ) (n=13)
Female, no.(%) 45 (69.3) 8  (80.0) 4 (44.4) 7 (87.5) 7 (53.8) 0.25
Age, years 61.0 (49.5-68.0)J 50.5 (37.5-67.8)§ 73.0 (57.0-79.5) 68.5 (66.0-74.0) 62.0 (51.5-74.5) 0.03
DAS28 score 3.1 (2.3-3.9)$ 3.7 (2.3-5.3) 4.2 (2.7-5.4) 4.1 (3.9-4.7) 3.9 (3.1-4.3) 0 .0 2
DAS28<3.2, no. (%) 33 (50.0) 5 (50.0)§ 3 (33.3) 0 (0 ) 3 (42.9)
Hemoglobin, mmol/1 8.2 (7.8-8.6)1[ 6 .8  (6.4-7.1) 7.0 (5.9-7.2) 7.0 (6 .6-7.3) 6.9 (6 .6-7.2) < 0 .0 0 1
M C V, fL 88.1 (84.3-92.0) 82.9 (80.8-87.3)§ 86.9 (78.2-91.1) 91.4 (89.9-96.6) 89.4 (85.7-94.4) 0.03
Iron, mol/L 14.0 (10.0-18.0) 6.0 (6.0-15.0)§ 6.0 (4.5-8.5) 10.5 (8.0-13.8) 12.0 (8.0-15.5) 0 .0 0 1
Ferritin, g/L 90.0 (47.8-141)t 11.5 (8.3-22.8)1 53.0 (11.0-64.5)1 191 (102-262) 84.0 (61.0-133) < 0 .0 0 1
Transferrin, g/L 2.4 (2.2-2.7) 2.7 (2.4-3.0)t 2.5 (2.2-2.7)§ 2 .1  (1 .8 -2 .4) 2.2 (2.1-2.3) 0.06
TSAT, % 22.4 (16.8-28.1) 9.7 (7.5-22.8) 9.7 (7.2-13.6)f 21.9 (17.9-26.5) 21.1 (14.0-27.9) 0 .0 0 1
sTfR, mg/L 1.5 (1.2-1.8 ) 2.5 (2.0-3.1)1 2.4 (1.9-2.8)| 1.4 (1.3-1.9) 1 .6  (1 .2 -1 .9) < 0 .0 0 1
sTfR-index, mg/g 0.7 (0.6-1.0) 2.5( 2.5-3.1)! 1.4 (1.2-2.3)! 0.6 (0.6-0.9) 0.8 (0.7-0.9) < 0 .0 0 1
M D R D , ml/min/m2 97.6 (76.9-110) 102 (79.5-113) 101 (72.1-112) 101 (84.1-113) 88.3 (64.5-109) 0.78
ALT, U/L 22.0 (17.0-28.5) 21.5 (14.8-32.0) 16.0 (12.5-21.0) 21.5 (15.3-27.3) 20.0 (16.0-31.0) 0.36
LDH, U/L 400 (361-473) 447 (358.-479) 393 (331-473) 393 (342-475) 454 (390-521) 0.52
Haptoglobin, g/L 1.4 (0.9-2.0) 1 .1  (0 .8 -1 .9) 1.7 (1.4-2.4) 2.0 (1.5-3.1) 1 .6  (0 .9-2.0) 0.09
Folie acid, nmol/L 25.9 (15.5-36.6) 20.3 (14.2-38.5) 33.8 (16.5-46.5) 24.4 (16.9-38.6) 24.9 (16.2-42.7) 0.90
Vitamin B12, pmol/L 267 (196-378) 425 (212-601) 301 (214-629) 281 (176-485) 280 (157-406) 0.39
C RP, mg/L 4.0 (4.0-10.3)1 4.0 (4.0-7.0)1 13.0 (9.0-19.0) 17.0 (10.5-27.5) 13.0 (5.5-27.5) < 0 .0 0 1
ESR, mm/hour 11.0 (5.0-20.3)1 15.5 (8.0-20.5)1 32.0 (26.0-52.0) 46.0 (26.3-54.8) 16.0 (10.0-35.5) < 0 .0 0 1
T able 7.1: Baseline demographics and laboratory parameters in the RA patients studied
Except where indicated otherwiae, values are the median (interquartile range). RA, rheumatoid arthritis; IDA, iron deBciency anemia; ACD, 
anemia of chronic disease; DAS28, Disease Activity Score in 28 joints; MCV, mean corpuscular volume; TSAT, transferrin saturation; sTfR, 
Boluble transferrin receptor; sTfR, index sTfR/log ferritin; MDRD, ModiBcation of Diet in Renal Disease; ALT, alanine aminotransferase; LDH, 
lactate dehydrogenase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
fComparison between all groups, by analysis of variance, Kruska.1-Wallis test, or chi-square test, as appropriate. 
fP<0.01 versus ACD group, by independent t-test, Mann-Whitney test, or chi-square test, as appropriate.
§P<0.05 versus ACD group, by independent t-test, Mann-Whitney test, or chi-square test, as appropriate. 
fP<0.0001 versus ACD group, by independent t-test, Mann-Whitney test, or chi-square test, as appropriate.
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F igu re 7.1: Distribution of markers o f hepcidin and hemoglobin content in the 
predeHned groups of rheumatoid arthritis patients.
Data are presented as box plots, where the boxes represent the 25th to 75th percentiles, the lines 
within the boxes represent the median, and the lines outside the boxes represent the minimal and 
maximal values. The y-axes for serum and urine hepcidin levels are log transformcd. *P < 0.05; **P 
<0.01; ***p < 0.001, by independent t-test or nonpararnetric Mann-Whitney test. IDA, iron defi­
ciency anemia; ACD, anemia o f chronic disease; IDA/ACD, combined IDA and ACD; Cr, creatinine; 
Ret-He, reticulocytc hemoglobin content; RBC-He, erythrocyte (red blood cell) hemoglobin content.
No anemia
(n=66)
ID A
(n=10)
ID A /A C D
(n=9)
Serum hepcidin, nmol/L 
Urine hepcidin, nmol/mmol Cr 
Ret-He, fmol 
RBC-He, fmol
3.5 (2.8-6.2) 
0.6 (0.3-1.4) 
2.1 (2.0-2.3) 
1.9 (1.8-2.0)
0.4 (0.4-0.8)| 
0.06 (0.02-0.2)§ 
1.8 (1.7-2.1) 
1.7 (1.6-1.8)f
0.7 (0.4-2.2)§ 
0.2 (0.04-1.2) 
1.8 (1.5-2.0)f 
1.7 (1.5-1.8)
T able 7.2: Levels of hepcidin and novel indices of hemoglobin contents L 
forms of anemia and those without anemia
Values are the median (interquartile range). IDA, iron deficiency anemia; ACD, anemi, 
content; RBC-He, erythrocyte (red blood cell) hemoglobin content. 
fComparison between all groups, by analysis of variance, Kruskal-Wallis test, or chi-sqm 
<0.001 versus ACD group, by independent t-test, Mann-Whitney test, or chi-square t 
§P<0.01 versus ACD group, by independent t-test, Mann-Whitney test, or chi-square tei 
f P<0.05 versus ACD group, by independent t-test, Mann-Whitney test, or chi-square te
ooco
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Correlation of hepcidin levels with Ret-He and RBC-He levels
The relationship between novel and conventional parameters of iron in RA patients 
with anemia were explored. A strong association was observed between serum con­
centrations and urine concentrations of hepcidin (Spearmans r=0.84, PcO.OOl, Fig­
ure 7.5). Serum hepcidin levels correlated slightly better with ferritin and with the 
sTfR-index than did urine hepcidin levels (r=0.79 and r=0.79, respectively, versus 
r=0.71 and r=0.68). Ret-He and RBC-He levels correlated strongly with one another 
(r=0.88, P<0.001); however neither was strongly correlated with serum hepcidin lev­
els (r=0.39, P=0.014 and r=0.34; P=0.035, respectively.
Diagnostic characteristics for the detection of iron deficiency
ROC analysis was used to assess the diagnostic characteristics of serum hepcidin, 
RBC-He and Ret-He as diagnostic tests for iron deficiency in the RA patients with 
anemia in each specific category. Urine hepcidin was not further analyzed because of 
its inferiority to serum hepcidin for differentiating IDA/ACD from ACD.
First, we performed analyses to detect iron deficiency in the two patiënt groups with 
inflammation. The AUC for serum hepcidin in the combined IDA/ACD group ver­
sus the ACD patients was 0.88 (P=0.009, SE 0.09) (Figure 7.2). The optimal cutoff 
value for hepcidin was 2.4 nmol/L. A hepcidin level lower than this cutoff value distin- 
guished the IDA/ACD patiënt from the ACD patients with a sensitivity of 89% and 
a specificity of 88%. The AUC for Ret-He in the combined IDA/ACD group versus 
the ACD patients was 0.81 (P=0.03, SE 0.12) with a optimum cutoff of <1.9 fmoles 
(sensitivity 67% and specificity 100%) and the AUC for RBC-He was 0.78 (P=0.05, 
SE 0.12) with an optimal cutoff of <1.8 fmoles (sensitivity of 89% and specificity of 
75%).
Furthermore, the clinical accuracy of hepcidin and iron content indices in the discrim- 
ination between patients with iron deficiency anemia (IDA and IDA/ACD [n=19]) 
compared to all other patients with anemia (ACD and other anemia others [n=21]) 
was explored to investigate the suitability of these parameters for the detection of iron 
deficiency among all of the RA patients with anemia, thus including those without 
inflammation. The AUC for serum hepcidin in this analysis was 0.92 (P<0.001, SE 
0.05). Application of the same analyses for the hemoglobin content indices resulted 
in an AUC of 0.75 (P=0.006, SE 0.08) and 0.80 (P=0.001, SE 0.07) for Ret-He and 
RBC-He, respectively.
These results indicate that hepcidin is superior to Ret-He and RBC-He as a biomarker 
for the detection of iron deficiency among RA patients with anemia.
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Figure 7.2: Receiver Operator Characteristic analysis o f hepcidin and hemoglobin 
content parameters as diagnostic test for iron deficiency in rheumatoid arthritis 
patients with speciüc categories of anemia.
Area xmder the curve (AUC) values are shown. See Figure 7.1 for other deBnitions.
7.4 Discussion
In this cross-sectional exploratory study of RA patients attending an outpatient clinic, 
serum and urine hepcidin levels and hemoglobin content parameters were assessed in 
an effort to identify markers of iron deficiency anemia in patients with inflammatory 
disease.
The detection of absolute iron deficiency in RA patients with anemia is a clinical chal- 
lenge, since conventional iron status screening parameters, e.g., transferrin, iron and 
ferritin, are influenced by acute-phase responses. (-37) sTfR refiects iron stores linearly 
to the degree of iron demand of erythroblasts, but inflammatory stimuli may suppress 
its concentrations by inhibition of erythropoietic activity. (9’39) The sTfR-index was 
developed to overcome this effect (40) and has gained merit in diagnostic algorithms 
together with Ret-He; (45>220>44) however, each of these markers feature their own dis- 
advantages in predicting iron deficiency. (9>37>39>128) Figure 7.3 provides an overview of 
serum iron parameters and hemoglobin content parameters in patients with RA and 
anemia.
In our RA patients, serum hepcidin levels correlated highly with urine hepcidin 
and ferritin levels and the sTfR-index, but not with hemoglobin content parame-
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F igure 7.3: Overview of indicators of serum iron status in rheumatoid arthritis 
patients with ACD and in those with IDA.
(A) ACD. In states of inflammation, increased hepcidin quantities are released in to the circulation 
by hepatocytes. Hepcidin binds, intemalizes, and degrades the iron exporter ferroportin (FPN), 
which results in a decrease in iron export from enterocytes and macrophages int o the bloodstream. 
As a consequence, serum iron and transferrin saturation (TSAT) decrease while iron stored within 
macrophages increases, leading to elevated serum ferritin levels. The inflammation-induced suppres- 
sion of erythropoiesis counteracts the decreased availability of iron. Therefore, the serum (or soluble) 
transferrin receptor (sTfR) concentration and the hemoglobin content o f reticulocytes and erythro- 
cytes may remain relatively normal (see also Figure 7.1). (B), IDA. Iron deficiency reduces hepcidin 
(even in the presence of inflammation), which results in maximal release of iron from enterocytes 
and macrophages into the circulation. Nevertheless, ferritin and iron levels and TSAT decrease. 
Consequently, the limited iron supply to the bone marrow will increase the sTfR concentration to 
allow maximal iron uptake by erythroblasts. Ret-He and RBC-He levels are reduced, indicating 
insufficiënt iron availability for erythropoiesis. RES reticuloendothelial system (see Figure 7.1 for 
other definitions).
ters. Moreover, in the comparison of categories of anemia as defined by conventional 
parameters, serum hepcidin performed well as a diagnostic test of iron deficiency, in- 
cluding when inflammation was present, and discriminated both the IDA group and 
the combined IDA/ACD group from patients with ACD. Urine hepcidin, RBC-He, 
and Ret-He also enabled differentiation between iron deficiency and ACD, albeit with 
lower statistical significance compared to serum hepcidin.
Hepcidin levels below 2.4 nmol/L discriminated IDA and IDA/ACD patients from 
ACD patients with RA. Apparently, the induction of hepcidin by inflammation is 
blunted by low iron stores. This suppression of hepcidin in anemie patients with 
iron deficiency and inflammation is corroborated by findings of animal studies (23°)
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and in various other patients groups, i.e., in a mixed population of chronic infection, 
autoimmune disease or malignancy, (227>231) in cancer patients with inflammation (218) 
and in patients with acute inflammation in an intensive care unit/232) In contrast, 
in another heterogeneous population of patients with chronic inflammation and ane­
mia, hepcidin levels did not differentiate patients with IDA/ACD from those with 
ACD; (44) this may be attributed to the use of a different stratification scheme than 
was used in the present study.
Since hepcidin concentrations at the lowest level of detection (0.5 nmol/L) were in- 
dicative of IDA, we explored the added value of urine hepcidin as a more sensitive 
marker in the lower concentration range. Although measuring urine hepcidin instead 
of serum hepcidin did not add to the level of diagnostic accuracy in the current and 
previous studies, (20r) it might be an attractive alteraative in the developing world, 
as a noninvasive tooi for assessing iron deficiency as a safety measure before starting 
oral iron administration programs. (66-1
Our findings enable us to propose a novel model for selecting RA patients who would 
likely benefit from iron supplementation (Figure 7.4). Since rheumatoid anemia is 
heterogeneous, more than one single parameter might be necessary to allow diagno­
sis of iron deficiency. We reasoned that patients with inflammation (test 1) and a 
hepcidin level of 2.4 nmol/L (test 2) will have iron deficiency, while hepcidin lev­
els 7.6 nmol/L are diagnostic for ACD. Patients whose hepcidin levels feil between 
2.4 and 7.6 nmol/L were further characterized using Ret-He (test 3), with levels of 
1.9 fmoles being indicative of concomitant iron deficiency. For IDA, a hepcidin level 
of 0.5 nmol/L was highly specific. Using these definitions to assess the need for iron 
supplementation, all patients from the combined IDA/ACD group would benefit from 
such supplements, with no ACD patients receiving this treatment unnecessarily. This 
model needs to be confirmed in other populations and may benefit from further in­
ternational standardization of hepcidin measurements. (233^ The study also provides 
insights regarding hepcidin and hemoglobin content levels in IDA and ACD patients 
in comparison to control patients without anemia. Both Ret-He and RBC-He dis- 
criminated IDA patients from non-anemic Controls. These observations are consistent 
with previous reports of convincing ROC characteristics demonstrating the ability 
of these indices to detect iron deficiency in otherwise healthy subjects and patients 
undergoing dialysis. ( 22M 3 ,2 3 4 ,2 2 3 )
Interestingly, in RA patients with ACD, we found that levels of hepcidin and the 
hemoglobin content parameters did not differ significantly from those obtained of 
non-anemic patients. It appears that in RA patients with chronic disease activity, 
hepcidin concentrations do not increase to levels seen in acute inflammation. In 
accordance with the current concept of the causal role of hepcidin in iron-restricted 
erythropoiesis, the absence of significantly increased hepcidin levels in the ACD group 
likely explains the similarities in hemoglobin content parameters between the ACD
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Anemia
Inflammation
CRP > 10 or ESR > 30 yes
Hepcidin Hepcidin
Figure 7.4: Proposed algorithm for assessing which rheumatoid arthritis patients 
with anemia may benefit from iron treatment, based on test characteristics de­
scribed in the text.
CRP, C-reactivc protein; ESR, erythrocyte sedimentation rate (see Figure 7.1 for other deünitions)
and the non-anemic control RA patients. Moreover, the RA control group differs from 
a healthy population in terms of, e.g., the presence of inflammatory markers and/or 
other indices of disease activity.
There are very few reports comparing hemoglobin content parameters in healthy Con­
trols with those in patients with ACD. In a heterogeneous cohort of ACD patients, 
the mean cell hemoglobin level was similar to that in age-matched Controls, despite 
elevated hepcidin levels.^231) In another mixed group of patients with ACD, levels 
of hemoglobin content were normal as compared to reference values. (22°) A similar 
study showed a nonsignificant trend toward of reduced Ret-He concentrations in pa­
tients with inflammation; no hepcidin data were however available. (235^  Interestingly, 
increased hepcidin levels do not necessarily lead to reduced hemoglobin content, de­
spite the induction of iron withholding by hepcidin. Another mechanism related to 
ferroportin expression on reticulocytes is probably involved. (236>212) Clearly, more and 
larger studies are needed to further assess levels of hepcidin in patients with chronic 
inflammation and its association with parameters of hemoglobin content.
To our knowledge, this is the first study of both hepcidin and hemoglobin content 
parameters in a RA cohort. In the absence of a gold Standard, we were dependent 
on conventional iron parameters to classify the anemie groups IDA, IDA/ACD and 
ACD. Notably, this classiflcation scheme precludes direct comparison of hepcidin or 
the hemoglobin content parameters with any of the conventional parameters used for 
the detection of true iron deficiency in RA patients. We believe that the strength of
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this study lies in its unbiased cross- sectional inclusion of RA patients and its limita- 
tion lies in the small numbers of patients in the various anemie categories.
What lessons can be learned from this study? Is it time for the rheumatologist to 
add hepcidin and hemoglobin content parameters to the clinical measurements that 
are performed? This present results clearly demonstrate the potentiaJ utility of serum 
hepcidin, and to lesser extent Ret-He and RBC-He, in the detection of iron deficiency 
in RA patients with inflammation and anemia. Our findings indicate that these novel 
parameters can provide added value in diagnosing iron deficiency in patients with 
rheumatoid anemia; larger studies are needed to confirm this.
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F igu re 7.5: Correlation o f iron status indicators in rheumatoid arthritis patients 
with anemia.
Scatter plots with nonlinear regression line, Spearmans rho (R) and corresponding P-values are shown 
for serum hepcidin compared to urine hepcidin (A), ferritin (C), sTfR-index (E), and Ret-He versus 
He (B), serum hepcidin (D) and sTfR- index (E). Black circle represents the IDA group; the gray 
diamond the combined IDA/ACD group; the white quadrangle the ACD patients and the triangle 
the ’anemic other’ category (see Figure 7.1 for other definitions).
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8. Letter
To the Editor
We thank Dr. Jolobe for his interest in our study and his question regarding the 
interchangeability of RBC-He, MCH, and MCV in the diagnosis of iron deficiency in 
rheumatoid arthritis patients with anemia. RBC-He and MCH are representative of 
the hemoglobin (He) content (in fmoles) of mature erythrocytes (1 fmole=16.11 pg). 
In our study, both parameters were measured with a Sysmex-XE 2100 automated 
hematology analyzer and were found to correlate (r=0.85, PcO.OOl) (n=105). How­
ever, the parameters are not fully identical. MCH is calculated based on whole blood 
intra- and extracellular He concentrations (assessed by hemoglobin photometry) di- 
vided by erythrocyte concentrations (measured by impedance counting). In contrast, 
RBC-He content is measured as RBC He equivalents on a different channel of the in­
strument and is a direct measure of mature erythrocyte intracellular He content (by 
means of a fluorescent optical count). (237>238) As a consequence, in hemolytic sam­
ples, the MCH count might be falsely elevated since this assessment also includes the 
determination of extracellular He. In our study, we did not find laboratory evidence 
of in vivo or ex vivo hemolysis in any of the patients.
ROC analysis was performed, and in comparisons between patients with IDA, patients 
with anemia of chronic disease, and the two anemia groups combined, we observed 
a slightly better test performance for RBC-He compared to MCH and MCV in diag- 
nosing iron deficiency in our rheumatoid arthritis study population (Figure 1). The 
area under the ROC curve (AUC) for RBC-He was 0.78 (P=0.05, SE 0.12) in the 
analysis of combined IDA/ACD patients (n=9) versus the ACD patients (n=8). The 
AUC for the same patients was 0.69 (P=0.18, SE 0.13) for MCH and 0.76 (P=0.07, 
SE 0.13) for MCV. For the IDA and IDA/ACD patients (n=19) versus patients with 
ACD and other forms of anemia (n=21) the AUC values for RBC-He, MCH, and 
MCV were 0.80 (P=0.001, SE 0.07), 0.69 (P=0.04, SE 0.09), and 0.73 (P=0.01, SE 
0.08), respectively.
Identification df iron deficiency in rheumatoid arthritis patients with anemia and in­
flammation is a challenge. In our study, the test performances of serum hepcidin and 
He content parameters (reticulocyte He content (Ret-He), measured as reticulocyte 
He equivalents and RBC-He) were better than those of MCV and MCH in the de- 
tection of iron deficiency. Yet, the differences among RBC-He, MCH, and MCV in 
our study were small, and for that reason in the absence of hemolysis, RBC-He and 
MCH might be interchangeable. However, our data do not corroborate Dr. Jolobe’s 
suggestion that MCH might be a better indicator than MCV in the identification of 
IDA in these patients.
Furthermore, we would like to mention additional features that may support the 
preferred use of He content parameters (as opposed to MCH and MCV) in the man­
agement of iron deficiency in this patiënt population. The difference between Ret-He
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F igu re 8.1: Receiver operator characteristic analysis o f hepcidin and hemoglobin 
content parameters as diagnostic tests for iron deBciency in rheumatoid arthritis 
patients with speciBc categories of anemia.
Area under the curve (AUC) values are shown. IDA, iron deficiency anemia; ACD, anemia of chronic 
disease; Ret-He, reticulocyte hemoglobin content; RBC-He, erythrocyte (red blood cell) hemoglobin 
content; MCH, mean corpuscular hemoglobin; MCV, mean corpuscular volume.
and RBC-He, expressed as He, provides information on the current iron availability 
and short-term iron incorporation for erythropoiesis owing to the long life span of 
mature erythrocytes compared to reticulocytes. (96) As a consequence, in the presence 
of absolute iron deficiency, iron supplementation is expected to substantially raise the 
Ret-He and He within several days, (239,240,217) while no effect, or only limited effect, 
is expected in the pure functional iron deficiency of the inflammatory state (patients 
with ACD). The combined use of Ret-He and RBC-He might thus prove an indicator 
of the effectiveness of oral iron supplementation in these patients, and as such, these 
parameters are promising additional markers for the management of anemia in pa­
tients with rheumatoid arthritis; we are currently investigating this hypothesis.
We agree with Dr. Jolobe that laboratories lacking the facilities to assess He content 
parameters could use MCH (or MCV) in addition to serum hepcidin to diagnose iron 
deficiency in patients with anemia and chronic inflammation. However, our findings, 
and the findings of others, suggest that He content parameters can provide added 
value in the management of patients with rheumatoid arthritis; more studies are 
needed to confirm this.
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a response to oral iron therapy in 
chronic inflammation
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W. Swinkels and Andrc J.A.M. van der Ven
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9. Iron Supplementation in Chronic Anemia
9.1 Introduction
In anemie patients with chronic inflammatory conditions, the assessment of iron sta­
tus and the selection of those who may benefit from iron therapy frequently presents 
diagnostie challenges. t1,217) Traditional biochemical iron parameters, such as ferritin, 
serum iron and transferrin, are affected by inflammation making them less suitable 
indicators. (9)
Recently, iron parameters have become available that provide direct information 
on iron availability for erythropoiesis: the central iron regulatory hormone hep- 
cidin^34’218’219’180) and the hemoglobin content of reticulocytes and erythrocytes (Ret- 
He and RBC-He). (221-4M 3>42) We hypothesized that changes in these functional iron 
parameters shortly after start of iron supplements may predict an increase in hemo­
globin in a longer course of iron supplements in patients with chronic inflammation.
9.2 Methods
Forty adult patients diagnosed with a chronic rheumatic disease and anemia were 
selected during routine visits in 2012 at the rheumatology outpatient clinic of the 
Radboud University Medical Center, Nijmegen, the Netherlands. Anemia was de­
fined as a hemoglobin concentration below 12.1 g/dL for males and below 11.3 g/dL 
for females, respectively. Exclusion criteria were signs of hemolysis (increased levels 
of lactate dehydrogenase), end stage renal disease, liver disease (two times the upper 
limit of the reference value of alanine aminotransaminase (ALT)), known malignan- 
cies, vitamin B12 or folie acid deficiency, use of iron supplements, erythropoietin or 
medications with potential drug interactions with the iron supplements and a blood 
transfusion in the previous two months. Patientscharacteristics, including age, sex, 
medication and the type of inflammatory condition were recorded at baseline (Table 
9.1).
Rheumatoid arthritis was the most common diagnosis (58%) and disease-modifying 
drugs (60%) and non-steroidal anti-inflammatory drugs (53%) were frequently used. 
Ethical clearance was granted by the Radboud University Medical Center, and writ- 
ten informed consent was obtained from all participants.
Ferrofumarate 200 mg BD (130 mg of elemental iron per day) was prescribed during 
six weeks. Blood samples were collected at baseline, after one, two and six weeks. 
Responders to iron therapy were defined as patients with an increase in hemoglobin 
of at least 0.81 g/dL (0.5 mmol/L) after six weeks of oral iron supplementation. 
The hemoglobin content parameters were measured on a Sysmex XE5000 analyzer 
(Sysmex Corporation). Serum hepcidin-25 measurements were performed using a 
combination of weak cation exchange chromatography and time-of-flight mass spec-
104
9.3. Results
trometry as described previously. (182) The other iron parameters were determined as 
previously described. (18°)
Variable Total
(n=40)
Female, No. (%) 26 (65)
A ge, mean (SD), y 62 (15)
C ondition , No. (%)
Rheumatoid arthritis 23 (57.5)
Spondylarthropathy 2 (5 )
PMR 3 (7.5)
Arthritis ns 6 (15)
Other auto-immune disease 6(15)
Drugs* , No. (%)
NSAID 21 (52.5)
Glucocorticosteroids 20 (50)
DMARD 24 (60)
Biological 7 (17.5)
Combination of 2 16 (40)
Combination of 3 or more 9 (22.5)
H em oglobin , mean (SD), g/dL
Male 11.8 (0.9)
Female 11.3 (0.7)
C R P , median (IQR), mg/L 9.5 (4.3-20.3)
C reatinine, mean (SD), /xmol/L 75.9 (20.9)
A L T , mean (SD), U /L 29.2 (15.2)
Folie acid, mean (SD), nmol/L 22.7 (13.8)
V itam in  B12, mean (SD), pmol/L 350.7 (164.0)
T able 9.1: Baseline characteristics o f study population.
* Drugs related to inflammatory condition. Abbreviations: SD, Standard deviation; PMR, polymyal- 
gia rheumatica; ns, non speciËed; NSAID, non-steroidal anti-inSammatory drugs; DMARD, disease- 
modifying drugs; CRP, C-reactive protein; IQR, interquartile range; ALT, alanine aminotransferase.
9.3 Results
At week 6, two patients had withdrawn from the study: one at personal request 
and one because of pneumonia. Sixteen of 38 participants who had completed the 
study were responders. Responders had significantly lower baseline values of ferritin, 
hepcidin, Ret-He and RBC-He and transferrin saturation (TS), and higher total iron 
binding capacity (TIBC), soluble transferrin receptor (sTfR) and its ratio to log fer­
ritin (sTfR-index) levels in comparison to non responders (Figure 9.1). Levels of CRP 
were similar between the groups.
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F igu re 9.1: Box and whisker plots of iron status parameters at baseline and af­
ter one and two weeks of iron supplementation for responders (white) and non- 
responders (gray).
* represent significant P-values of t-test comparisons or Mann-Whitney tests between responders 
and non-responders.
#  represent significant P-values of paired samples t-test or Wilcoxon Signed Rank test comparisons 
between baseline and week 1 or week 2 of responders and non-responders.
P-values xxx <0.001, xx <0.01, x  <0.05.
For abbreviations and SI conversion factors see Table 9.2. Reference values (when applicable): Ret- 
He 2.00-2.41 fmoles, reticulocytes 20-80 l ( f /L ,  hepcidin <14.7 (males), <12.3 nM  (premenopausal 
females), <15.6 nM  (postmenopausal women), iron 10-30 fimol/L, TIBC 45-80 fj,mol/L, ferritin 15- 
180 fig/L (males), 6-80 jig/L (premenopausal females), 15-280 ng/L  (postmenopausal women), sTfR
0.76-1.76 mg/L.
At one week of iron therapy, responders had a significantly larger increase in Ret-He 
level (0.28±0.26 fmol) compared to the non-responders (0.18±0.04 fmol, P<0.000) 
and a larger change in reticulocyte numbers (Figure 9.1). There was no increase in 
Ret-He between week 1 and 2. In contrast, there were no significant differences in the 
change in hepcidin levels at either time point. Moreover, responders had significantly 
larger increases in serum iron and TS values at one week with a concurrent significant
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decline in sTfR-index levels after two weeks of iron therapy.
Regression analyses were applied to predict the change in hemoglobin and the out- 
come of being a responder after six weeks of iron therapy. The strongest association 
with the hemoglobin response at six weeks was found for baseline RBC-He, ferritin, 
Ret-He and hepcidin levels, and the increase after one week in values of TS, serum 
iron, Ret-He, reticulocytes and ferritin, both in descending order (Table 9.2).
The diagnostic performance of parameters was subsequently assessed using Receiver 
Operating Characteristic (ROC) analyses. The change in values of serum iron, TS, 
Ret-He and reticulocytes at one week had the highest areas under the curve (AUC) 
(Table 2). At one week, an increase in serum iron and Ret-He of more than 4 mmol/L 
and 0.11 fmol, respectively, had a the sensitivity of 80 and 81%, and specificity of 91% 
and 86%, respectively. At baseline, values of ferritin, hepcidin and the sTfR-index 
had the highest AUC values, but the change in these parameters at week 1 was not 
a useful predictor of the response to iron therapy. The combination of the change 
in values of Ret-He and TS at one week provided the highest discriminatory power 
(AUC 0.906, SE 0.054, P <0.000).
Overall, the increase after one week of oral iron therapy in Ret-He, TS, serum iron 
level and the reticulocyte count best predicted an increase in hemoglobin level of at 
least 0.81 g/dL at week 6 of iron therapy. Baseline values of ferritin, hepcidin, sTfR- 
index and RBC-He also predicted the hematopoietic response but to a lesser degree.
9.4 Discussion
There are still no established diagnostic criteria to identify absolute iron deficiency 
in patients with inflammation. Our study design is unique in that we evaluated the 
predictive value of iron status indicators in response to oral iron therapy in patients 
with rheumatic diseases. The value of Ret-He as a screening tooi for ID has been rec- 
ognized before^241,180) and our current findings support its role as a marker for iron 
responsiveness. This may be of particular diagnostic value when results of conven- 
tional iron status parameters are inconclusive. The advantage of reticulocyte count 
and hemoglobin content parameters is that their results can be obtained quickly and 
extra blood tests are not required. However, before these hemoglobin content param­
eters can be widely implemented, additional research in the various patients groups 
and clinician education and training is required. (242)
Our study was designed with minimal inclusion criteria in order to maximize the 
generalizability of our results. Potential limitations are: i) the self-reported drug 
compliance; ii) the possible interaction of iron absorption with frequently used proton 
pump inhibitors (specific intake instructions were given); iii) the relatively modest 
degree of inflammation in our study population, and, finally, iv) the duration of iron
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Linear regression^ A t baseline
(n=38)
C hange at 1 week
(n=38)
Change at 2 weeks
(n=37)
R eticu locytes, 109/L  
R et-H e, fmol 
R B C -H e, fmol* 
H epcidin , nmol/1 
Iron, /imol/L 
T IB C , /imol/L 
TS , %
Ferritin, (ig /L  
sT fR , mg/L 
sT fR -in dex, m g/ g
ns
40.5%; -6.2, Pc.001 
52.8%; -7.9, P<.001 
35.4%; -.56, P<.001 
16.8%; -1.3, P.006 
22.8%; 4.5, P.008 
25.4%; -1.4, P.001 
41.4%; -.80, P<.001 
24.1%; 1.8, P.001 
43.9%; 1.5, P<.001
31.1%; 2.94, P<.001 
24.9%; 4.4, P.001 
22.5%; 22.9, P.005 
ns
47.5%; 1.04, Pc.001 
ns
48.9%; 1.04, P<.001 
17.8%; 0.93, P.006 
ns
16.0%; -2.6, P.009
23.7 %; 2.15, P.001 
19.8%; 4.1, P.003 
41.5%; 21.8, P<.001 
ns
21.9%; 0.77, P.002 
ns
23.7%; 0.76, P.001 
20.1%; 1.0, P.003 
ns
23.7%; -3.2, P.001
R O C  analyses §
R eticu locytes, 109/L  
R et-H e, fmol 
R B C -H e, fmol* 
H epcidin , nmol/1 
Iron, ftmol/L 
T IB C , p,mol/L 
TS, %
Ferritin, ng/L  
sT fR , mg/L 
sT fR -in dex, mg//ig
ns
,720±.088; P.02 
.771±.087; P.01 
,808±.075; P.001 
ns
,774±.079; P.004 
ns
.828±.067; P.001 
,727±.090; P.02 
,801±.079; P.002
.807±.075; P.001
,824± .080; P.001 
ns 
ns
.894±.058; P.000 
ns
,889±.058; P.000 
ns 
ns 
ns
,783±.090; P.004 
,783±.080; P.004 
.765±.010; P.02 
ns
,786±.080; P.003 
ns
,783±.079; P.004 
.762±.081; P.007 
ns
,716±.089; P.03
Table 9.2: Prediction of the response to six weeks of iron therapy.
Table shows the (i) linear regression model to predict the change in hemoglobin at week 6 and
(ii) ROC analyses to assess the chance of being responder o f  baseline parameters and their relative 
changes after one or two weeks of iron therapy.
^ Depicted are the adjusted squared R (x 100%), the unstandardized B-coefficient and P-value, calcu- 
lated on log- transformed variables. The B- coëfficiënt expresses the (relative) change in hemoglobin 
concentration after six weeks iron therapy that is associated with a 1-unit change in the independent 
variable.
§ Depicted are: the area under the curve, Standard error and corrcsponding P-value.
* n=32, n=36 and n=34, respectively.
Abbreviations: Ret-He, reticulocyte- hemoglobin content; ns, non-signiGcant; RBC-He, erythrocyte- 
hemoglobin content; TIBC, total iron binding capacity; TS, transferrin saturation; sTfR, soluble 
transferrin receptor; sTfR-index, sTfR/log ferritin; ROC, receiver operator curve.
SI conversion factors: To convert Ret-He, RBC-He to pg, multiply by 16.1.
treatment in our study may not have been sufficiënt to replete iron stores in all pa­
tients.
In conclusion, in anemie patients with a chronic rheumatologic disease, the increase 
in hemoglobin concentration to six weeks of iron supplementation was best predicted 
by the change in Ret-He, TS and serum iron levels and the reticulocyte count after
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one week of oral iron therapy. Prospective analysis of these parameters is especially 
useful when initial values of iron status indicators, such as a normal or elevated serum 
ferritin level, cannot be used to reliably exclude iron deficiency.
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General Discussion and Summary
10.1 General Discussion
Anemia of chronic disease, hepcidin and iron homeostasis
Anemia of chronic disease (ACD) is frequently encountered in patients with diseases 
involving acute or chronic immune activation such as infections, malignancies or au- 
toimmune disorders. ^  The etiology of ACD is multifactorial and involves the sup- 
pressive effects of pro-inflammatory cytokines on erythropoiesis, reduction of erythro- 
poietin sensitivity and retention of iron within macrophages of the reticuloendothelial 
system. The latter leads to hypoferremia with functional iron deficiency (ID) at the 
site of the bone marrow. The iron regulatory hepatic hormone hepcidin plays a key 
role in the pathogenesis of ACD. ®  Hepcidin functions by binding to the sole cellu­
lar iron exporter ferroportin, present on duodenal cells and macrophages, causing its 
intemalization and degradation. This loss of function of ferroportin leads to suppres- 
sion of dietary iron uptake, and iron sequestration in macrophages. The influence 
of macrophage iron retention on normal erythropoiesis is major considering that most 
of the required iron is derived from the recycling of iron from senescent red blood cells 
(RBCs) after phagocytosis by macrophages. Therefore, ACD is typically featured by 
a sufficiënt total body iron content, but an insufficiënt availability of iron for erythro­
poiesis.
Hepcidin production -and thereby body iron homeostasis- is affected by different 
counterbalancing processes. Pro-inflammatory cytokines (especially interleukin-6) 
and iron loading induce the production of hepcidin, whereas ID, hypoxia and in­
creased erythropoiesis reduce its production, allowing maximal intestinal iron uptake 
and iron availability for erythropoiesis. (243’7>34) ID is frequently observed in preg-
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nancy, but also caused by dietary factors, diseases that impair iron uptake or induce 
(chronic) gastrointestinal blood loss.
In daily practice, combinations of ACD and absolute ID are often encountered. Dif- 
ferentiating ACD from ID is a diagnostic challenge, but it has important therapeutic 
and diagnostic implications as patients with absolute ID may benefit from iron sup­
plementation and from a diagnostic workup of the cause of the ID. The discovery of 
hepcidin has proved to be a major advance in our understanding of the pathophysi- 
ology of ACD and ID and may offer new ways to approach these challenges.
In my thesis, I studied the role of hepcidin and iron in the presence of the inflammation 
induced by malaria and rheumatic diseases. Malaria is having a deleterious effect on 
pregnancy-anemia, therefore, iron parameters were studied during pregnancy as well. 
In particular the present thesis focuses on, i) the effect of malaria and erythrophagocy- 
tosis on macrophage iron handling; which was studied in a set of in vitro experiments, 
ii) iron homeostasis in healthy pregnant women and in pregnancy malaria, so a com- 
parison between the two conditions could be made, and iii) the diagnostic potential 
of hepcidin and other new serum iron parameters in patients with rheumatic diseases.
The interaction between malaria and iron
Anemia is highly prevalent in many malaria-endemic regions whereby children and 
pregnant women are mostly affected. Important underlying causes of anemia in these 
regions are malaria itself and ID due to insufficiënt iron intake and helminth-associated 
blood loss. (244,11,12) Previous studies by our group and others showed that malarial 
anemia has the phenotype of ACD: hepcidin levels in both asymptomatic (22’97) and 
febrile malaria (95>94>166) are increased and associated with body iron maldistribu- 
tion. (245) Hemolysis and increased erythrophagocytosis of both uninfected and in- 
fected erythrocyt.es may further increase macrophage iron stores. (14,18)
An increasing amount of evidence suggests that iron status and changes in body iron 
distribution influence the risk for and severity of malaria and co-infections. (246>67-247) 
ID protects against malaria infections in young children (102) and pregnant women (54) 
and large iron supplementation trials in malaria-endemic regions showed increased 
mortality in iron replete children that were assigned to the iron supplementation 
group/100,248) Hypoferremia induced by hepcidin is considered an ancient defense 
mechanism by depriving extracellular proliferating microorganisms from iron. Hep­
cidin was also shown to have direct defensin-like antimicrobial properties, (249,113) 
although in vivo circulating levels were too low to exert bactericidal functions/34) 
During malaria, upregulation of hepcidin may thus protect against severe disease by 
inducing hypoferremia. In addition, hepcidin may inhibit development of the liver 
stages of P. falciparum infections by redistribution of iron to macrophages at cost of
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the iron content of hepatocytes. 1^06-*
Iron supplementation may abrogate this iron withholding response facilitating the 
growth of Plasmodiae, which offers an explanation for the observed increases in 
malaria-associated morbidity and mortality during iron supplementation. However, 
it is currently uncertain whether a surplus of circulating iron could augment blood 
stage virulence. (67>247) Also this increased body iron availability may negatively influ- 
ence the innate immune responses required to control the infection. (25°) Alternatively, 
the increased morbidity in malaria may be related to the occurrence of co-infections. 
The amount of intra-macrophageal iron is likely to be higher after iron supplementa­
tion, which may, in turn, benefit other intracellular replicating microorganisms such 
as Salmonella spp. and Mycobacterium tuberculosis whose growth is dependent on 
1^ .  (8>2 5 ° . 5 ? )
Non-typhoidal Salmonella (NTS) are among the most common blood stream isolates 
in febrile individuals in sub-Saharan Africa. (80>251) Invasive NTS disease has a high 
morbidity and mortality, particularly in individuals infected with HIV or malaria 
and in those with anemia and malnutrition. (60>63>251) ln Chapter 2, we describe the 
epidemiological evidence linking malaria with NTS infections. Recently, a new study 
from Tanzania confirmed that febrile children from a high malaria risk area were more 
prone to NTS infections than those from a low-risk area. (252^ In addition, Scott and 
coworkers reported that protection against Gram-negative bacteremia, mainly NTS, 
was attributable to the falling malaria incidence in children in Kenya. (82) We hy- 
pothesized and provided evidence that malaria-induced iron maldistribution promotes 
replication of Salmonella. Apart from iron, several other factors may be of importance 
in the relation between malaria and NTS infections such as host immune status, age, 
environmental and social economic factors (like sanitation and hygiene). (253.252)
An additional explanation for the association between malaria and co-infections is the 
presence of circulating heme resulting from malaria-induced hemolysis. As a result of 
the hemolysis, the enzyme heme-oxygenase 1 (HO-1) is up-regulated in macrophages, 
neutralizing heme into iron, biliverdin and carbon monoxide. In a mice malaria-NTS 
co-infection model, both HO-1 and heme suppressed the oxidative burst function of 
granulocytes resulting in impaired bacterial killing function of these granulocytes. (125) 
In addition, treatment of the co-infected mice with HO-1 inhibitors suppressed the 
growth of the NTS bacteria, which underscores the negative effects of hemolysis during 
malaria. Interestingly, this importance of HO-1 may also be linked to recent observa- 
tions that Salmonella induce and maintain hemophagocyte macrophages which could 
serve as a nutriënt source for iron (requiring HO-1 activity). (-254-) This observation 
may also explain the described asymptomatic persistence of the bacteria in the hu- 
man host, provided the Salmonella can reside in the hemophagocytic macrophage, 
as described in mice experiments. (254>255) Although speculative, it suggests that NTS 
could profit from the malaria-induced erythrophagocytosis which we discussed be-
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fore.
As different reports mention a link between anemia and NTS, (60>63) macrophageal 
iron handling may thus appear to be an important process in malaria-associated ane­
mia and in co-infections with NTS. Iron handling by macrophages during malaria 
infection may change because of erythrophagocytosis of P. falciparum infected RBCs 
(pRBCs) or uninfected red blood cells (uRBCs), which may result in the release of 
heme or inflammatory mediators. Therefore, in a set of in vitro experiments that are 
described in Chapter 4, we explored the effects of pRBCs and uRBCs on macrophage 
iron homeostasis in more detail. Different cellular iron related proteins are involved 
in iron recycling of phagocytosed erythrocytes, including HO-1, the iron transporters 
divalent metal transporter-1 (DMT-1) and natural resistance-associated macrophage 
protein-1 (Nramp-1), the iron storage protein ferritin and the sole iron exporter ferro­
portin. (16>84) We found that both pRBCs and uRBCs increased the gene expressions of 
human or mouse macrophage HO-1, ferritin and ferroportin as well as the intracellular 
iron content. Heme is involved in the transcriptional regulation of many of the iron 
regulatory proteins. (160-85-84) ln contrast, expression of the hepcidin gene (Hamp) in 
macrophages did not increase upon stimulation with pRBCs. Finally, gene expression 
profiles of other iron genes, ferritin, DMT-1 or Nramp-1 were not significantly altered 
by parasitized RBCs. Since these proteins encoded by these genes have functional 
roles in macrophage iron handling after erythrophagocytosis, this finding suggests 
that the protein expression is post-transcriptional controlled. The iron-responsive el- 
ement/iron regulatory protein (IRE/IRP) regulatory system is important hereby to 
maintain cellular iron homeostasis. ^ 87-* The binding of the IRPs to IREs to the un- 
translated regions of the target mRNA of H- and L-ferritin, DMT-1 and ferroportin 
regulate the expression of their encoded proteins.
Overall, the effects of erythrophagocytosis with release of heme within macrophages 
appeared to overwhelm inflammatory-dependent changes on macrophage iron han­
dling, which complicated the assessment of Plasmodium-specific changes in iron han­
dling by macrophages. However, our data suggest that macrophage iron homeostasis 
is more influenced by the parasite-effects on the RBCs than by the direct effect of the 
parasite itself. Our data were in contrast to findings by Armitage et al. who reported 
that pRBCs did increase hepcidin transcripts in macrophages. (88^  These differences 
might be attributed to the use of higher pRBC to monocyte/macrophage ratio, or the 
use of two different plasmodial strains. In addition, we have examined the effects of 
pRBCs on hepcidin transcripts in different human macrophages (Ml-differentiated, 
M2-differentiated and PBMCs, the latter two are unpublished explorative data) and 
mouse macrophages with similar negative results.
We also found increases in mouse macrophage ferroportin gene expression after chal- 
lenge with pRBCs, which we also attributed to heme, (85>84) but this increase tended 
to be lower after phagocytosis of pRBCs compared to uRBCs. Pro-inflammatory
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cytokines are known to decrease ferroportin transcription, (9M59) and Plasmodium- 
associated inflammation may limit the heme-induced increase in ferroportin. The 
net result might be a further increase in iron loading of macrophages. The expres­
sion of ferroportin at the protein level appeared however technically complex which 
is an important limitation of our studies as ferroportin protein levels are also post- 
transcriptionally controlled. (87)
Salmonella spp. reside in phagosomes in macrophages and high iron concentrations 
in these organelles could therefore facilitate their multiplication. At present, there 
is however no reliable method to analysis of the intracellular iron distribution under 
various conditions. Iron is namely a toxic compound that is mostly protein-bound 
and only detectable when unbound (labile). Furthermore, cellular concentrations of 
labile iron are very low and easily subjected to changes in medium composites, redox- 
potentials and pH. (256) Techniques that are currently under development include the 
visualization of iron with the aim of fluorophores that are able to chelate and quenche 
iron, ideally in a subcellular specific manner. However the precise quantification of 
iron in the various cellular compartments is complicated by factors as described above 
and the uncertainty of the chemical structures of these fluorophores that exist under 
in vivo conditions.(-257)
As the association between malaria and NTS infections seems important, we suggest 
future studies that should explore the occurrence of salmonellosis and other intra­
cellular bacterial infection in iron supplementation trials in malaria endemic regions. 
The hypothesis that Salmonella susceptibility is increased in iron-rich macrophages 
could be further supported by studying the relation between salmonellose and sickle 
cell disease, (258-259) as the latter condition is also characterized by increased hemoly- 
sis and hence macrophage iron turnover rate. Furthermore, in vitro studies could be 
used to explore whether the persistence or multiplication of Salmonella is increased 
upon stimulation with parasitized RBCs and supplemental iron. Finally, in mice ex­
periments the effects of malaria could be further analyzed and related to the host 
iron status, hepcidin and inflammatory parameters. All these experiments will hope- 
fully improve our insight of the complex interaction of inflammatory, erythropoietic 
and iron sensing signals of hepcidin regulation in an infectious environment. (260>67) 
Ultimately, these insights may hopefully improve iron supplementation strategies in 
malaria-endemic areas.
Iron metabolism in pregnancy and placental malaria
ID is very common during pregnancy and is related to fetal growth restrictions, cogni- 
tive impairments and anemia of mother and child. (26i) Also, malaria during pregnancy 
is associated with maternal anemia and adverse outcomes for the child, including fe-
115
10. General Discussion and Summary
tal anemia. (247>27) In line with this is the observation that intermittent antimalarial 
chemoprophylaxis early in pregnancy prevents severe maternal anemia. (262^  To un- 
derstand the relative importance of the various factors involved in maternal iron 
homeostasis and hu man placental iron transport, we explored the influence of anemia 
and placental malaria on iron homeostasis of both the mother and the child. More in- 
sights in gestational hepcidin levels are relevant regarding the rationale of widespread 
iron supplementation strategies in pregnancy as the absorption of iron may be im- 
paired in conditions of raised hepcidin levels.
At first we studied hepcidin responses during normal pregnancy (healthy Dutch preg­
nant women), as these data were lacking so far (Chapter 5). Thereafter, hepcidin 
and iron status parameters were assessed in stored blood from mothers from Gabon 
with and without placental malaria, and we related the data of these mothers with 
cord-blood levels of hepcidin and other iron parameters from their offspring (Chap­
ter 6). The main finding in normal pregnancy is the decrease in serum hepcidin 
with the nadir in the third trimester. The almost undetectable hepcidin levels that 
we found, indicating absolute ID, together with the data on concomitant changes 
in serum ferritin, iron and transferrin saturation, reflect the mothers efforts to meet 
the increased iron requirements throughout the pregnancy. The signals that decrease 
hepcidin levels during gestation are unknown but are likely driven by maternal ID 
due to transfer of iron to the fetus and the physiological enhancement of the ery­
thropoiesis. Studies that include hepcidin in pregnant women are scarce: a recent 
systematic review reported the data from ten studies, including the two chapters of 
this thesis. (30) Although differences in methodology preclude a direct comparison, the 
overall conclusion that hepcidin levels drop when pregnancy progresses is in line with 
our findings.
Furthermore we found that hepcidin levels raised immediately after the delivery in 
healthy pregnant women and the observed concentrations were similar to the levels 
at parturition in Gabonese mothers. Together, these findings support the hypothesis 
that the observed hepcidin levels directly postpartum were an effect of inflammatory 
cytokines, which are produced due to the intense demands of birth. t-263^
In the Gabonese mothers, parturition hepcidin levels were equal regardless of the 
presence of anemia or placental malaria, which may have been the consequence of 
the cytokine activation during parturition that may dominate subtle changes induced 
by placental malaria. This is in line with the finding that the hepcidin levels of the 
Gabonese mothers were relatively high for the degree of ID, as defined by their low 
serum iron indices. In general, the number of studies on serum iron parameters in 
pregnant women in developing countries is limited. A recent meta-analysis of iron 
indices in pregnant women with or without malaria infection, including our Gabon 
study, found similar to our report increased ferritin levels in the women with malaria, 
but no differences in serum iron, total iron binding capacity or transferrin, transferrin
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saturation and soluble transferrin receptor (sTfR)/54)
In addition, the Gabon study allowed us to study the association between placental 
malaria or maternal iron status and fetal iron stores at term. We found no difference 
in hepcidin levels, iron parameters or inflammatory marker C- reactive protein (CRP) 
in cord-blood between children born to mothers with and without placental malaria. 
Neither had any of the newborn signs of anemia or ID in their cord-blood parame­
ters. From this and other studies it appears that the iron transport over the placenta 
is maintained during placental malaria. (261’3°) However, the success of malaria pre- 
vention and iron supplementation strategies in improving infant outcomes even so 
suggest that these adaptation mechanisms are somehow compromised. *-54) Also, ges- 
tation period can be of influence as experiments in rats showed that the dams were 
more vulnerable to ID early in the pregnancy. (264) Nonetheless, it is unknown how 
exactly the transfer of iron across the placenta is regulated. Transferrin-bound iron 
is transported across the maternal site of the placenta and iron, after being released 
into the cytosol, is likely to be transported into the fetal circulation by ferroportin 
that is present on the basolateral side of the syncytiotrophoblast. (25fl’26°) Current 
opinion is that both maternal and fetal hepcidin play a role in the regulation of pla­
cental iron transport, and that maternal ID results in increased iron transfer over the 
placenta. (202>261-30) However, we and other researchers found no correlation between 
maternal hepcidin and fetal hepcidin or iron stores/176,265) Nevertheless, maternal 
hepcidin correlated strongly to placental iron transport in a small human iron tracer 
study/265) One can argue that association studies between maternal and fetal iron 
indices might be insufficiënt to unravel placental iron transport regulators, because 
maternal and neonatal iron status are inherently linked, not all placental iron trans- 
porters are yet known, and, because specifically under more complex situations as 
with placental malaria different regulatory mechanisms are involved.
Although our studies revealed some important data on iron homeostasis in pregnancy, 
they are not designed to inform us about the role of these iron status parameters in 
guiding iron supplementation programs. However, the low hepcidin levels observed 
in normal pregnancy suggest that hepcidin can be used as a marker for ID to pre- 
dict response to oral iron supplementation. Clearly, more research is needed on the 
possible role of serum hepcidin levels in selecting those pregnant women who might 
benefit most from iron supplementation. Most importantly, the changes of hepcidin 
in the course of pregnancy should be explored in malaria-endemic areas to enhance 
our insights of human iron biology under these conditions. In addition, we recom- 
mend to include the assessment of hepcidin and iron status parameters in malaria 
prevention studies in pregnant women. The ultimate goal of these studies is to de- 
fine a biomarker that can be used to optimize iron supplementation during pregnancy.
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The value of hepcidin and hemoglobin content parameters 
in evaluating body iron status during chronic inflammatory 
conditions
Similar to malarial anemia, the diagnosis of absolute ID in anemie patients with 
chronic inflammatory conditions is a diagnostic challenge. The correct differentiation 
between ACD, ID, and concurrent ID/ACD is important as patients with the latter 
two conditions may benefit from iron therapy and a diagnostic work up of the etiol- 
ogy of the anemia. Currently available iron status indicators, such as serum ferritin, 
transferrin and serum iron, are not well suited to differentiate between these condi­
tions as they are affected by inflammation.
In Chapters 7,8 and 9, we studied the potential role of hepcidin and the hemoglobin 
content of reticulocytes and mature erythrocytes (Ret-He and RBC-He, respectively, 
assessed on a Sysmex analyzer). These new parameters provide insight in iron incor- 
poration in hemoglobin of red blood cells over the past few days (Ret-He) and weeks 
(RBC-He) and as such may be tools to diagnose ID. (42) The hematology analyzer 
of Siemens evaluates similar parameters (assessing CHr and CH, similar to Ret-He 
and RBC-He, respectively) and a high correlation has been observed between data 
retrieved from both analyzers. (222) Previous studies have confirmed the clinical util- 
ity of Ret-He as au early marker of iron restricted erythropoiesis, and as a guidance 
for diagnosing functional ID in patients receiving erythropoietin for end stage renal 
failure. (221 >24i ,234,223,221,43,44) Only few data were available for the diagnostic value of 
hepcidin and Ret-He/RBC-He in differentiating ID among patients with anemia and 
a chronic inflammatory disease. We performed therefore two studies in patients with 
chronic rheumatic diseases assessing the value of hepcidin and the new iron incorpo- 
ration parameters of the Sysmex analyzer: a cross-sectional study (Chapter 7) and 
an intervention study in which anemie patients were prescribed oral iron supplemen­
tation (Chapter 9).
The main finding of the cross-sectional study was that serum hepcidin levels, and 
to lesser extent Ret-He and RBC-He values, were reliable indicators of ID in this 
population. Still, hepcidin levels were only modestly increased in ACD compared 
to the ID/ACD group and remained within the reference range. (184) The degree of 
inflammation in our cohort was probably too low to induce a pronounced rise in 
hepcidin production. Alternatively, the inflammation-mediated up-regulation of hep­
cidin may have been overruled by the suppressive effects of ID (the iron, erythropoi- 
etic or hypoxia signaling pathways). Indeed, animal studies in rats with ACD and 
ID/ACD indicate that iron-dependent down regulation of SMAD phosphorylation, a 
process that is required for transcription of hepcidin, overrules the upregulation of the 
inflammatory-mediated pathway (via STAT 3).(266) Iron deficient rat and not those 
with enhanced erythropoiesis blunted the increase of hepatic hepcidin expression in
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a model with acute inflammation in another study/169) This hierarchy in hepcidin 
regulation favors a role for hepcidin as a parameter to distinguish ID among ane­
mie patients with a inflammatory disease. Similar results for hepcidin as a potential
biomarker for ID in the presence of inflammation have been demonstrated by oth- 
ers (227,231)
In addition, we observed that Ret-He and RBC-He discriminated -albeit with less 
power- patients with ID/ACD from those with only ACD. This observation has not 
been documented before. While Ret-He levels decrease rapidly in conditions with 
acute inflammation, such as pneumonia or acute malaria/96,267) we found Ret-He 
levels similar (and not reduced) in ACD compared to the non-anemic RA patients, 
suggesting that iron incorporation in hemoglobin is largely undisturbed despite the 
low-grade inflammation and hypoferremia. The observation that erythroblasts pos- 
sess speciflc ferroportin proteins that are only influenced by hepcidin and not by 
iron levels (268) may explain why iron incorporation remains normal: in inflammatory 
conditions, hepcidin degrades ferroportin limiting the iron export from erythroblasts. 
This also explains why Ret-He and RBC-He are also lower in ID/ACD than ACD 
alone despite the presence of hypoferremia in both conditions. This iron withholding 
mechanism may fail in situations with more pronounced inflammation and this may 
explain why others found lower Ret-He levels in ACD patients compared to healthy 
Controls/235) Of note, both RBC-He and the mean cell hemoglobin (MCH) concen­
trations represent the hemoglobin content, but these parameters differ in the way 
they are analyzed (Chapter 8). The former is a direct measure of intra-erythrocyte 
hemoglobin content (assessed by fluorescent optica! counting), whereas MCH is a 
calculation based on whole blood intra- and extracellular hemoglobin concentrations 
(assessed by hemoglobin photometry) divided by erythrocyte concentrations (mea- 
sured by impedance counting). In our cohort of chronically diseased patients, these 
two parameters correlated highly, but the diagnostic accuracy was slightly better for 
RBC-He in differentiating ID in patients with inflammation. One has to acknowledge 
that the assessment of the hemoglobin contents Ret-He/RBC-He or CHr/CH will be 
more costly due to the requirement of additional reagents.
An important limiting factor for the studies exploring the value of iron deficiency 
parameters is the lack of a golden Standard for ID. In fact, in our first study, an 
algorithm, including data on serum iron, ferritin, transferrin saturation and sTfR, 
was used to determine ID. In a second study we used the increase in hemoglobin 
after 6 weeks of iron supplementation as gold Standard for absolute ID in patients 
with chronic inflammation. The rationale of our approach was supported by earlier 
findings that ora! iron could still be absorbed despite the inflammatory status. (46-48) 
Furthermore, it provides medical practitioners with a practical tooi which patients 
may profit form iron treatment. The main findings of our study were that the increase 
in Ret-He, serum iron and transferrin saturation after one week iron therapy were the
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best predictors for the ultimate response to 6 weeks of iron therapy. In contrast to 
serum hepcidin levels at baseline, the change in these levels had no predictive value for 
the hemoglobin response to iron. Baseline levels of ferritin, hepcidin, the sTfR-index 
and RBC-He were also relative good parameters in predicting the response to iron 
therapy in ACD patients.
Despite the fact that parameters such as Ret-He may be a useful addition to our di­
agnostic array in patients with ACD, the ideal iron parameter to diagnose ID in these 
patients still does not exist. The promise of both hepcidin and hemoglobin content 
parameters is at present restrained by the relatively low accessibility of clinically val- 
idated and standardized assays, and the absence of the definition of clinical decision 
limits. Whereas the measurement of hepcidin requires a separate blood sample, the 
advantage of hemoglobin content parameters such as Ret-He can be measured from 
the same full blood sample as for the whole blood count and hemoglobin, which fa- 
cilitates their routine use in the daily practice.
A combination of hemoglobin content parameters with traditional biochemical iron 
parameters might especially prove useful in daily practice. Based on the findings in 
this thesis, a diagnostic strategy for the assessment of anemie patients with chronic 
inflammatory conditions is proposed in Figure 10.1. When not conclusive at step one, 
oral iron could be prescribed for one week and the hemoglobin content parameters 
re-assessed after one week. In case Ret-He is not increased in comparison to baseline, 
continuation of iron supplementation is not expected to be particularly useful. Of 
course, our studies were relatively small and intended as ’proof of concept’ studies. 
Larger cohort studies should be performed in anemie patients with chronic inflamma­
tory conditions to test this algorithm before it can be introduced in the clinic.
10.2 Summary
Section 1. The interaction between iron, hepcidin and malaria
Absolute iron deficiency (ID) and malaria are among the most important factors 
underlying anemia in malaria-endemic regions. Universal iron supplementation pro­
grams have been considered, but its implementation has been delayed after the results 
of a large randomized controlled trial in Tanzania were published that found increased 
malaria-related mortality and morbidity in iron-replete children that were assigned to 
the iron supplementation arm. The precise mechanisms responsible for the adverse 
events of iron supplementation in this landmark study were unclear.
The aim of the studies described in the first section of my thesis was to study the 
effects of malaria, caused by Plasmodium falciparum, on macrophage iron handling, 
including the role of hepcidin. Hepcidin regulates body iron homeostasis by control-
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Anemia and chronic 
inflammation
step 1
Exclusion of other common 
causes of anemia
Ferritin Ferritin yes
£ 30 Mg/ml* > 200 yg/mr
*
yes
RBC- He
< 1.75 fmoles
and/or
Ret- He
£ 1 .9 5  fmoles
step 2 
n o ------>
1 week iron therapy
1 week Ret- He 
increase
2 0.11 fmoles
-» (ID/ACDi <- yes no -> ( ACD }
may benefit from iron treatment :<
Figure 10.1: Concept diagnostic algorithm for differentiating ID /A C D  from  ACD  
in patients with chronic inflammation.
Determination o f  cut-off vaiues needs to be explored further.
* This level is based on expert-opinion
Abbreviations: ACD, anemia of chronic diseases; Ret-He, reticulocyte-hemoglobin content; RBC-He, 
erythrocyte- hemoglobin content.
ling the uptake of iron in the gut and the release of iron in macrophages. Hepcidin- 
mediated macrophage iron retention is a key process in the pathogenesis of anemia 
of chronic disease (ACD) and it may determine the risk for infections with intracellu­
lar growing micro-organisms, of which Salmonella spp. are the most relevant in the 
African setting. Chapter 2 is a literature review on the epidemiologie evidence of 
the co-occurrence of malaria and invasive non-typhoidal Salmonella (NTS) infections 
and the possible role of iron in this association. Salmonella spp. are obligatory intra­
cellular living bacteria that require iron for multiplication. We review evidence that 
an iron-rich environment is created intracellularly during malaria infections, which is 
likely to promote multiplication of NTS.
In Chapter 4 a set of in vitro experiments are described in which the effects of ery- 
throphagocytosis of uninfected and parasitized red blood cells (RBCs) on macrophage 
iron metabolism were studied. The primary read-outs were the change in iron reg- 
ulatory genes and cellular iron distribution. Our results showed that erythrophago- 
cytosis of both parasitized as well as uninfected RBCs had pronounced effects on 
human or mouse macrophageal iron homeostasis including increased gene expression
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of ferroportin, ferritin and HO-1 and increased intracellular iron contents. There was 
no change in the expression of the hepcidin gene. These dominant effects of ery- 
throphagocytosis suggested that the assessed effects on macrophage iron metabolism 
occur independently of the malaria parasite or its inflammatory response, and may 
be regarded as an effect of the parasite on the RBCs.
Section 2. Iron homeostasis during pregnancy in healthy and 
malaria infection
Anemia is common during pregnancy. In malaria-endemic regions, both ID and 
malaria are important underlying causes. During pregnancy, maternal iron stores 
are depleted by the growing fetus and placenta and by physiologic increases in ery- 
throid mass. In addition, maternal and fetal anemias are well known complications 
of pregnancy-associated malaria. Iron supplementation is frequently given to preg­
nant women, but its efficacy may be reduced in placental malaria by upregulation of 
the iron regulating hormone hepcidin and this may also limit the iron supply to the 
fetus. To have insight in changes in iron homeostasis during normal pregnancies, con­
centrations of serum hepcidin and other iron parameters were determined at various 
time points during pregnancy in healthy Dutch women (Chapter 5). We found that 
hepcidin concentrations decreased gradually to undetectable levels from the first to 
the third trimester. This decrease was paralleled by a decline in hemoglobin levels 
and changes in iron parameters that are consistent with absolute ID. Hepcidin levels 
increased rapidly postpartum to levels similar as in early pregnancy.
Subsequently, in Chapter 6 we describe our study using stored blood that was sam- 
pled at parturition from a cohort of women from Gabon with and without placental 
malaria and in cord blood samples. The main results of this study were that mothers 
had relatively high hepcidin levels considering their low iron status, which was regard- 
less of the presence of placental malaria infection or maternal anemia. In cord blood, 
levels of hepcidin, hemoglobin and other iron parameters were also similar across the 
groups. These findings suggest that placenta malaria has a limited impact on ma­
ternal and fetal iron homeostasis. The data also suggested that iron metabolism is 
biased towards maintaining the fetal iron supply, even in the presence of maternal 
anemia and iron deficiency.
Section 3. The diagnosis of iron deficiency in chronic inflam­
mation
Differentiating ID in patients with anemia and chronic inflammatory conditions (ID/ACD) 
has remained an important diagnostic challenge because most of the available iron
10.2. Summary
status parameters are affected by inflammation. Serum hepcidin levels and the 
hemoglobin content of reticulocytes and erythrocytes have become available as func- 
tional parameters for diagnosing ID. In this section, we assess the potential of these 
relatively new parameters to diagnose ID in concomitant chronic inflammation, and 
aim to select those patients who will benefit from iron therapy.
Chapter 7 compares the value of hepcidin and the hemoglobin content of reticulo­
cyte and erythrocytes (named Ret-He and RBC-He on Sysmex hematology analyzers) 
with conventional iron status parameters in differentiating ID/ACD from ACD in a 
cohort of patients with rheumatoid arthritis. We found that serum hepcidin levels, 
and to a lesser degree values of Ret-He and RBC-He, were significantly lower in pa­
tients with ID/ACD, compared to those with ACD alone. The major limitation of 
this study was the definition of ID: by lack of a gold Standard an algorithm was ap- 
plied that used conventional iron parameters which preludes comparison of these with 
the new biomarkers. Moreover, these parameters are potentially influenced by the in­
flammation. To overcome this issue, a follow-up study was conducted in which the 
definition of ID/ACD was deflned on the hemoglobin response to iron supplementa­
tion. In Chapter 9, we report our findings of the value of Ret-He, RBC-He, hepcidin 
and conventional iron parameters, and their change after one and two weeks of iron 
supplementation, to predict the increase in hemoglobin level and to determine the 
chance of being a responder after six weeks of iron therapy. We found that changes in 
Ret-He, serum iron and transferrin saturation -and not hepcidin- one week after start 
of iron therapy were superior in predicting the hematopoietic response after six weeks 
of this therapy in anemie patients with a chronic rheumatic disorder. Baseline levels 
of ferritin, hepcidin, the sTfR-index and RBC-He were also relative good parameters 
in predicting the response to iron therapy in ACD patients. We conclude that when 
baseline results of ferritin or other conventional iron parameters do not allow to es- 
tablish a diagnosis of ID, the change in Ret-He values after one week of oral iron may 
guide whether continuation or iron supplements is justifled.
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Voor de meesten van u, familieleden, vrienden, kennissen en collegae, is dit proefschrift 
waarschijnlijk geen gemakkelijke kost. Toch hoop ik u met onderstaande uitleg en 
samenvatting mee te kunnen nemen naar dat wat mij de afgelopen jaren zo enorm 
heeft geïntrigeerd én bezig gehouden.
Deel 1. De interactie tussen ijzer, hepcidine en malaria
Anemie (bloedarmoede) kan verschillende oorzaken hebben, maar in de tropische ge­
bieden waar malaria voorkomt is dat meestal het gevolg van ijzertekort en een malaria 
infectie. Malaria wordt veroorzaakt door een parasiet (genaamd Plasmodium Falci­
parum) die via een mug wordt overgebracht naar de mens om daar zijn levenscyclus 
in lever en in rode bloedcellen (RBC) te volbrengen. Vooral deze laatste ’bloedfase’ 
kan tot anemie lijden. Het ijzertekort, door bijvoorbeeld slechte voeding, worminfec- 
ties of bloedverlies speelt met name bij kinderen en jonge (zwangere) vrouwen een 
belangrijke rol in het ontstaan van de anemie in deze gebieden. Er werden program- 
mas bedacht om extra ijzer te kunnen geven, maar de uitvoer hiervan moest worden 
uitgesteld met de uitkomst van een grote gerandomiseerde en gecontroleerde studie 
in Tanzania naar het effect van ijzersupplementatie in kinderen. Deze belangrijke 
studie rapporteerde dat er meer malaria-gerelateerde mortaliteit en morbiditeit was 
in die kinderen die géén ijzerdeficiëntic hadden, maar wél ijzersuppletie kregen. Het 
onderliggende mechanisme van deze nadelige effecten van ijzersupplementatie is on­
duidelijk en deze uitkomst heeft een aantal vragen opgeroepen die (ten dele) de basis 
vormen van dit deel van mijn proefschrift.
Het doel van mijn studies zoals beschreven in het eerste deel van dit proefschrift, 
is het bestuderen van het effect van malaria op het ijzermetabolisme van macrofa- 
gen (witte bloedcellen die een functie hebben in de afweer). Het merendeel van het 
lichaamsijzer wordt namelijk hergebruikt en opgeslagen in macrofagen en daarom
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brengen deze cellen verschillende eiwitten tot expressie die van belang zijn voor het 
ijzermetabolisme (bijvoorbeeld voor opslag en transport van ijzer). Ijzer is belangrijk 
voor de opbouw van de RBC. In de verdeling van het lichaamsijzer speelt het centrale 
ijzer regulerende hormoon hepcidine een belangrijke rol: het bepaalt de mate van 
opname van ijzer uit de darmen en de vrijgave van ijzer uit de macrofaag. Infecties 
of ontstekingen kunnen tot anemie lijden, onder andere door een verhoging van het 
hepcidine waardoor het ijzer wordt vastgehouden in de macrofaag. Er lijkt een relatie 
te bestaan tussen het ijzermetabolisme van deze cellen en het risico op infecties met 
micro-organismen die in de macrofaag (intracellulair) groeien én ijzer nodig hebben 
voor hun groei. Het meest relevante voorbeeld voor de Afrikaanse setting zijn de 
Salmonella bacteriën. Vooral niet-typhoidale Salmonella (NTS) soorten kunnen tot 
gevaarlijke (invasieve) bloedbaan infecties lijden.
Hoofdstuk 2 is een literatuuronderzoek naar het epidemiologische bewijs van het 
samen vóórkomen van malaria en invasieve NTS infecties en een studie naar de mo­
gelijke rol van ijzer in deze associatie. Wij beschrijven dat door de malaria infectie 
om verschillende redenen het macrofaag ijzergehalte kan toenemen, hetgeen voordelig 
kan zijn voor de NTS bacteriën om te kunnen groeien en vermeerderen.
In Hoofdstuk 4 wordt verslag gedaan van laboratoriumexperimenten waarin het ef­
fect van erythrofagocytose (het fagocyteren/ ’opeten’ van RBC door de macrofaag) 
wordt bestudeerd op het ijzermetabolisme van de macrofaag. Meer specifiek, er is 
gekeken naar de invloed van zowel P. falciparum geparasiteerde, als gewone niet- 
geïnfecteerde RBC op de verandering in ijzer-regulatoire genen en ijzerverdeling. Wij 
vonden dat erythrofagocytose van zowel geparasiteerde als ongeïnfecteerde RBC be­
langrijke effecten heeft op het macrofaag ijzer metabolisme en dan met name op de 
genexpressie van ferroportin, heme-oxygenase-1 (HO-1) en op een toename van het 
intracellulaire ijzergehalte. De genexpressie van hepcidine veranderde niet. De sterke 
effecten van de erythrofagocytose in deze experimenten suggereren dat de onderzochte 
veranderingen in macrofaag ijzermetabolisme onafhankelijk van de malaria infectie of 
de bijkomende ontstekingsreactie gebeuren, en waarschijnlijk meer een effect zijn van 
de parasiet op de RBC zelf.
Deel 2. IJzerhomeostase tijdens een gezonde zwangerschap 
en tijdens een malaria infectie van de placenta
Anemie komt veelvuldig voor tijdens de zwangerschap. Tijdens de zwangerschap 
worden de ijzervoorraden van de moeder gebruikt door de groeiende foetus en pla­
centa, en voor de aanmaak van nieuwe RBC. In malaria-endemische gebieden is in 
de zwangerschap naast het ijzertekort (ID) ook de malaria infectie zelf geassocieerd 
met anemie van zowel moeder als pasgeborene. IJzersupplementen worden daarom
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frequent voorgeschreven aan zwangere vrouwen, maar in het geval van malaria is het 
de vraag of het ijzer ook kan worden opgenomen. Het is namelijk aannemelijk dat 
de concentratie van het ijzerregulorende hormoon hepcidine in bloed omhoog gaat. 
Als hepcidine verhoogd is wordt het oraal ijzer mogelijk minder goed geresorbeerd en 
wordt mogelijk ook de foetale ijzertoevoer beperkt. In dit deel van het proefschrift 
worden hepcidine en andere serum ijzer parameters tijdens de zwangerschap geanal­
yseerd om het inzicht in het ijzermetabolisme tijdens zwangerschap te vergroten.
In Hoofdstuk 5 werden deze ijzerparameters op verschillende tijdspunten in de 
zwangerschap van gezonde Nederlandse vrouwen bepaald. We vonden dat hepcidine 
concentraties langzaam afnamen tot onmeetbaar lage waarden in het derde trimester. 
Dit ging samen met een afname in het hemoglobine gehalte en met veranderingen 
in ijzerparameters passend bij de ontwikkeling van een absoluut ijzertekort. De hep­
cidine concentratie nam postpartum weer toe naar waarden zoals gemeten aan het 
begin van de zwangerschap.
Vervolgens beschrijven we in Hoofdstuk 6 onze studie naar hepcidinewaarden in 
zwangeren uit Gabon, met en zonder malaria infectie van de placenta of anemie, en 
hun pasgeborenen. De ijzerparameters werden bepaald in bloedmonsters afgenomen 
tijdens de partus en in navelstrengbloed van de pasgeborenen. De belangrijkste resul­
taten van deze studie waren dat de maternale hepcidine concentraties relatief hoog 
waren gezien hun lage ijzerstatus, en dat deze bevinding onafhankelijk was van het 
hebben van placenta malaria of anemie. In het navelstrengbloed waren concentraties 
van hepcidine, hemoglobine en andere ijzerparameters ook gelijk tussen moeders met 
of zonder placenta malaria of anemie. Deze resultaten suggereren dat de invloed van 
placenta malaria op maternale en foetale ijzerhomeostase beperkt is. Ook sugger­
eren deze data dat het ijzermetabolisme tijdens de zwangerschap er opgericht is om 
de foetale ijzertoevoer te waarborgen, ondanks de aanwezigheid van anemie of ijz­
ertekort bij de moeder.
Deel 3. De diagnose van ijzer deficiëntie tijdens chronische 
inflammatie
Het differentiëren van ijzerdefïciëntie (ID) bij patiënten met chronische inflammatoire 
ziekten en anemie (ID/anemie van de chronische ziekten ACZ) is een diagnostische 
uitdaging, omdat de concentraties van de meest gebruikte ijzerparameters (bijvoor­
beeld ijzer, ferritine, transferritine) beïnvloedt worden door de inflammatie. De bloed- 
bepaling van de hepcidine concentratie en de hemoglobine-inhoud van reticulocyten 
en erytrocyten zijn recentelijk beschikbaar gekomen als functionele parameters voor 
ID. In dit deel van het proefschrift wordt onderzocht in hoeverre deze nieuwere pa­
rameters geschikt zijn om ijzertekort vast te stellen in patiënten die ook inflammatie
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hebben, met andere woorden om patiënten met ID/ACZ te selecteren die voordeel 
kunnen hebben van ijzertherapie.
In Hoofdstuk 7 wordt de waarde van hepcidine en de hemoglobine-inhoud van reticu- 
locyten en erytrocyten (afgekort als Ret-He en RBC-He op laboratoriummachines van 
Sysmex) vergeleken met conventionele ijzerstatus parameters om ID/ACZ van ACZ te 
onderscheiden in een cohort van patiënten met reumatoïde arthritis. Wij vonden dat 
bloed hepcidine concentraties, en in minder mate ook Ret-He en RBC-He waarden, 
significant lager waren in patiënten met ID/ACZ vergeleken met patiënten met alleen 
ACZ. Echter de grote beperking van deze studie was dat de ID werd gedefinieerd bij 
gebrek aan een gouden standaard, aan de hand van de conventionele ijzerparameters 
die beïnvloed kunnen zijn door de inflammatie. Bovendien is geen directe vergelijking 
met de nieuwe biomarkers mogelijk. Om dit te overkomen werd een vervolgstudie 
ontworpen waarin de definitie van ID was gebaseerd op een toename in hemoglobine 
concentratie na orale ijzersupplementatie.
In Hoofdstuk 9 doen we verslag van onze bevindingen van de waarde van Ret-He, 
RBC-He, hepcidine en conventionele ijzerparameters, en hun veranderingen na 1 of 
2 weken ijzersuppletie, om te kunnen voorspellen wat (i) de toename in hemoglobine 
concentratie is en (ii) de kans is op een respons na 6 weken ijzertherapie. Wij vonden 
dat in patiënten met anemie en een chronische reumatoïde ziekte de veranderingen 
in Ret-He, serum ijzer en transferrine saturatie -en dus niet hepcidine- 1 week na het 
starten van de ijzertherapie het beste de hemoglobine respons na 6 weken ijzertherapie 
voorspelde. Initiële waarden van ferritine, hepcidine, de sTfR-index (transferrine re­
ceptor/ log ferritine) en RBC-He waren ook relatieve goede parameters om de respons 
op ijzertherapie te voorspellen in deze patiënten. Wij concludeerden dat wanneer de 
ID niet te diagnosticeren is met ferritine of andere conventionele ijzerstatus param­
eters, de verandering van Ret-He concentratie na een week orale ijzertherapie een 
goede marker is om te bepalen of het zinvol is de suppletie voort te zetten.
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Dankwoord
Zelf open ik altijd als eerste déze pagina van een proefschrift en het zal u dan ook 
niet verbazen dat ik mijn uiterste best heb gedaan op dit hoofdstuk... en dat is een 
uitdaging op zich geworden, nu mijn promotietraject zich zoetjesaan over heel wat 
jaren uitgespreid heeft...
Mijn grote dank gaat allereerst uit naar de patiënten en zwangere vrouwen die vrij­
willig meegewerkt hebben aan ’de’ wetenschap, ookal hield dat in dat ze een of 
meerdere malen hun bloed moesten laten prikken of ijzertabletten innemen. Het con­
tact met hen heeft een bijzondere extra dimensie aan mijn onderzoekstraject gegeven.
Uiteraard wil ik graag mijn promotoren en co-promotor bedanken. Professor André 
van der Ven, beste André, toen ik mijn ambities voor wetenschappelijk onderzoek 
kenbaar maakte aan professor van der Meer raadde hij mij aan met jou contact op 
te nemen. Dat heb ik geweten! Enthousiast en vol ideeën als jij altijd bent gin­
gen we aan de slag om beurzen aan te kunnen vragen. We zijn over pieken en dalen 
gegaan, maar bevinden ons inmiddels op een prettig plateau. Ik heb veel bewondering 
voor jouw energie, jouw passie in het vak, de wetenschap en jouw nooit ophoudende 
ideeënstroom. Ik heb veel van je geleerd, dank je wel daarvoor.
Professor Dorine Swinkels, lieve Dorine, bij onze eerste ontmoeting vroeg je me of ik 
handig was in het lab -geen idee natuurlijk- , maar ik knikte maar ja en zo startte 
onze samenwerking. Jij hebt mij begeleid in het pittigste deel van dit proefschrift, 
en bleef, ondanks de tegenslagen in het onderzoek resultaten zien: tekenend voor 
jouw positivisme en oplossingsgerichte manier van werken. Jouw kracht, energie 
en doorzettingsvermogen, maar ook de inzet waarmee jij je hard maakt voor jouw 
mensen, laboratorium en ijzeronderzoek is inspirerend om te zien en ik kan alleen 
maar hopen dat ik daar maar een greintje van meeneem in mijn verdere carrière. De 
mooie momenten buiten de werkvloer zal ik ook niet snel vergeten: het samenspelen
in het CWZ (!) bedrijfshockeyteam, de jaarlijkse barbecue bij jouw thuis, een dans­
feest in Porto of biertjes in St Gallen___Dank voor je begeleiding in dit project.
Quirijn, ik nam jouw stoel over in de ’Priorkamer’. In de periode dat jij mij begeleidde 
ben je gegroeid van aios naar staf en van promovendus naar begeleider van promovendi 
(van diverse nationaliteiten) en ondertussen ook vader geworden. Ik bewonder hoe jij, 
altijd goedlachs, die transitie vrijwel geruisloos hebt doorstaan en mij ook nog hebt 
weten te begeleiden. Jij bent een kei in het condenseren van resultaten tot de kern 
en dat verwoorden in leesbare taal. Dank voor al je inspanningen!
Speciale dank ook voor de leden van de manuscriptcommissie, professor Sauerwein, 
professor Boele van Hensbroek en dr. Van Dillen voor hun inspanningen en het goed­
keuren van mijn manuscript.
Als ik Priorkamer, de overlegruimte van de afdeling internationale infectieziekten 
(NIIH), zeg, dan zeg ik ook Hinta Meijerink. Hinta, wij hebben zo ongelofelijk veel 
gedeeld als partners in crime, dat valt niet meer te beschrijven en dat ga ik ook niet 
proberen. Jij bent vorig jaar gepromoveerd en werkt nu vanuit Oslo. Ik wens je heel 
veel succes toe in je carrière en hoop je niet uit het oog te verliezen. Alle passanten 
en bewoners van de Priorkamer, vanuit alle windstreken, van Indonesië tot Tanzania, 
dank voor de gezellige momenten en succes in jullie carrières. De afdeling NIIH kon 
niet bestaan zonder het lieftallige trio Mieke, Carla en Maureen, jullie support ging 
zo veel verder dan het secretaresse werk! Henri van Asten, dank voor je hulp met de 
statistiek. Meta, onze projecten, zowel qua opleiding, wetenschap als zwangerschap­
pen liepen grotendeels parallel, hetgeen maakte dat wij elkaar op al deze fronten goed 
konden ondersteunenen ook zeker nog zullen blijven afspreken.
Mijn onderzoek heeft zich grotendeels afgespeeld op twee laboratoria, die van de ex­
perimentele interne geneeskunde en die van de ijzergroep. Professor Leo Joosten, als 
hoofd van het lab interne geneeskunde waak jij op een bijzonder prettige en vrien­
delijke wijze over het uitdijende schip aan projecten van studenten en promovendi en 
heb jij ook mij, als vreemde eend in de bijt, meerdere malen van nuttige adviezen 
voorzien. Ook professor Mihai Netea ben ik veel dank verschuldigd voor zijn inter­
esse, ideeën en suggesties ten aanzien van mijn project. De grondvesten van het lab 
bestaan (en bestonden) uit Liesbeth, Trees, Heidy, Anneke, Ineke, Magda, Helga en 
natuurlijk ook Cor, die ik in het bijzonder wil bedanken voor zijn hulp met de FACS. 
Jullie hebben mij ontelbare keren geholpen en wegwijs gemaakt in het bedrijven van 
basaal wetenschappelijk onderzoek. Ook de vele andere (ex) collega- onderzoekers 
dank voor jullie hulp en succes met jullie carrières!
Het ijzerlab met professor Dorine Swinkels aan het hoofd bestaat uit een bijzondere 
groep mensen met wie ik veel mooie momenten zowel op de werkvloer als erbuiten 
heb mogen beleven. April Kartikasari, als post-doc leerde jij mij de eerste stappen 
van het onderzoek: pipetteren, cellen kweken, etc. etc.. Jouw carrière heeft zich 
elders voortgezet en ik wens je daar veel succes bij. Erwin Wiegerinck jij bent een
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ongelofelijk vrolijke, snelle en harde werker en samen hebben wij heel wat uurtjes 
RNA gesoleerd, dank voor je hulp en inzet voor mijn project! Rianne, Coby en Siem 
jullie hebben mij ook ontelbare keren van hulp voorzien, Harold, Joyce, Annemarie 
en Guus dank voor de vele kofüemomenten en discussies tijdens de dinsdagmiddag 
meeting.
Diverse personen buiten deze afdelingen hebben mij geholpen op verschillende mo­
menten binnen het onderzoekstraject. Ik noem de afdeling parasitologie van het 
Radboudumc onder leiding van professor Sauerwein en dan met name Marga van 
de Vegte en Wouter Graumans. Jullie hebben je ongelofelijk ingezet om voor mij 
veel en ’mooie’ parasieten te kweken. Dank jullie. Matthew McCall je was een fij­
ne ’malaria vraagbaak’. Bas Pennings en Frank Wagener, nooit bedacht dat ik me 
binnen het tandheelkundegebouw zou begeven voor discussies en metingen aangaande 
het metabolisme van heem. Fantastisch dat jullie mij ’zomaar’ hielpen. Diverse malen 
ben ik de tunnel doorgestept die naar het Triganongebouw voert om mijn Salmonella 
bacteriën te kweken in het laboratorium van professor Hermans. Dank voor jul­
lie gastvrijheid en hulp bij het opzetten en uitvoeren van mijn experimenten, ookal 
hebben die de drukpersen nooit gehaald. Henri Dijkman van de afdeling patholo­
gie ben ik ook veel dank verschuldigd voor het meedenken om intracellulair ijzer te 
meten en het maken van prachtige plaatjes (zie Hoofdstuk 4). Vele uren heb ik 
achter jullie microscoop doorgebracht, dank daarvoor. Special thanks to professor 
Ioav Cabantchik (Department of Biochemistry, Institute of Life Sciences, Hebrew 
University of Jerusalem, Israël) and his PhD students Sohn and Shvartsman for your 
sharing of knowledge and skills regarding cellular iron measurements and your warm 
hospitality in Israel. Thanks for all our fruitfull discussions and it was nice to show 
you around in Nijmegen.
Dit onderzoek heb ik gecombineerd met mijn opleiding tot internist. Ik ben profes­
soren Jos van der Meer en Jacqueline de Graaf veel dank verschuldigd voor hun steun 
en hun flexibiliteit in het telkens weer ombuigen van het opleidingsschema. Vera 
Matthijssen, als opleider in Arnhem heb jij mij maximaal gesteund in mijn onder- 
zoeksambities en mij de ruimte gegeven om een start te maken met dit project. Dank 
je wel hiervoor en ik hoop dat wij elkaar in de toekomst nog mogen tegen komen, al 
was het om onze verjaardagen te vieren. In de jaren heb ik ook veel collega- aiossen 
en -onderzoekers leren kennen, jullie maakten het op werk extra leuk. Buurvrouw 
Johanneke, jouw promotiedatum komt ook in zicht en ook jij bent bijna internist- 
infectioloog, gek idee dat we een tijdperk samen gaan afsluiten. Je bent een lieve 
vriendin, dank voor al je hulp en fijn dat je mijn paranimf wil zijn!
Hard werken kan ik niet non-stop. Gelukkig zijn er mijn lieve vriendinnen Emie, 
Elske, Maartje, Esther, Maaike, Femke, en Lot. Ik ben er trots op jullie vriendin te 
zijn en vind het machtig mooi te zien hoe wij eenieder ons weg in het leven vinden. 
Carolien, heerlijk om met jouw te kunnen discussiëren over andere zaken dan het
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ziekenhuis. Als eerstejaars binnen dispuut Pleiadis was jij mijn praeses, maar die 
hiërarchie heeft niet lang stand gehouden en het is voor mij niet meer dan logisch dat 
jij mijn paranimf bent. Pauline, Suzanne, Nynke, Eefje, Maite, Nienke, Guusje en 
alle andere pleiaden, ik hoop jullie eindelijk weer veel te kunnen zien. Union dames 4, 
pas maar op, ik ben er weer voor de derde helft. Zus meer dan dank voor je liefde en 
support en ik verheug me op meer weekendjes in de bergen met onze gezinnetjes (in 
welk werelddeel dan ook). Julien, merci beaucoup pour tes très belles illustrations! 
Obbe, ontzettende dank dat je de lay-out hebt willen verzorgen.
Ook oma Els kan hier niet ontbreken: dank dat je altijd voor ons en de kindjes klaar 
staat.
Lieve pa en ma, ik weet niet of ik dankzij of ondanks jullie opvoeding dit werk heb 
ik kunnen schrijven, maar dank voor jullie voorwaardelijke steun in alle plannen die 
eigenlijk wel de revue gepasseerd zijn en ook voor de eeuwige gastvrijheid op de 
boerderij.
En dan is er altijd nog mijn grote steun en toeverlaat, mijn lieve lief Arnoud. Het is 
dat je me zo vaak naar mijn bureau hebt gestuurd en mij veelvuldig van de lekkerste 
koffietjes hebt voorzien, anders was dit boekwerk nooit af gekomen. Het is eindelijk 
tijd voor nieuw avontuur, samen én met z’n viertjes. Spannend waar de wind ons 
gaat brengen!
133
Curriculum Vitae
Susanne van Santen (1980) groeide op in Heerlen en begon in 1998, meteen na het 
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